Fatty acids and their use in conjugation to biomolecules
Conjugating biomolecules with fatty acids via linkers addresses the short half-life issue of therapeutic peptides and proteins, enhancing their duration and reducing administration frequency and side effects.
Patent Information
- Application Number
- KR1020267035964
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-01-23
- Filing Date
- 2015-06-18
- Publication Date
- 2026-11-09
AI Technical Summary
Therapeutic peptides and proteins have short half-lives due to rapid degradation, necessitating frequent administration and high costs, which is inconvenient for patients and can lead to undesirable side effects.
Conjugating biomolecules with fatty acids via linkers to extend their half-life, using chemical formulas A1, A2, or A3, which provide a longer duration of action while maintaining therapeutic benefits.
The conjugation significantly extends the half-life of biomolecules, reducing the frequency of administration and minimizing side effects, thus improving treatment efficacy and cost-effectiveness.
Smart Images

Figure P1020267035964_ABST
Abstract
Description
Technology Field
[0001] Field of invention
[0002] The present invention relates to a novel conjugate of GDF15 with improved half-life and duration of action, a method for preparing the same, and a method for using the same. Additionally, the present invention relates to a novel fatty acid and its use in extending the half-life of a biomolecule through conjugation. Background Technology
[0003] Prior art literature
[0004] WO 2014 / 083505 A1 (2014. 6. 5.)
[0005] Background of the Invention
[0006] Peptides and proteins are widely used in the medical field, and because they can be produced using recombinant DNA technology, their importance is expected to increase in the future. Furthermore, as a result of ongoing human genome research, the number of known endogenous peptides and proteins with interesting biological activities is rapidly increasing. Due to their biological activity, many of these polypeptides and proteins could, in principle, be used as therapeutic agents. However, endogenous peptides or proteins are not always suitable as drug candidates because their half-lives are often minutes, due to rapid degradation by peptidases and / or renal filtration and excretion in urine. The half-lives of polypeptides or proteins in human plasma vary significantly (from minutes to over a week).
[0007] The high clearance rate of therapeutic agents is inconvenient when it is desired to maintain high blood levels over an extended period. To overcome this drawback, one currently used approach is to administer a large dose of the therapeutic peptide or protein of interest to the patient so that a sufficient amount remains therapeutically effective, even if some of the therapeutic peptide or protein is degraded. However, this method is inconvenient for the patient. Since most therapeutic peptides or proteins cannot be administered orally, they must be continuously infused, frequently administered via intravenous injection, or frequently administered via an inconvenient subcutaneous injection route. The need for frequent administration also results in more potential peptide or protein therapeutic agents, leading to unacceptably high anticipated treatment costs. Furthermore, the presence of large amounts of degraded peptides or proteins can produce undesirable side effects.
[0008] Inconvenient administration and high cost are two reasons why most therapeutic peptides or proteins with attractive bioactive profiles cannot be developed as drug candidates.
[0009] Therefore, one approach to extending the half-life of a peptide or protein is to modify the therapeutic peptide or protein in a way that slows its degradation while still maintaining its biological activity. Serum albumin has a half-life exceeding one week, and one approach to increasing the plasma half-life of a peptide or protein was to derivatize it with a chemical that binds to serum albumin or other plasma proteins.
[0010] However, there is still a need to identify novel half-life extension moiety that modify therapeutic biomolecules, such as peptides and proteins, to provide a longer duration of action in vivo while maintaining low toxicity and therapeutic benefits.
[0011] Summary of the Invention
[0012] The present invention relates to the following chemical formulas A1, A2, or A3 through a linker
[0013]
[0014] [R 1 is CO2H or H;
[0015] R 2 , R 3 and R 4 are independently H, OH, CO2H, -CH=CH2 or -C≡CH;
[0016] Ak is a branched C6-C 30 It is an alkylene;
[0017] The invention relates to a conjugate comprising a biomolecule conjugated to a fatty acid having [n, m and p are independently integers from 6 to 30], or an amide, ester, or pharmaceutically acceptable salt thereof.
[0018] Fatty acids of chemical formulas A1, A2, and A3 were found to increase the half-life of the biomolecule of interest to a much greater extent than more commonly used fatty acid residues when linked to the biomolecule of interest via a linker.
[0019] In another embodiment, the present invention relates to a conjugate comprising a biomolecule linked to a fatty acid of formula A1, wherein at least one of R2 and R3 is CO2H.
[0020] In another embodiment of the present invention, the biomolecule of interest is a therapeutic peptide, a therapeutic protein, or RNA. In another aspect of this embodiment, the biomolecule of interest is a peptide or polypeptide. In a further aspect of this embodiment, the peptide or polypeptide is an APJ agonist peptide, an oxytocin receptor agonist peptide, serelaxin, NPFF, PIP peptide, FGF23 peptide, AgRP peptide, or growth differentiation factor 15 (GDF15) protein, its homologs, variants, fragments, and other modified forms.
[0021] In another embodiment, the present invention relates to a pharmaceutical composition comprising a conjugate of the present invention and one or more pharmaceutically acceptable carriers.
[0022] In another embodiment, the present invention relates to a combination comprising a conjugate of the present invention and a pharmaceutical combination of one or more therapeutically active agents.
[0023] In another embodiment, the present invention relates to a fatty acid of formula A1, A2 or A3.
[0024] In another embodiment, the present invention considers the use of the conjugate and its composition described herein for treating and / or preventing various diseases, disorders and conditions, and / or symptoms thereof.
[0025] For example, the present invention relates to a method for activating APJ receptors in a subject requiring APJ receptor activation, comprising administering to the subject a therapeutically effective amount of the conjugate of the present invention in which the biomolecule is an APJ agonist. The conjugate of the present invention is useful in the treatment of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular disease, cardiomyopathy, cardiac fibrosis, arrhythmia, fluid retention, diabetes mellitus (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accident, transient ischemic attack, traumatic brain injury, amyotrophic lateral sclerosis, burn injury (including sunburn), and preeclampsia through the activation of APJ receptors. In a preferred aspect of such an embodiment, the conjugate of the present invention is useful in the treatment of acute decompensated heart failure (ADHF) or chronic heart failure.
[0026] In another embodiment, the present invention relates to a method for activating oxytocin receptors in a subject requiring oxytocin receptor activation, comprising administering a therapeutically effective amount of the conjugate of the present invention, wherein the biomolecule is an oxytocin receptor agonist peptide, to the subject. The conjugate of the present invention, through the activation of oxytocin receptors, autism (therapeutic or prophylactic), migraine, attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), stress (including post-traumatic stress disorder), anxiety (including anxiety disorders and depression), schizophrenia, psychiatric disorders and amnesia, alcohol withdrawal, drug addiction, Prader-Willi syndrome, metabolic disorders or diseases, type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy, fibromyalgia, sleep disorders, sleep apnea, diastolic heart failure, urinary incontinence, atherosclerosis, hypertension, erectile dysfunction, symptoms of benign prostatic hyperplasia, non-alcoholic fatty liver disease, lactation impairment, labor induction injury, uterine atony, excessive bleeding, inflammation, pain, abdominal pain, back pain, male and female sexual dysfunction, irritable bowel syndrome (IBS), constipation, gastrointestinal obstruction, surgical blood loss, postpartum hemorrhage, It is useful in the treatment of wound healing, infection, mastitis, placental expulsion injury, and osteoporosis; and, for the diagnosis of cancer and placental insufficiency. In a preferred aspect of such an embodiment, the conjugate of the present invention is useful in the treatment of autism, anxiety (including anxiety disorders and depression), migraine, ADHD, oppositional defiant disorder, schizophrenia, psychiatric disorders, obesity, lactation injury, labor induction injury, uterine atony, excessive bleeding, and postpartum hemorrhage. In a more preferred embodiment, the conjugate of the present invention is useful in the treatment of Prader-Willi syndrome.
[0027] In another embodiment, the present invention relates to a method for treating Cushing's syndrome, hypercortisolism, ectopic ACTH syndrome, changes in adrenal cortical mass, primary pigmented nodular adrenal cortical disease (PPNAD), Cani complex (CNC), cortisol-induced mineralocorticoid excess, conditions associated with post-traumatic stress disorder, hirsutism, thin skin, myopathy, osteoporosis, increased tissue fragility, poor wound healing, hypertension, diabetes mellitus, low serum potassium, low eosinophils, and lymphopenia, comprising administering a therapeutically effective amount of the conjugate of the present invention, in which the biomolecule is an AgRP peptide, to a subject. In a preferred aspect of this embodiment, the conjugate of the present invention is useful in the treatment of Cushing's syndrome, hypercortisolism, ectopic ACTH syndrome, and osteoporosis.
[0028] In another embodiment, the present invention relates to a method for treating or preventing FGF23-related diseases, such as age-related conditions (selected from the group consisting of sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataract, age-related macular degeneration, prostate cancer, stroke, reduced life expectancy, memory loss, wrinkles, impaired renal function, and age-related hearing loss), metabolic disorders (selected from the group consisting of type II diabetes, metabolic syndrome, hyperglycemia, and obesity), hyperphosphatemia (tumor calcification, hyperphosphatemic osteoporosis syndrome), chronic kidney disease, chronic renal failure, cancer, breast cancer, and / or muscle atrophy, comprising administering a therapeutically effective amount of the conjugate of the present invention, in which the biomolecule is an FGF23 peptide, to a subject.
[0029] In another embodiment, the present invention relates to a method for treating acute heart failure, chronic heart failure with reduced ejection fraction (HFrEF), chronic heart failure with preserved ejection fraction (HFpEF), diastolic dysfunction, post-myocardial infarction remodeling, angina pectoris, hypertension, pulmonary hypertension, pulmonary arterial hypertension, fibrosis (diffuse, cardiac, renal, pulmonary, hepatic), scleroderma, wound healing, severe limb ischemia, peripheral vascular disease, intermittent claudication, renal dysfunction, and chronic renal disease, comprising administering a therapeutically effective amount of the conjugate of the present invention, wherein the biomolecule is a serylexin peptide, to a subject. In a preferred aspect of this embodiment, the serylexin conjugate of the present invention is useful in the treatment of acute heart failure, chronic heart failure with reduced ejection fraction (HFrEF), chronic heart failure with preserved ejection fraction (HFpEF), diastolic dysfunction, post-myocardial infarction remodeling, angina pectoris, hypertension, pulmonary hypertension, or pulmonary arterial hypertension.
[0030] In another embodiment, the present invention relates to a method for treating or preventing metabolic disorders, such as type 2 diabetes mellitus (T2DM), pancreatic beta-cell damage, glucose intolerance, hyperglycemia, insulin resistance, obesity, dyslipidemia, non-alcoholic fatty liver disease (NASH), metabolic syndrome, and other metabolic disorders, comprising administering a therapeutically effective amount of the conjugate of the present invention, in which the biomolecule is a PIP peptide, to a subject.
[0031] In another embodiment, the present invention relates to a method for treating or preventing metabolic disorders or diseases, type 2 diabetes, obesity, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis, urge incontinence, sedation, neuropathic and inflammatory pain, amnesia, and other metabolic disorders, comprising administering a therapeutically effective amount of the conjugate of the present invention, in which the biomolecule is an NPFF peptide, to a subject.
[0032] In another aspect of the present invention, the present invention relates to a method for treating a subject requiring treatment for a metabolic disorder or disease, diabetes mellitus, type 2 diabetes mellitus, obesity, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver disease, pancreatitis, dyslipidemia, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, complications of diabetes mellitus (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders, comprising administering to the subject a therapeutically effective amount of the conjugate of the present invention in which the biomolecule is human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments and other modified forms.
[0033] These and other aspects of the present invention will be described in the following detailed description of the present invention. Brief explanation of the drawing
[0034] Brief explanation of the drawing Figure 1 shows that Example 24 reduced plasma APOC3 levels more effectively than Reference Example 3. Specific details for implementing the invention
[0035] details
[0036] definition:
[0037] For the purpose of interpreting the present invention, the following definitions shall apply unless otherwise specified, and whenever appropriate, terms used in the singular form shall also include the plural form, and vice versa.
[0038] It should be noted that, as used in this application and the appended claims, the singular forms (“a,” “an,” and “the”) include multiple referents unless the context clearly indicates otherwise. Thus, for example, a reference to “conjugate” includes a reference to one or more conjugates, and a reference to “polypeptide” includes a reference to one or more polypeptides.
[0039] The term alkyl refers to a fully saturated branched or unbranched (or straight-chain or linear) hydrocarbon moiety comprising 1 to 30 carbon atoms. Preferably, the alkyl comprises 5 to 20 carbon atoms, more preferably 10 to 15 carbon atoms. C 10-15 Alkyl refers to an alkyl chain containing 10 to 15 carbons. The term "alkylene" refers to a divalent alkyl as defined above.
[0040] The term "alkenyl" refers to branched or unbranched hydrocarbons having at least one carbon-carbon double bond. 2-30 The term "-alkynyl" refers to a hydrocarbon having 2 to 7 carbon atoms and containing at least one carbon-carbon triple bond.
[0041] The term "alkynyl" refers to branched or unbranched hydrocarbons having at least one carbon-carbon triple bond. 2-30The term "-alkynyl" refers to a hydrocarbon having 2 to 7 carbon atoms and containing at least one carbon-carbon triple bond.
[0042] The term aryl refers to a monocyclic or dicyclic aromatic hydrocarbon group having 6 to 10 carbon atoms in the ring portion. Representative examples of aryls are phenyl or naphthyl.
[0043] The term heteroaryl comprises monocyclic or dicyclic heteroaryls containing a carbon atom and 5 to 10 ring members selected from 1 to 5 heteroatoms, each heteroatom being independently selected from O, N, or S, wherein S and N can be oxidized to various oxidation states. In the case of a dicyclic heteroaryl system, the system is entirely aromatic (i.e., all rings are aromatic).
[0044] The term cycloalkyl refers to a monocyclic, dicyclic, or tricyclic hydrocarbon group of 3 to 12 carbon atoms, preferably 3 to 8 or 3 to 7 carbon atoms, that is saturated or unsaturated but non-aromatic. In the case of dicyclic and tricyclic cycloalkyl systems, all rings are non-aromatic. For example, cycloalkyls include cycloalkenyls and cycloalkynyls. The term "cycloalkenyl" refers to a dicyclic or tricyclic hydrocarbon group of 3 to 12 carbon atoms having at least one carbon-carbon double bond. The term "cycloalkynyl" refers to a dicyclic or tricyclic hydrocarbon group of 3 to 12 carbon atoms having at least one carbon-carbon triple bond.
[0045] The term heterocyclyl refers to a monocyclic, dicyclic, or tricyclic ring system that is saturated or unsaturated and non-aromatic (partially unsaturated but non-aromatic), containing at least one heteroatom selected from O, S, and N, wherein N and S can be optionally oxidized to various oxidation states. In one embodiment, the heterocyclyl moiety represents a saturated monocyclic ring containing 5 to 7 ring atoms and optionally containing additional heteroatoms selected from O, S, or N. The heterocyclic ring may be substituted with alkyl, halo, oxo, alkoxy, haloalkyl, or haloalkoxy. In another embodiment, the heterocyclyl is dicyclic or tricyclic. In the case of a polycyclic system, some rings may be aromatic and may be fused to saturated or partially saturated rings or rings. The entire fused system is not entirely aromatic. For example, the heterocyclic ring system may be an aromatic heteroaryl fused with a saturated or partially saturated cycloalkyl ring system.
[0046] The term "conjugate" is intended to refer to an entity formed as a result of the covalent attachment of a biomolecule and a fatty acid moiety via a linker. The term "conjugation" refers to the chemical reaction that results in the covalent attachment of a biomolecule and a fatty acid moiety.
[0047] Biomolecules:
[0048] The term "biomolecule" as used herein refers to antibodies (e.g., monoclonal, chimeric, humanized, nanobodies, and fragments thereof), cholesterol, hormones, peptides, proteins, chemotherapeutic agents and other types of antineoplastic agents, low molecular weight drugs, vitamins, cofactors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex-forming oligonucleotides, antisense DNA or RNA compositions, chimeric DNA:RNA compositions, allozymes, aptamers, ribozymes, decoys and analogs thereof, plasmids and other types of expression vectors, and small nucleic acid molecules, RNAi agonists, short interfering nucleic acids (siNA), messenger ribonucleic acid (messenger RNA, mRNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), and short hairpin RNA (shRNA) molecules, peptide nucleic acids (PNA), lock nucleic acid ribonucleotides (LNA), morpholinonucleotides, and threose nucleic acids. Compounds include, but are not limited to, (TNA), glycol nucleic acid (GNA), sisiRNA (small internal fragmentation interfering RNA), aiRNA (asymmetric interfering RNA), and siRNA having one, two, or more than one mismatch between the sense strand and the antisense strand for related cells and / or tissues, such as those in cell cultures, subjects, or organisms. Such compounds may be purified or partially purified, may be naturally occurring or synthetic compounds, and may be chemically modified.
[0049] In one embodiment, the biomolecule is a polypeptide, peptide, protein, or RNAi agonist, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), or short hairpin RNA (shRNA) molecule.
[0050] In another embodiment, the biomolecule is a polypeptide (or protein) or a peptide. Examples of polypeptides or peptides are APJ agonist peptide, oxytocin peptide, ceryllexin, NPFF, PIP peptide, FGF23 peptide, AgRP peptide, and GDF15 peptide. In a preferred embodiment, the biomolecule is GDF15 polypeptide, its homologs, variants, mutants, fragments, and other modified forms.
[0051] "Ribonucleic acid" (RNA) is a polymer of nucleotides linked by phosphodiester bonds, where each nucleotide contains ribose or a variant thereof as a sugar component. Each nucleotide contains adenine (A), guanine (G), cytosine (C), uracil (U), or a variant thereof as a base. The genetic information within an mRNA molecule is encoded in the sequence of nucleotide bases of the mRNA molecule, which is arranged into codons, each consisting of three nucleotide bases. Except for stop codons that terminate translation (protein synthesis), each codon codes for a specific amino acid of the polypeptide. In living cells, mRNA is transported to ribosomes, the site of protein synthesis, where it provides the genetic information for protein synthesis (translation). For a more complete explanation, see the literature [Alberts B et al. (2007) Molecular Biology of the Cell, Fifth Edition, Refer to Garland Science.
[0052] Terms such as “RNAi agonist,” “short interfering RNA,” “siRNA,” “short interfering nucleic acid,” and “siNA” as used herein refer to any nucleic acid molecule capable of inhibiting or downregulating gene expression or viral replication by mediating RNA interference (RNAi) or gene silencing in a sequence-specific manner. These terms include short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), short interfering oligonucleotides, chemically modified short interfering nucleic acid molecules, sisiRNA (small internal fragmentation interfering RNA), aiRNA (asymmetric interfering RNA), siRNA having one, two, or more than one mismatch between the sense strand and the antisense strand for the relevant cell and / or tissue, RNAi agonists having one or more mismatches between the sense strand and the antisense strand, RNAi agonists having a sense strand that is very short relative to the antisense strand or has one or more single-strand nicks, or any other molecule capable of mediating RNA interference. RNAi agents may comprise ribonucleotides or may be modified or substituted at one or more sugars, bases, and / or phosphates. As a non-limiting example, RNAi agents may be modified at the 2' position with 2'-modifiers selected from the group consisting of 2'-deoxy, 2'-deoxy-2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethyloxyethyl (2'-O-DMAEOE), and 2'-ON-methylacetamido (2'-O-NMA). In one embodiment, all pyrimidines (uridine and cytidine) are 2'-O-methyl-modified nucleosides.In various embodiments, one or more phosphates may be substituted with a modified internucleoside linker selected from phosphorothioate, phosphorodithioate, phosphoramidate, boranophosphonoate, and amide linkers. In various embodiments, one or more nucleotides may be modified or substituted with DNA, peptide nucleic acid (PNA), lock nucleic acid (LNA), morpholino nucleotide, threose nucleic acid (TNA), glycol nucleic acid (GNA), arabinose nucleic acid (ANA), 2'-fluoroarabinose nucleic acid (FANA), cyclohexene nucleic acid (CeNA), anhydrohexitol nucleic acid (HNA), or unlocked nucleic acid (UNA). Various modifications and substitutions of RNAi agents are known in the art and may be used in the context of this disclosure. siRNA is responsible for RNA interference, which is a sequence-specific post-transcriptional gene silencing process in animals and plants. siRNA is naturally generated by ribonuclease III cleavage from longer double-stranded RNA (dsRNA) that is homologous to or specific to the gene target to be silenced; artificial RNAi agents can be produced by any method known in the relevant art.
[0053] The term “polypeptide” as used herein refers to a polymer of amino acid residues linked by peptide bonds, whether naturally occurring or synthetically produced. Polypeptides of about 10 or fewer amino acid residues are typically referred to as “peptides.” The term “peptide” is intended to indicate a sequence of two or more amino acids linked by peptide bonds, wherein said amino acids may be natural or non-natural amino acids. These terms include polypeptides and proteins that may consist of two or more peptides held together by covalent interactions, e.g., cysteine bridges, or non-covalent interactions. Three-letter or one-letter abbreviations recognized in the relevant art are used to denote the amino acid residues constituting the peptides and polypeptides of the present invention. Except where preceded by “D,” amino acids are L-amino acids. If the one-letter abbreviation is uppercase, it refers to a D-amino acid. If the one-letter abbreviation is lowercase, it refers to an L-amino acid. Peptides are represented using groups or strings of amino acid abbreviations. Peptides are indicated with the N-terminus on the left, and the sequence is written from the N-terminus to the C-terminus.
[0054] The peptide of the present invention contains a non-natural amino acid (i.e., a compound that does not occur naturally), and other amino acid analogs as known in the relevant art may be used alternatively.
[0055] Specific non-natural amino acids may be introduced by the techniques described in the literature [Deiters et al., J Am Chem Soc 125:11782-11783, 2003]; [Wang and Schultz, Science 301:964-967, 2003]; [Wang et al., Science 292:498-500, 2001]; [Zhang et al., Science 303:371-373, 2004] or U.S. Patent No. 7,083,970. Briefly, some of these expression systems involve site-directed mutagenesis to introduce nonsense codons, such as amber TAGs, into the open reading frame encoding the polypeptide of the present invention. Then, such an expression vector is introduced into a host capable of using tRNA filled with selected non-natural amino acids specific to the introduced nonsense codon. Specific non-natural amino acids beneficial for the purpose of conjugating a moiety to the polypeptide of the present invention include those having acetylene and azido side chains.
[0056] "Protein" is a macromolecule containing one or more polypeptide chains. Each of these polypeptide chains may be conjugated to a fatty acid molecule of chemical formula A1, A2, or A3. Proteins may also contain non-peptide components, such as carbohydrate groups. Carbohydrates and other non-peptide substituents may be added to the protein by the cell in which the protein is produced, and this will vary depending on the cell type. In this document, proteins are defined in terms of their amino acid backbone structure: substituents, such as carbohydrate groups, are generally not specified, but may nevertheless be present. Proteins or polypeptides encoded by non-host DNA molecules are "heterogeneous" proteins or polypeptides.
[0057] “Isolated polypeptide or isolated protein” is a polypeptide or protein (e.g., GDF15) that is essentially free of cellular components associated with such polypeptide in nature, such as carbohydrates, lipids, or other proteinaceous impurities. Typically, a preparation of isolated polypeptide or protein contains the polypeptide or protein in a highly pure form, that is, at least about 80% pure, at least about 90% pure, at least about 95% pure, more than 95% pure, e.g., 96%, 97%, or 98% or greater than these values, or more than 99% pure. One way to indicate that a particular protein preparation contains isolated polypeptide or protein is by the appearance of a single band after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the protein preparation and Coomassie Brilliant Blue staining of the gel. However, the term “isolated” does not exclude the existence of the same polypeptide or protein in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms. Preferably, the isolated polypeptide is substantially free of any other contaminating polypeptides or other contaminants found in its natural environment that would interfere with its therapeutic, diagnostic, preventive, or research use.
[0058] A person skilled in the art will understand that various amino acid substitutions, e.g., conservative amino acid substitutions, may be made in any polypeptide or protein described herein without necessarily reducing its activity. "Amino acids commonly used as substituents thereof," as used herein, include conservative substitutions (i.e., substitution with amino acids of similar chemical properties). For the purpose of conservative substitutions, non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, glycine, proline, phenylalanine, tryptophan, and methionine. Polar (hydrophilic), neutral amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine, and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of amino acid substitution include an L-amino acid substituting its corresponding D-amino acid, cysteine substituting homocysteine or other non-natural amino acids having a thiol-containing side chain, lysine substituting homolysine, diaminobutyric acid, diaminopropionic acid, ornithine or other non-natural amino acids having an amino-containing side chain, or alanine substituting norvaline, etc.
[0059] The term “amino acid” as used herein refers to naturally occurring amino acids, non-natural amino acids that function in a manner similar to naturally occurring amino acids, amino acid analogs, and amino acid mimics, all of which exist as such stereoisomers where their structure allows for D and L stereoisomer forms. In this document, amino acids are referred to by their names, their commonly known three-letter symbols, or the one-letter symbol recommended by the IUPAC-IUB Biochemical Nomenclature Committee.
[0060] The term "naturally occurring" refers to a substance found in nature and not manipulated by humans. Similarly, terms such as "non-naturally occurring" and "non-natural" as used herein refer to substances that are not found in nature or that have been structurally modified or synthesized by humans. When used in relation to amino acids, the term “naturally occurring” refers to the 20 common amino acids (i.e., alanine (A or Ala), cysteine (C or Cys), aspartic acid (D or Asp), glutamic acid (E or Glu), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or Ile), lysine (K or Lys), leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gln), arginine (R or Arg), serine (S or Ser), threonine (T or Thr), valine (V or Val), tryptophan (W or Trp), and tyrosine (Y or Tyr)).
[0061] The terms “non-natural amino acid” and “non-natural amino acid” as used herein are used interchangeably to denote amino acid structures that cannot be produced by biosynthesis using unmodified or modified genes from any organism, whether identical or different from any organism. These terms refer to amino acid residues that are not present in the naturally occurring (wild-type) protein sequence or the sequence of the present invention. These include, but are not limited to, modified amino acids and / or amino acid analogs other than one of the 20 naturally occurring amino acids, selenocysteine, pyrrolicine (Pyl), or pyrroline-carboxylysine (Pcl, as described, for example, in PCT Patent Publication WO2010 / 48582). Such non-natural amino acid residues may be introduced by substitution of naturally occurring amino acids and / or insertion of non-natural amino acids into the naturally occurring (wild-type) protein sequence or the sequence of the present invention. Non-natural amino acid residues may be introduced to impart to the molecule the ability to link desired functionality, for example, functional moiety (e.g., PEG). When used in relation to amino acids, the symbol "U" will mean "non-natural amino acid" and "non-natural amino acid" as used herein.
[0062] The term "analogous" as used herein to refer to a polypeptide or protein means a modified peptide or protein in which one or more amino acid residues of the peptide / protein are substituted with other amino acid residues, one or more amino acid residues are deleted from the peptide / protein, or one or more amino acid residues are added to the peptide / protein. Such addition or deletion of amino acid residues may occur at the N-terminus and / or the C-terminus of the peptide.
[0063] The term "ester of a conjugate" as used herein refers to a conjugate comprising a peptide or polypeptide in which an ester derivative form of a carboxylic acid group exists (e.g., in which the C-terminal -CO2H is converted to -COOR), and R of the ester in the formula is C 1-6 Alkyl groups, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, etc., C 3-8 Cycloalkyl groups, e.g., cyclopentyl, cyclohexyl, etc., C 6-10 Aryl groups, e.g., phenyl, α-naphthyl, etc., C 6-10 Aryl-C 1-6 Alkyl groups, e.g., phenyl-C 1-2 Alkyl groups, e.g., benzyl, phenethyl, benzhydryl, etc., and α-naphthyl-C 1-2 The alkyl group refers to, for example, α-naphthylmethyl. If the peptide or polypeptide moiety of the conjugate has additional carboxyl or carboxylate groups at positions other than the C-terminus, the polypeptide in which such groups are aided or esterified also falls within the category of polypeptides of the present invention. In such cases, for example, the ester may be an ester of the same type as the C-terminal ester mentioned above.
[0064] The term “amide of a conjugate” as used herein refers to a conjugate comprising a peptide or polypeptide in which an amide derivative of a carboxylic acid group is present (e.g., -CO2H converted to -CO(NR'R'), wherein R' is H or R, and R is defined above. The term “amide of a conjugate” also refers to a conjugate comprising a peptide or polypeptide in which an amide derivative of an amino group (i.e., one other than an amino group conjugated to a fatty acid) is present (e.g., -NH2 converted to -NH-C(O)R), wherein R is defined above. In a preferred embodiment, the “amide of a conjugate” is a peptide in which the C-terminal carboxylic acid group is amidated (e.g., -CO2H converted to -C(O)NH2, -C(O)NH-C 1-6Alkyl, -C(O)NH-C 1-2 Alkylphenyl, or -C(O)N(C 1-6 It is a conjugate containing a peptide or polypeptide converted to an alkyl)2.
[0065] The term "APJ" (also referred to as "apelin receptor," "angiotensin-like-1 receptor," "angiotensin II-like-1 receptor," etc.) refers to 380 residues with 7 transmembrane domains Gi - Refers to a coupling receptor, and its gene is localized on the long arm of chromosome 11 in humans (NCBI reference sequence: NP_005152.1, coded by NCBI reference sequence: NM_005161). APJ was first cloned from human genomic DNA in 1993 using degenerate oligonucleotide primers (O'Dowd et al. Gene, 136:355-60, 1993) and shares significant homology with the type 1 angiotensin II receptor. However, despite this homology, angiotensin II does not bind to APJ. Although it remained orphaned for many years, the endogenous ligand was isolated and named apelin (Tatemoto et al., Biochem Biophys Res Commun 251, 471-6 (1998)).
[0066] The term "APJ agonist" includes the apelin polypeptide; apelin refers to a residue 77 precursor protein (NCBI reference sequence: NP_0059109.3 and coded by NCBI reference sequence: NM_017413.3), which is processed into biologically active forms of apelin peptides, such as apelin-36, apelin-17, apelin-16, apelin-13, and apelin-12. The full-length mature peptide designated as "apelin-36" contains 36 amino acids, but the most potent isoform is "Pyr-1-apelin-13" or Pyr-1-apelin-12. 1It is a pyroglutamate form of the 13meric apelin (apelin-13), referred to as "-apelin-13". Several forms of apelin are described, for example, in U.S. Patent 6,492,324B1. Apelin peptide agonists are also described in patent application no. WO 2013 / 111110, U.S. application no. 14 / 082771, and U.S. provisional applications no. 61 / 858263, 61 / 858280, and 61 / 858290, which are incorporated herein by reference.
[0067] The terms "oxytocin receptor agonist peptide" or "oxytocin peptide" are used interchangeably and include oxytocin and its analogs. Oxytocin is a nine-amino acid cyclic peptide hormone with two cysteine residues forming a disulfide bond between positions 1 and 6. Human oxytocin comprises the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly (Sequence Identification No.: 14). The term "oxytocin receptor agonist peptide" also includes oxytocin analogs that retain biological activity. Such analog molecules may act in a manner similar to endogenous oxytocin, including by binding to oxytocin receptors. Particularly interesting oxytocin analogs are those disclosed in PCT application No. WO 2014 / 095773 (particularly Example 13); and those disclosed in U.S. patent application No. US2011 / 044905 (particularly Example 49); and includes those disclosed in the literature [Kazimierz Wisniewski et al., Journal of Medicinal Chemistry 2014, 57, 5306-5317] and [Zbigniew Grzonka et al., Journal of Medicinal Chemistry 1983, 26, 1786-1787], all of which are incorporated herein by reference.
[0068] "PIP" or "prolactin-inducible peptide" refers to the protein of GenBank registry number NP_002643, which represents a role in various biological processes. PIP is also known in the relevant technical field as Total Cystic Disease Fluid-15 (GCDFP-15); Secretory Actin-Binding Protein (SABP); Extraparotid Glycoprotein (EP-GP); and 17-kDa CD4-Binding Protein (GP17). PIP is expressed in exocrine organs and in benign and malignant human breast tumors. Secreted mature PIP protein has a molecular mass of 13 kDa and runs as a 17-20 kDa polypeptide on SDS-PAGE, suggesting glycosylation events. PIP is expressed in most organs contributing to human body fluids; PIP expression is highest in the salivary glands, followed by the lacrimal glands, prostate, muscles, trachea, and mammary glands. The PIP gene codes for the PIP polypeptide.
[0069] "PIP peptide" as used herein means human PIP, or a homolog, variant, fragment, or modified form thereof that retains at least one activity of human PIP.
[0070] The sequence of an unrestricted example of human PIP is presented at SEQ ID NO: 11:
[0071]
[0072] Sequence identification number 11 represents a full-length human wild-type PIP containing a signal peptide (amino acids 1-28) that is not required for function.
[0073] Another non-limiting example of the term "PIP" as used herein is amino acids (aa) 29-146 of sequence identification number: 11, which thus lacks a signal peptide (amino acids 1-28) and is presented below as sequence identification number: 12.
[0074]
[0075] "Homologous," "variant," "fragment," or "modified form" of PIP refers to polypeptides that are similar to but not identical to human PIP, but retain at least one activity of human PIP. Such polypeptides may have sequences that are not identical to those of human PIP (e.g., sequence identification number: 12), or may have sequences identical to those of human PIP (e.g., sequence identification number: 12), but differ in some other way (e.g., post-translational modification). Such polypeptides may contain, for example, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity with respect to SEQ ID NO: 12, or may have, for example, up to 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid differences (e.g., substitutions, deletions, and / or additions) from the amino acid sequence of SEQ ID NO: 12. In some embodiments, PIP homologs, variants, fragments, or modified forms retain at least 90% sequence identity with respect to SEQ ID NO: 12 or have up to 25 amino acid differences. PIP homologs, variants, fragments, or modified forms retain at least one activity of human PIP.
[0076] "FGF23" or "fibroblast growth factor 23" refers to the polypeptide also known as FGF-23, ADHR; FGFN; HPDR2; HYPF; and PHPTC; External ID: OMIM: 605380 MGI: 1891427 HomoloGene: 10771 GeneCards: FGF23 gene; Species: Human; Entrez 8074; Ensembl ENSG00000118972; UniProt: Q9GZV9; RefSeq (mRNA): NM_020638; RefSeq (protein): NP_065689; Location (UCSC): Chromosome 12: 4.48 - 4.49 Mb; Species: Mouse; Entrez: 64654; Ensemble: ENSMUSG00000000182; Uniprot: Q9EPC2; RefSeq (mRNA): NM_022657; RefSeq (protein): NP_073148; Location (UCSC): Chromosome 6: 127.07 - 127.08 Mb. The FGF23 gene codes for the FGF23 polypeptide.
[0077] "FGF23 peptide" as used herein means human FGF23, or a homolog, variant, fragment, or modified form thereof that retains at least one activity of human FGF23.
[0078] A sequence of a non-restrictive example of human FGF23 containing a signal peptide is presented at sequence identification number: 9:
[0079]
[0080] Sequence ID number 9 represents full-length human wild-type FGF23 containing a signal peptide (amino acids 1-24) not required for function. References [Yamashita et al. 2000 Biochem. Biophys. Res. Comm. 277: 494-498]; [Shimada et al. 2001 Proc. Natl. Acad. Sci. USA 98: 6500-6505]; and [Zhang et al. 2004 Protein Sci. 13: 2819-2824].
[0081] A non-limiting example of the term "FGF23" as used herein is amino acids (aa) 25-251 of sequence identification number: 9, which therefore lacks a signal peptide (amino acids 1-24) and is presented below as sequence identification number: 8.
[0082]
[0083] "Homologous," "variant," "fragment," or "modified form" of FGF23, etc., means a polypeptide that is similar to but not identical to human FGF23 (e.g., SEQ ID NO: 8), but retains at least one activity of human FGF23. Such polypeptides may contain, for example, at least 70%, at least 80%, at least 90%, or at least 95% sequence identity with respect to SEQ ID NO: 8, or may have, for example, up to 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid differences (e.g., substitutions, deletions, and / or additions) from the amino acid sequence of SEQ ID NO: 8. In some embodiments, the FGF23 homologous, variant, fragment, or modified form retains at least 90% sequence identity with respect to SEQ ID NO: 8 or has up to 25 amino acid differences. FGF23 homologs, variants, fragments, or modified forms retain at least one activity of human FGF23.Such activity (or function) includes, as non-limiting examples, binding to the FGF23 receptor, interacting with the Klotho protein, roles in cell proliferation and cell signaling; and activity in various in vitro assays of FGF23 activity, including the Egr-1-luciferase assay; and FGF23-related diseases, e.g., age-related conditions (selected from the group consisting of sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataract, age-related macular degeneration, prostate cancer, stroke, reduced life expectancy, memory loss, wrinkles, renal impairment, and age-related hearing loss), metabolic disorders (selected from the group consisting of type II diabetes, metabolic syndrome, hyperglycemia, and obesity), hyperphosphatemia (tumor calcification, hyperphosphatemic osteoporosis syndrome), chronic kidney disease, chronic renal failure, cancer, breast cancer, and / or muscle atrophy, including activities known for human FGF23. Literature [Yamashita et al. 2000 Biochem. Biophys. Res. Comm. 277: 494-498]; [Shimada et al. 2001 Proc. Natl. Acad. Sci. USA 98: 6500-6505]; [Urakawa et al. 2006 Nature 444: 770-774]; [Zhang et al. 2004 Protein Sci. 13: 2819-2824]; WO 2013 / 027191, WO 2011 / 092234 and WO 2009 / 095372. In some embodiments, the present invention comprises the fatty acid and FGF23 peptide described herein, wherein the FGF23 peptide provides a conjugate in which at least one activity of FGF23 is retained; and in some embodiments, the retained FGF23 activity is activity in an in vitro Egr-1-luciferase assay.
[0084] "Homologous" of FGF23 refers to a polypeptide that corresponds to human FGF23 but is from a different source, such as mammals, such as mice, rats, cynomolgus monkeys, cattle, pigs, sheep, horses, dogs, etc., while retaining at least one function of human FGF23.
[0085] "Variants" of FGF23 refer to FGF23 that, for example, compared to sequence identification number: 8, contain one or more mutations (e.g., deletion, substitution, or addition) but retain at least one function of human FGF23. Mutations in FGF23 include those at positions Y154, Q156, R176, R179, C206, and C244. Such mutations have been previously described. A mutation at R179 confers proteolytic resistance to FGF23; in ADHR, a mutation at the 176RXXR179 site prevents the cleavage and inactivation of FGF23. References [White et al. 2000 Nat. Genet. 26: 345-348]; [Liu et al. 2003 J. Biol. Chem. 278: 37419-37426]. A mutation at Y154 reduces degradation; Mutations at Q156 remove the cleavage site; mutations at C206 and C244 reduce dimerization and aggregation. WO 2013 / 027191 and WO 2011 / 092234. FGF23 homologs, variants, or modified forms may additionally contain one or more additional amino acids (generally not found in wild-type human FGF23).
[0086] Non-limiting examples of FGF23 variants are presented here:
[0087]
[0088] Sequence identification number 10 represents an FGF23 variant in which the signal peptide (aa 1-24) is deleted, but the initial M at position 1 is reintroduced, and the amino acid corresponding to R179 is mutated to Q. Sequence identification number 10 is also designated as "hFGF23 R 179Q", "FGF23 R179", "hFGF23(R179Q)", etc., and represents the FGF23 variant used in Example 28C.
[0089] Additional FGF23 variants include, as a non-limiting example, having the sequence of sequence identification number: 8 or sequence identification number: 10, but also having mutations in one or more of Y154, Q156, R176, R179, C206 and C244. Additional FGF23 variants include, as a non-limiting example, having the sequence of sequence identification number: 8 or sequence identification number: 10, but also having mutations in one or more of Y154, Q156, R176, R179, C206 and C244, and additionally containing one or more additional amino acids (generally not found in wild-type human FGF23).
[0090] The “fragment” of FGF23 means FGF23 that contains one or more deleted amino acids compared to, for example, SEQ ID No. 8, but retains at least one function of human FGF23. The functional fragment of FGF23 contains amino acids 180–251 of SEQ ID No. 8 (Goetz et al. 2010 Proc. Natl. Acad. Sci. USA 107: 407–412). The FGF23 fragment may also have one or more mutations at any one or more of, for example, positions Y154, Q156, R176, R179, C206, and C244, but retains at least one function of human FGF23.
[0091] "A modified form" of FGF23 means FGF23 that comprises a sequence similar or identical to that of FGF23, e.g., SEQ ID No. 8, but has one or more modifications and retains at least one function of human FGF23. Such modifications may, by non-limiting example, include post-translational modifications (phosphorylation, methylation, or carbohydrate addition) or conjugation to a second moiety other than FGF23. Such a second moiety may, by non-limiting example, be a signal peptide, alpha or beta clotho or a fragment thereof (e.g., soluble clotho or s-clotho), Fc (e.g., FcLALA), or other modifications. WO 2011 / 092234 and WO 2009 / 095372.
[0092] As used herein, the terms “AgRP peptide or polypeptide” and similar terms refer to Agouti-associated peptides, i.e., signaling molecules composed of 132 amino acids, which are processed after translation into their active or mature form, AgRP (83-132) (containing 10 cysteine residues and forming a network of 5 disulfide bonds). AgRP acts as a reversal agonist for melanocortin receptors MC3R and MC4R. In all cases, the term “AgRP peptide” includes its salts. In some embodiments, AgRP may be in an amide form, for example, where the C-terminal -CO2H is amidated to form C(O)-NH2. In other embodiments, AgRP may be in an acid form.
[0093] The term "AgRP peptide" also includes shorter, biologically active fragments of AgRP. The fragments are sequences identical but shorter in length than the parent sequence and are parts of the parent sequence that retain biological activity (i.e., reversal efficacy). Fragments of AgRP polypeptides, as well as variants thereof, are also described in the literature [Jackson, PJ et al., Biochemistry 41, 7565-7572], which is incorporated herein by reference. For example, AgRP (87-120) and AgRP (87-132) possess MC3R and MC4R affinities approximately identical to AgRP (83-132) and exhibit equivalent reversal efficacy. Additional fragments of AgRP polypeptides are described in the literature [Christine G. Joseph et al., Peptides 24 (2003), 263-270], which is incorporated herein by reference. Examples of fragments are AgRP (86-132) and monocyclic AgRP (109-118), as well as their extensions at the N- and / or C-terminus.
[0094] The term "AgRP polypeptide" also includes "AgRP mutant polypeptide," which is an AgRP polypeptide in which the naturally occurring AgRP polypeptide sequence is modified. Such modifications are described in PCT application No. WO2013 / 006656, incorporated herein by reference.
[0095] The terms "GDF15 peptide," "GDF15 polypeptide," and "GDF15 protein" are used interchangeably and refer to a naturally occurring wild-type polypeptide expressed in mammals, e.g., humans or mice. For the purposes of this disclosure, the term "GDF15 protein" may be used interchangeably to refer to any full-length GDF15 polypeptide (NCI Ref. Seq. NP_004855.2) consisting of 308 amino acid residues containing a signal peptide of 29 amino acids (amino acids 1-29), a pro-domain of 167 amino acids (amino acids 30-196), and a maturation domain of 112 amino acids (amino acids 197-308) (cleaved from the pro-domain by a furin-like protease). A GDF15 polypeptide of 308 amino acids is referred to as the "full-length" GDF15 polypeptide; The 112-amino acid GDF15 polypeptide (e.g., amino acids 197–308) is the "mature" GDF15 polypeptide. The mature GDF15 peptide contains a cysteine knot motif typical of TGF~ superfamily members (containing three intrachain disulfide bonds) and seven conserved cysteine residues required to form one interchain disulfide bond. The mature GDF15 peptide contains two additional cysteine residues that form a fourth intrachain disulfide bond. Thus, biologically active GDF15 is a homomer of the mature peptide covalently linked by one interchain disulfide bond. Therefore, the GDF15 protein or polypeptide also contains a protein polymer, more particularly a dimer. Each monomer unit constituting the homomer GDF15 can be linked to a fatty acid of chemical formula A1, A2, or A3.
[0096] "GDF15" or "GDF15 protein" as used herein also means human GDF15, or homologs, variants, mutants, fragments, or modified forms thereof that retain at least one activity of human GDF15.
[0097] The terms "GDF15 mutant polypeptide" or "GDF15 variant polypeptide" include GDF15 polypeptides in which the naturally occurring GDF15 polypeptide sequence is modified. Such modifications include, but are not limited to, one or more amino acid substitutions, including substitutions to non-naturally occurring amino acids, non-naturally occurring amino acid analogs, and amino acid mimics.
[0098] In one aspect, the term "GDF15 mutant protein" or "GDF15 variant polypeptide" refers to a GDF15 protein sequence in which at least one residue typically found at a specific location in the natural GDF15 polypeptide is deleted or replaced with a residue not typically found at such location in the natural GDF15 sequence. In some cases, it may be desirable to replace a single residue typically found at a specific location in the natural GDF15 polypeptide with more than one residue not typically found at such location; in other cases, it may be desirable to retain the natural GDF15 polypeptide sequence and insert one or more residues at a specific location within the protein; in yet other cases, it may be desirable to completely remove a specific residue; all such constructs are included in the term "GDF15 mutant protein" or "GDF15 variant protein". In one aspect of the invention, the GDF15 mutant protein or "GDF15 variant protein" has a sequence selected from any one of Sequence Identification Nos. 1 to 7. The present invention also includes such a GDF15 mutant polypeptide sequence or a nucleic acid molecule encoding a GDF15 mutant polypeptide sequence.
[0099] "Homologous," "variant," "fragment," or "modified form" of GDF15 refers to a polypeptide that is similar to but not identical to human GDF15, while retaining at least one activity of human GDF15.
[0100] "A modified form" of GDF15 refers to GDF15 that contains a sequence similar or identical to that of GDF15 but has one or more modifications and retains at least one activity of human GDF15. Such modifications may include, as a non-limiting example, post-translational modifications (phosphorylation, methylation, or carbohydrate addition).
[0101] "Homologous" of GDF15 refers to a polypeptide that corresponds to human GDF15 but is derived from different sources, such as mammals, e.g., cynomolgus monkeys, mice, and rats, while retaining at least one function of human GDF15. In some cases, GDF15 homologous can be used to treat or improve metabolic disorders in subjects in the mature form of a GDF15 mutant polypeptide derived from the same species as the subject.
[0102] In various embodiments, the GDF15 polypeptide, its homologs, variants, mutants, fragments, or modified forms comprise an amino acid sequence that is at least about 85 percent identical to the naturally occurring GDF15 protein. In other embodiments, the GDF15 polypeptide comprises an amino acid sequence that is at least about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the naturally occurring GDF15 polypeptide amino acid sequence. Such GDF15 polypeptides, their homologs, variants, mutants, fragments, or modified forms possess at least one activity of the wild-type GDF15 mutant polypeptide, such as the ability to lower blood glucose, insulin, triglyceride, or cholesterol levels; the ability to reduce body weight; or the ability to improve glucose tolerance, energy expenditure, or insulin sensitivity.
[0103] In each of the various embodiments, the GDF15 polypeptide, or its homologs, variants, mutants, fragments, or modified forms, has biological activity that is equivalent to, greater than, or less than that of the naturally occurring mature GDF15 protein. Examples of biological activity include the ability to lower blood glucose, insulin, triglyceride, or cholesterol levels; the ability to reduce body weight; or the ability to improve glucose tolerance, lipid tolerance, or insulin sensitivity; and the ability to lower urinary glucose and protein excretion.
[0104] In the context of the structure of polypeptides or proteins, the terms “N-terminus” (or “amino terminus”) and “C-terminus” (or “carboxyl terminus”) as used herein refer to the amino and carboxyl ends of the polypeptide, respectively.
[0105] The terms "therapeutic polypeptide" or "therapeutic protein" as used herein refer to polypeptides or proteins that are being developed for therapeutic use or have been developed for therapeutic use.
[0106] Linkers separate biomolecules and fatty acid moiety. Since they primarily function as spacers, their chemical structure is not important.
[0107] A linker is a chemical moiety containing two reactive / functional groups, one of which can react with a biomolecule and the other with a fatty acid moiety. The two reactive / functional groups of the linker are connected through a linking moiety or a spacer, and the structure of the linking moiety or spacer is not important as long as it does not hinder the linker from coupling to the biomolecule and the fatty acid moiety of formula A1, A2, or A3.
[0108] The linker may consist of amino acids linked together by peptide bonds. In some embodiments of the invention, the linker consists of 1 to 20 amino acids linked together by peptide bonds, wherein the amino acids are selected from 20 naturally occurring amino acids. In various embodiments, the 1 to 20 amino acids are selected from glycine, serine, alanine, methionine, asparagine, glutamine, cysteine, and lysine amino acids. In some embodiments, the linker consists of a plurality of sterically unhindered amino acids, such as glycine and alanine. In some embodiments, the linker is a combination of polyglycine, polyalanine, glycine, and alanine (e.g., poly(Gly-Ala)), or a combination of glycine and serine (e.g., poly(Gly-Ser)). In some embodiments, the linker consists of a plurality of amino acids selected from histidine, alanine, methionine, glutamine, asparagine, and glycine. In some embodiments, the linker contains a poly-histidine moiety.
[0109] In some embodiments, the linker comprises 1 to 20 amino acids selected from non-natural amino acids. While a linker with 1 to 10 amino acid residues is preferred for conjugation with a fatty acid moiety, the present invention considers linkers of any length or composition. Examples of non-natural amino acid linkers are given by the following chemical formulas.
[0110] It is 8-amino-3,6-dioxaoctanic acid or its repeating unit.
[0111] The linkers described herein are exemplary, and linkers containing much longer and different residues are considered by the present invention. Non-peptide linkers are also considered by the present invention.
[0112] In another embodiment, the linker comprises one or more alkyl groups, alkenyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclic groups, polyethylene glycol and / or one or more natural or non-natural amino acids, or a combination thereof, and each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, polyethylene glycol and / or natural or non-natural amino acid is optionally combined and is linked together or linked to a biomolecule and / or fatty acid moiety through a chemical group selected from -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -O-, -NH-, -S-, -C(O)-, -OC(O)NH-, -NHC(O)-O-, =NH-O-, =NH-NH- or =NH-N(alkyl)-.
[0113] Linkers containing alkyl spacers, e.g., -NH-(CH2) z -C(O)- or -S-(CH2) z -C(O)- or -O-(CH2) z -C(O)-, -NH-(CH2) z -NH-, -OC(O)-(CH2) z -C(O)-O-, -C(O)-(CH2) z -O-, -NHC(O)-(CH2) z-C(O)-NH- etc. [wherein z is 2-20] may be used. These alkyl linkers may be further substituted with any sterically non-interfering group including but not limited to lower alkyl (e.g., C1-C6), lower acyl, halogen (e.g., Cl, Br), CN, NH2, or phenyl.
[0114] The linker may be of polymeric properties. The linker may comprise a biostable or biodegradable polymer chain or unit. Polymers with repeating linkages may vary in degree of stability under physiological conditions depending on bond instability. The polymer may contain bonds such as polycarbonate (-OC(O)-O-), polyester (-C(O)-O-), polyurethane (-NH-C(O)-O-), and polyamide (-C(O)-NH-). These bonds are provided as examples and are not intended to limit the types of bonds that may be used in the polymer chains or linkers of the present invention. Suitable polymers include, for example, polyethylene glycol (PEG), polyvinylpyrrolidone, polyvinyl alcohol, polyamino acids, divinyl ether maleic anhydride, N-(2-hydroxypropyl)-methacrylate amide, dextran, dextran derivatives, polypropylene glycol, polyoxyethylated polyols, heparin, heparin fragments, polysaccharides, cellulose and cellulose derivatives, starch and starch derivatives, polyalkylene glycol and its derivatives, copolymers of polyalkylene glycol and its derivatives, polyvinyl ethyl ether, etc., and mixtures thereof. The polymer linker is, for example, polyethylene glycol (PEG). The PEG linker may be linear or branched. The molecular weight of the PEG linker in the present invention is not limited to any specific size, but in certain embodiments, the molecular weight is 100 to 5000 Daltons, for example, 500 to 1500 Daltons.
[0115] The linker contains suitable functional-reactive groups at both ends that form a bridge between the amino group of the peptide or polypeptide / protein and the functional group / reactive group on the fatty acid moiety (e.g., the carboxylic acid functional group of the fatty acid moiety of formulas A1, A2, and A3).
[0116] The linker may comprise several linking moiety (or spacer) of different properties (e.g., combinations of amino acids, heterocyclyl moiety, PEG and / or alkyl moiety). In such cases, each linking moiety contains a suitable functional-reactive group at both ends that forms a bridge between the amino group of the peptide or polypeptide / protein and the next linking moiety of different properties, and / or contains a suitable functional-reactive group that forms a bridge between the previous linking moiety of different properties and the fatty acid moiety.
[0117] A modified peptide or polypeptide and / or a partial construct of a peptide-polypeptide (i.e., a peptide / polypeptide attached to a partial linker) comprises a reactive group capable of reacting with available reactive functional groups on a fatty acid moiety (or a modified fatty acid moiety: i.e., already attached to a partial linker) to form a covalent bond. The reactive group is a chemical group capable of forming a covalent bond. The reactive group is located at one junction site and may generally be a carboxyl, phosphoryl, acyl group, ester or mixed anhydride, maleimide, N-hydroxysuccinimide, tetrazine, alkyne, imidate, or pyridine-2-yldisulfanyl, thereby forming a covalent bond with a functional group at another junction site, such as an amino group, hydroxyl group, alkene group, hydrazine group, hydroxylamine group, azide group, or thiol group.
[0118] Particularly interesting reactive groups for conjugating biomolecules or modified biomolecules to a linker and / or conjugating a linker to a fatty acid moiety and / or conjugating various linking moietyes of different properties together are N-hydroxysuccinimide, alkyne (more particularly cyclooctine).
[0119] The functional groups include: 1. a thiol group for reacting with maleimide, tosylsulfone, or pyridine-2-yldisulfanyl; 2. an amino group for binding to a carboxylic acid or an activated carboxylic acid (e.g., forming an amide bond via N-hydroxysuccinamide chemistry), a phosphoryl group, an acyl group, or a mixed anhydride (e.g., an amino functional group of an amino acid); 3. an azide for proceeding with a Huisgen cyclization substitution (more commonly known as click chemistry) with a terminal alkyne, more particularly with cyclooctine; 4. a carbonyl group for reacting with hydroxylamine or hydrazine to form an oxime or hydrazine, respectively; 5. an alkene, more particularly a strained alkene, for reacting with tetrazine in an aza [4+2] substitution. Although various examples of linkers and functional groups / reactors are described herein, the present invention considers linkers of any length and composition.
[0120] Mode of implementation
[0121] Various embodiments of the present invention are described herein. It will be recognized that in each embodiment, the features described above may be combined with other features described above to provide additional embodiments.
[0122] In Embodiment 1, the present invention relates to the following formula A1, A2, or A3 through a linker
[0123]
[0124] [R 1 It is CO2H, H;
[0125] R 2 , R 3 and R 4are independently H, OH, CO2H, -CH=CH2 or -C≡CH;
[0126] Ak is a branched C6-C 30 It is an alkylene;
[0127] The invention relates to a conjugate comprising a biomolecule connected to a fatty acid moiety having [n, m and p are independently integers from 6 to 30], or an amide, ester, or pharmaceutically acceptable salt thereof.
[0128] In a further aspect of Embodiment 1, the conjugate according to Embodiment 1 may further comprise a fatty acid of Formula A1, A2, or A3 as described above. Considering the difficulty of achieving selective conjugation of a fatty acid to a biomolecule and / or achieving a single conjugation, the conjugate of the present invention may comprise a biomolecule connected to one or more fatty acid moieties of Formula A1, A2, or A3. Additionally, considering the polymeric nature of some proteins, each monomer unit constituting the polymeric protein may be connected to a fatty acid moiety, but as long as at least one of the monomer units is connected to a fatty acid moiety, not all monomer units must necessarily be connected to a fatty acid moiety. In a further aspect, the present invention relates to a mixture of the conjugates of the present invention. For example, the mixture may comprise a biomolecule connected to one fatty acid moiety of formula A1, A2 or A3, e.g., a polymeric biomolecule, e.g., a dimeric biomolecule, and a biomolecule connected to more than one fatty acid moiety of formula A1, A2 or A3, e.g., a polymeric biomolecule, e.g., a dimeric biomolecule. The following examples of the invention further highlight this aspect of the selective or non-selective multiple conjugation of fatty acids to proteins or polypeptides.
[0129] In Embodiment 1A, the present invention relates to a conjugate according to Embodiment 1 in which the fatty acid moiety is of Formula A1. In a specific aspect of this embodiment, the conjugate comprises a fatty acid moiety of Formula A1 in which n and m are independently 8 to 20, preferably 10 to 16. In another aspect of this embodiment, the present invention relates to a fatty acid moiety in which the fatty acid moiety is of Formula A1 and R 2 and R 3 The present invention relates to a composite according to embodiment 1 or 1A in which at least one of the components is CO2H.
[0130] In Embodiment 2, the present invention comprises a fatty acid moiety having the following chemical formula
[0131]
[0132] [During the meal, Ak 3 , Ak 4 , Ak 5 , Ak 6 and Ak 7 is independently (C 8-20 )alkylene, and R 5 and R 6 is independently (C 8-20 The present invention relates to a conjugate according to embodiment 1 or 1A selected from )alkyl.
[0133] In Embodiment 3, the present invention comprises a fatty acid moiety having the following chemical formula
[0134]
[0135] The invention relates to a composite according to embodiment 1, 1A, or 2 selected from.
[0136] In Embodiment 3A, the present invention comprises a fatty acid moiety having the following chemical formula
[0137]
[0138] The invention relates to a composite according to embodiment 1, 1A, or 2 selected from.
[0139] In Embodiment 3B, the present invention relates to a conjugate according to Embodiment 1 in which the fatty acid moiety is of formula A2 or A3. In a specific aspect of this embodiment, the conjugate is a fatty acid moiety of formula A2 in which p is 8 to 20 or Ak is C 8-20 It contains a fatty acid moiety of chemical formula A3, which is an alkylene.
[0140] In Embodiment 3C, the present invention comprises a fatty acid moiety having the following chemical formula
[0141]
[0142] [During the meal, Ak 2 is C 8-20 The present invention relates to a conjugate according to embodiment 1 or 3B selected from [alkylene].
[0143] In Embodiment 4, the present invention relates to a conjugate according to any of the prior embodiments, wherein the linker comprises one or more alkyl groups, alkenyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclic groups, polyethylene glycol, one or more natural or non-natural amino acids, or combinations thereof, and each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, polyethylene glycol and / or natural or non-natural amino acid is optionally combined and is connected together through a chemical group selected from -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -O-, -NH-, -S-, -C(O)-, -OC(O)NH-, -NHC(O)-O-, =NH-O-, =NH-NH- or =NH-N(alkyl)- or connected to a biomolecule and / or fatty acid moiety.
[0144] In Embodiment 5, the present invention has a linker with a chemical formula
[0145]
[0146] The present invention relates to a conjugate according to any of the prior embodiments comprising a non-branched oligoethylene glycol moiety of [wherein y is 0 to 34].
[0147] In Embodiment 6, the present invention comprises a linker having the following chemical formula
[0148]
[0149]
[0150] The present invention relates to a conjugate according to any of the prior embodiments comprising (or additionally comprising) a heterocyclic moiety selected from.
[0151] Such heterocyclil-containing linkers are obtained, for example, by an azide-alkyne fuisgen cyclization (more commonly known as click chemistry). More specifically, some of the heterocyclils described above result from the reaction of a cycloalkyne with an azide-containing moiety.
[0152] Cycloalkynes are readily available from commercial sources and can therefore be functionalized through cyclization with a moiety containing an azide functional group (e.g., a linker containing a terminal azide functional group). An example of using cyclic alkyne click chemistry in protein labeling is described in U.S. 2009 / 0068738, which is incorporated herein by reference.
[0153] Non-limiting examples of cycloalkyne agonists that can be used in the cyclization of Huisgen are as follows:
[0154]
[0155]
[0156] In Embodiment 6A, the present invention comprises a linker having the following chemical formula
[0157]
[0158] The invention relates to a conjugate according to any one of embodiments 1 to 5 comprising (or additionally comprising) a heterocyclyl selected from [wherein r is an integer from 0 to 2 and s is an integer from 0 to 3].
[0159] Such a heterocyclic linker is an alkene, preferably a strain alkene such as a cycloalkane and the following moiety
[0160]
[0161] [In the formula, Rf is, for example, -CH2NH2, -OH, -CH2-CO2H, -S-CH2-CO2H, -(O-CH2) 4-6 -C(O)-OH or
[0162]
[0163] [4+2] can be obtained through the cyclization of [Ida].
[0164] Such tetrazine moiety is readily available from commercial sources and can be reacted with an alkene-containing moiety, for example, a linker containing a terminal alkene functional group.
[0165] In Embodiment 6B, the present invention has a linker with a chemical formula
[0166]
[0167] The invention relates to a conjugate according to any one of embodiments 1 to 5, comprising (or additionally comprising) a heterocyclyl.
[0168] Such a heterocyclic moiety can be obtained by reacting a maleimide with a thiol-containing moiety, for example, a linker containing a terminal thiol functional group.
[0169] These readily available and / or commercially available reagents are attached to the peptide or polypeptide of interest either directly or through a linker as described above. An alkyne, maleimide, or tetrazine reactive group reacts with a functional group (azide, thiol, and alkene, respectively) present on a fatty acid moiety or on a linker-fatty acid construct (e.g., a PEG-fatty acid construct).
[0170] In Embodiment 7, the present invention relates to a conjugate according to any of the prior embodiments, wherein the linker comprises or additionally comprises one or more amino acids independently selected from histidine, methionine, alanine, glutamine, asparagine, and glycine. In one particular aspect of such embodiment, the linker comprises 1 to 6 amino acids selected from histidine, alanine, and methionine.
[0171] In Embodiment 8, the present invention relates to a conjugate according to any one of the prior embodiments in which the biomolecule is a peptide or polypeptide. In one particular aspect of Embodiment 8, the present invention relates to a conjugate according to any one of the prior embodiments in which the peptide or polypeptide is 1) human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments and other modified forms; 2) APJ agonist peptide, 3) oxytocin receptor agonist peptide, 4) ceryllexin, 5) NPFF, 6) PIP peptide, 7) FGF23 peptide, 8) AgRP peptide, or 9) siRNA.
[0172] In Embodiment 8A, the present invention relates to a conjugate according to any one of the prior embodiments in which the biomolecule is human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments, and other modified forms; or a dimer thereof. In one aspect of such embodiments, the biomolecule is a human growth differentiation factor 15 (GDF15) mutant or variant. In a preferred embodiment, the biomolecule is a dimer of GDF15 or its variant or mutant. Considering the homomeric nature of the GDF15 polypeptide or its mutant or variant, each of the two polypeptide chains constituting the homomer (i.e., each monomer unit) may be connected via a linker to a fatty acid molecule of formula A1, A2, or A3. Thus, the GDF15 homomer may be connected via a linker to one or two fatty acids. The structure of GDF15 connected to a fatty acid moiety via a linker is
[0173]
[0174] [In the formula, FA represents a fatty acid moiety and L represents a linker, and both GDF15 monomer unit 1 and monomer unit 2 are connected to the fatty acid moiety through the linker]; or
[0175]
[0176] [In the formula, FA is a fatty acid moiety, L is a linker, and only one of the monomer units is connected to the fatty acid moiety through the linker] can be expressed as, and the line between two monomer units in the above formulas represents a disulfide bond. Additionally, the present invention also relates to a mixture comprising a conjugate of structure A and a conjugate of structure B.
[0177] In Embodiment 8B, the present invention conceives a conjugate according to Embodiment 8A in which a human GDF15 mutant is obtained by replacing one or more amino acid residues of a mature polypeptide with another residue. In one particular aspect of this embodiment, the last two amino acid residues of the N-terminus of human GDF15 (i.e., arginine 198 and alanine 197) are replaced with the amino acid sequence XH- [wherein H is histidine and X is an amino acid selected from methionine, alanine, glutamine, asparagine, and glycine]. In a preferred aspect of this embodiment, the hGDF15 mutant is MH(199-308)hGDF15 or AH(199-308)hGDF15.
[0178] In embodiment 8C, the last three amino acid residues of the N-terminus of human GDF15 (i.e., asparagine 199, arginine 198, and alanine 197) were replaced with the amino acid sequence XHX'- [wherein H is histidine, and X' and X are amino acids independently selected from methionine, alanine, glutamine, asparagine, and glycine]. In another aspect of this embodiment, the last three amino acid residues of the N-terminus of human GDF15 (i.e., asparagine 199, arginine 198, and alanine 197) were replaced with the amino acid sequence AHX'- [wherein H is histidine, and X' is an amino acid independently selected from methionine, alanine, glutamine, asparagine, and glycine]. In a preferred aspect of this embodiment, the modified GDF15 protein is MHA(200-308)hGDF15 or AHA(200-308)hGDF15.
[0179] Compared to the natural GDF15 protein, the GDF15 mutant enables the selective labeling of the protein at the N-terminus (i.e., fatty acid conjugation at the preferred N-terminus of GDF15). The selective labeling of peptides and proteins is further described in detail in the jointly filed U.S. applications No. 62 / 015,858 (Agent Case PAT056275-US-PSP) and 62 / 082,337 (Agent Case No. PAT056275-US-PSP02).
[0180] In Embodiment 8D, the present invention relates to a conjugate according to any one of Embodiments 1 to 8 in which the biomolecule is an APJ agonist peptide. In a particular aspect of these embodiments, the APJ agonist peptide is the peptide described in PCT patent applications No. WO 2013 / 111110, WO 2014 / 081702, WO 2015 / 013168, WO 2015 / 013165, WO 2015 / 013167 and WO 2015 / 013169 incorporated herein by reference.
[0181] In Embodiment 8E, the present invention relates to a conjugate according to any one of Embodiments 1 to 8 in which the biomolecule is an oxytocin receptor agonist peptide. In a particular aspect of these embodiments, the oxytocin receptor agonist peptide is the peptide described in PCT patent applications WO 2009 / 122285 (Ferring BV) and WO 2014 / 095773 (Hoffman-La Roche), incorporated herein by reference.
[0182] In embodiment 8F, the present invention relates to a conjugate according to any one of embodiments 1 to 8 in which the biomolecule is an AgRP peptide. In a particular aspect of these embodiments, the AgRP peptide is an AgRP (83-132) in which the C-terminus is in the form of -free CO2H or its amide (e.g., -C(O)NH2).
[0183] In Embodiment 8G, the present invention relates to a conjugate according to any one of Embodiments 1 to 8 in which the biomolecule is an FGF23 peptide. In a specific aspect of this embodiment, the FGF23 peptide is an FGF23 variant of SEQ ID No. 8 comprising a mutation at R179 and optionally comprising one or more additional mutations at Y154, Q156, R176, R179, C206, and C244. In another specific aspect of this embodiment, the FGF23 peptide is an FGF23 variant of SEQ ID No. 8 having mutations at R179, Q156, C206, and C244.
[0184] In embodiment 8H, the present invention relates to a conjugate according to any one of embodiments 1 to 8 in which the biomolecule is serylexine.
[0185] In Embodiment 8I, the present invention relates to a conjugate according to any one of Embodiments 1 to 8 in which the biomolecule is an NPFF peptide.
[0186] In embodiment 8J, the present invention relates to a conjugate according to any one of embodiments 1 to 8 in which the biomolecule is a PIP peptide. In a specific aspect of such embodiment, the PIP peptide is a his-tagged protein MHHHHHHHH-PIP (SEQ ID: 15) [wherein PIP is of SEQ ID: 12].
[0187] In embodiment 8K, the present invention relates to a conjugate according to any one of embodiments 1 to 8 in which the biomolecule is siRNA.
[0188] In Embodiment 8L, the present invention relates to a conjugate according to any one of the prior embodiments, further comprising a second fatty acid moiety connected to a biomolecule through a linker. Preferably, the two fatty acid-linker moietys have the same structure.
[0189] In Embodiment 9, the present invention has the following structure
[0190]
[0191]
[0192] [In the formula, hGDF15* is hGDF15, or a dimer thereof, in which 2 or 3 amino acids at the N-terminus are replaced with the amino acid sequence XH- or XHX'-, respectively (in the formula, H is histidine, and X and X' are independently selected from M and A);
[0193] his-hGDF15 is hGDF15, or a dimer thereof, to which a tag comprising 1 to 6 histidine amino acids and any 1 or 2 methionine amino acids is attached to the N-terminus of hGDF15;
[0194] The invention relates to a composite according to embodiments 1, 2, 8, 8A, 8B, or 8C having [s is an integer of 20-30].
[0195] In one aspect of this embodiment, the tag comprises a histidine amino acid and one or two non-contiguous methionine amino acids. In another aspect of this embodiment, the histidine and methionine amino acids are arranged such that the amino acid at a position adjacent to the N-terminal amino acid is histidine. In a further aspect of this embodiment, the tag is selected from MHHHHHHM- (Sequence Identification No.: 16) and MHHHHHH- (Sequence Identification No.: 17).
[0196] In a specific aspect of Embodiment 9, considering the homomeric properties of hGDF15* and his-hGDF15, one or two polypeptide chains (monomer units) constituting the homomer may be connected to a fatty acid molecule via a linker. As a result, the homomer may be connected to one fatty acid molecule or to two fatty acid molecules via a linker at the N-terminus. Such an embodiment may be represented by a GDF15 biomolecule connected to a fatty acid via a linker having the following chemical formula:
[0197] [Chemical Formula C]
[0198] ; or
[0199] [Chemical Formula D]
[0200]
[0201] [In the formula, both monomer units of his-hGDF15 or hGDF15* (as defined above) are linked to a fatty acid moiety via a linker at both N-terminals]; or
[0202] [Chemical Formula E]
[0203] ; or
[0204] [Chemical Formula F]
[0205]
[0206] [In the formula, only one of the monomer units of his-hGDF15 or hGDF15* (as defined above) is connected to a fatty acid moiety via a linker at the N-terminus]. Additionally, the present invention also conceives a mixture of the conjugates of the present invention; for example, a mixture comprising a conjugate of formula C and a conjugate of formula E, or a mixture comprising a conjugate of formula D and a conjugate of formula F.
[0207] In Embodiment 10, the present invention relates to a composition comprising a mixture of a conjugate of Formula C and a conjugate of Formula E. In Embodiment 10A, the present invention relates to a composition comprising a mixture of a conjugate of Formula D and a conjugate of Formula F.
[0208] Accordingly, in Embodiment 10B, the present invention
[0209] 1. A variant of the homomer hGDF15 in which two or three amino acids at the N-terminus are replaced with the amino acid sequences XH- or XHX'-, respectively (wherein H is histidine, and X and X' are independently selected from M and A); or
[0210] A homomer hGDF15 having a tag comprising 1 to 6 histidine amino acids and any 1 or 2 methionine amino acids attached to the N-terminus of hGDF15; and
[0211] 2. One or two chemical formulas
[0212]
[0213] The invention relates to a conjugate according to claim 1, 2, 9 or 10 comprising a fatty acid, wherein the fatty acid is connected to the N-terminus of a polypeptide chain through a linker; or a mixture of conjugates.
[0214] In embodiment 10C, the present invention is hGDF15*, in which two or three amino acids at the N-terminus are each replaced with the amino acid sequence XH- or XHX'- (wherein H is histidine, and X and X' are independently selected from M and A), or a dimer thereof;
[0215] his-hGDF15 is hGDF15, or a dimer thereof, to which a tag comprising 4 to 6 histidine amino acids and 1 or 2 methionine amino acids is attached to the N-terminus of hGDF15;
[0216] s relates to a conjugate of embodiment 9, 10, 10A or 10B, where s is an integer from 22 to 28. In one aspect of this embodiment, the tag comprises a histidine amino acid and one or two non-contiguous methionine amino acids. In another aspect of this embodiment, the histidine and methionine amino acids are arranged such that the amino acid at a position adjacent to the N-terminal amino acid is histidine. In a further aspect of this embodiment, the tag is selected from MHHHHHHM- (Sequence Identification No.: 16) and MHHHHHH- (Sequence Identification No.: 17).
[0217] In Embodiment 11, the present invention relates to a conjugate according to any one of the prior embodiments, wherein the biomolecule is selected from M-(His)6-hGDF15 (Sequence Identification No.: 1), M-(his)6-M-hGDF15 (Sequence Identification No.: 2), MH(199-308)hGDF15 (Sequence Identification No.: 4), MHA(200-308)hGDF15 (Sequence Identification No.: 6), AHA(200-308)hGDF15 (Sequence Identification No.: 7) and AH(199-308)GDF15 (Sequence Identification No.: 5); or a dimer thereof.
[0218] In Embodiment 11A, the present invention relates to a conjugate according to Embodiment 11, wherein the biomolecule is selected from MH(199-308)hGDF15 (Sequence Identification No.: 4), MHA(200-308)hGDF15 (Sequence Identification No.: 6), AHA(200-308)hGDF15 (Sequence Identification No.: 7) and AH(199-308)GDF15 (Sequence Identification No.: 5); or a dimer thereof.
[0219] In Embodiment 11B, the present invention relates to a conjugate according to Embodiment 11, wherein the biomolecule is selected from AHA(200-308)hGDF15 (Sequence Identification No.: 7); or a dimer thereof.
[0220] In Embodiment 12, the present invention comprises a biomolecule connected to a fatty acid through a linker, wherein the biomolecule is of formula G or formula H:
[0221] [Chemical Formula G]
[0222]
[0223] [Chemical Formula H]
[0224]
[0225] The present invention relates to a conjugate according to Embodiment 11B, wherein AHA-hGDF15 in the above formula is sequence identification number: 7, and a fatty acid is connected at the N-terminus of one or two monomer units. Furthermore, the present invention conceives a mixture comprising a conjugate of formula G and a conjugate of formula H.
[0226] In Embodiment 13, the present invention relates to a composition comprising a mixture of a conjugate according to Embodiment 12 having formula G and a conjugate according to Embodiment 12 having formula H. In a specific aspect of this embodiment, the molar ratio of the conjugate of formula G and the conjugate of formula H in the mixture is 1:1.
[0227] AHA-(200-308)-hGDF15 (sequence identification number: 7) was designed to remove clipping sites observed in natural proteins, as well as potential methionine (M1) formylation sites and N-199 deamidation sites. The excellent quality and homogeneity of AHA were demonstrated by material quality inspections showing no clipping, deamidation, or methionine oxidation observed in the natural hGDF15 sequence.
[0228]
[0229] In Embodiment 14, the present invention relates to a conjugate according to any one of the prior embodiments, wherein a fatty acid residue is attached to the N-terminus of a peptide or protein via a linker. In Embodiment 15, the present invention relates to a conjugate according to any one of the prior embodiments, wherein the plasma stability half-life of the conjugate exceeds 5 hours. In one aspect of such an embodiment, the plasma stability half-life of the conjugate exceeds 10 hours. In another aspect of such an embodiment, the plasma stability half-life of the conjugate exceeds 20 hours or exceeds 30 hours. In yet another aspect of such an embodiment, the plasma stability half-life of the conjugate exceeds 40 hours or exceeds 50 hours.
[0230] In Embodiment 16, the present invention relates to a conjugate according to any one of the prior embodiments, wherein the improvement in plasma stability half-life compared to a non-conjugated biomolecule is 2, 5, 10, 20, 30, 40, 50, or 75 times.
[0231] In another embodiment, the biomolecule, linker, and fatty acid moiety (R 1 to R 4 , n, m, p and Ak) are defined by the following Examples section.
[0232] In one embodiment, the present invention has a formula
[0233]
[0234] [R 1 is CO2H or H;
[0235] R 2 and R 3 are independently H, OH, CO2H, -CH=CH2 or -C≡CH; provided that R 2 and R 3 is not identical;
[0236] R 4 is CO2H;
[0237] [n and m are independent integers from 6 to 30] relates to a compound, or its amide, ester, or pharmaceutically acceptable salt. In another aspect of such an embodiment, the present invention relates to R 2 and R 3 The present invention relates to a compound of formula A1 in which at least one of the compounds is CO2H. In another aspect of such an embodiment, the present invention
[0238]
[0239] It relates to a compound selected from the group consisting of
[0240] Synthesis of peptides / polypeptides and / or modified forms thereof
[0241] The peptides or polypeptides of the present invention may be produced by synthetic chemical processes or recombinant methods, or a combination of both methods. The peptides or polypeptide / protein constructs may be prepared in their full length or synthesized from non-full-length fragments and linked together. The peptides and polypeptides of the present invention may be produced by procedures known in themselves for peptide synthesis. The peptide synthesis method may be either solid-phase synthesis or liquid-phase synthesis. Thus, the peptides and polypeptides of interest may be produced by condensing a partial peptide or amino acid capable of constituting a protein with the remainder thereof, and if the product has a protecting group, the protecting group may be detached to produce the target peptide. Known condensation and deprotection methods include the procedures described in the following references (1)–(5).
[0242] (1) M. Bodanszky and M.A. Ondetti, Peptide Synthesis, Interscience Publishers, New York, 1966,
[0243] (2) Schroeder and Luebke, The Peptide, Academic Press, New York, 1965,
[0244] (3) Nobuo Izumiya et al., Fundamentals and Experiments in Peptide Synthesis, Maruzen, 1975,
[0245] (4) Haruaki Yajima and Shumpei Sakakibara, Biochemical Experiment Series 1, Protein Chemistry IV, 205, 1977, and
[0246] (5) Haruaki Yajima (ed.), Development of Drugs-Continued, 14, Peptide Synthesis, Hirokawa Shoten.
[0247] After the reaction, the peptide or polypeptide may be purified and isolated by conventional purification techniques, such as solvent extraction, column chromatography, liquid chromatography, size exclusion chromatography, and a combination of ion exchange chromatography and recrystallization. If the peptide isolated as described above is a free compound, it may be converted into a suitable salt by a known method. Conversely, if the isolated product is a salt, it may be converted into a free peptide by a known method.
[0248] An amide of a polypeptide can be obtained by using a resin for peptide synthesis suitable for amidation. Such resins include chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenz-hydrylamine resin, PAM resin, 4-hydroxymethylmethylphenylacetamidomethyl resin, polyacrylamide resin, 4-(2',4'-dimethoxyphenyl-hydroxymethyl)phenoxy resin, 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)phenoxy resin, 2-chlorotrityl chloride resin, etc. Using such resins, amino acids in which the α-amino group and the functional group of the side chain are suitably protected are condensed on the resin according to the sequence of the target peptide by various condensation techniques known in themselves. At the end of the series of reactions, the peptide or protected peptide is removed from the resin, the protecting group is removed, and if necessary, a disulfide bond is formed, and the target polypeptide is obtained.
[0249] For the condensation of the protected amino acid mentioned above, various activating reagents for peptide synthesis, such as HATU, HCTU, or, for example, carbodiimides, may be used. Carbodiimides include DCC, N,N'-diisopropylcarbodiimide, and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide. For activation with such reagents, racemization inhibitor additives, for example, HOBt or Oxyma Pure, may be used. The protected amino acid may be added directly to the resin with the activating reagent or racemization inhibitor, or may be added to the resin after being pre-activated as a symmetric acid anhydride, HOBt ester, or HOOBt ester. The solvent for the activation of the protected amino acid or resin condensation may be suitably selected from solvents known to be useful for peptide condensation reactions. For example, N,N-dimethylformamide, N-methylpyrrolidone, chloroform, trifluoroethanol, dimethyl sulfoxide, DMF, pyridine, dioxane, methylene chloride, tetrahydrofuran, acetonitrile, ethyl acetate, or a suitable mixture thereof may be mentioned. The reaction temperature may be selected from a range known to be useful for peptide bond formation, and is generally selected from the range of about -20°C to 50°C. The activated amino acid derivative is generally used in a ratio of 1.5 to 4 times excess. If the condensation is found to be insufficient by a test using the ninhydrin reaction, the condensation reaction may be repeated to achieve sufficient condensation without removing the protecting group. If repeated condensation still does not provide a sufficient degree of condensation, the unreacted amino group may be acetylated with acetic anhydride or acetylimidazole.
[0250] The protecting groups of the amino group for the starting material amino acid include Z, Boc, tertiary-amyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl, CI-Z, Br-Z, adamanthyloxycarbonyl, trifluoroacetyl, phthalyl, formyl, 2-nitrophenylsulfphenyl, diphenylphosphiothiol, or Fmoc. The carboxy-protecting groups that can be used include the aforementioned C 1-6 Alkyl, C 3-8 Cycloalkyl and C 6-10 Aryl-C 1-2 Alkyl, as well as 2-adamantyl, 4-nitrobenzyl, 4-methoxybenzyl, 4-chlorobenzyl, phenacyl, benzyloxycarbonylhydrazide, tert-butoxycarbonylhydrazide, and tritylhydrazide, are included but not limited thereto.
[0251] The hydroxyl groups of serine and threonine can be protected by esterification or etherification. Groups suitable for esterification include carbon-derived groups, such as lower alkanoyl groups, e.g., acetyl, etc., aroyl groups, e.g., benzoyl, etc., benzyloxycarbonyl, and ethoxycarbonyl. Groups suitable for etherification include benzyl, tetrahydropyranyl, and tertiary-butyl. Protecting groups for the phenolic hydroxyl groups of tyrosine include Bzl, Cl2-Bzl, 2-nitrobenzyl, Br-Z, and tertiary-butyl.
[0252] The protecting groups of imidazole for histidine include Tos, 4-methoxy-2,3,6-triethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt, and Fmoc.
[0253] The activated carboxyl group of the starting amino acid comprises an ester with the corresponding acid anhydride, azide, and active ester, for example, an alcohol such as pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, HOBt, etc. The activated amino group of the starting amino acid comprises the corresponding phosphoramide.
[0254] Methods for removing the protecting group include catalytic reduction using hydrogen gas in the presence of a catalyst such as palladium black or palladium-on-carbon, acid treatment with anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethanesulfonsine, trifluoroacetic acid, or a mixture of such acids, base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine, and reduction with sodium metal in liquid ammonia. The removal reaction by the aforementioned acid treatment is generally carried out at a temperature of -20°C to 40°C and can advantageously be carried out with the addition of a cation acceptor such as anisole, phenol, thioanisole, m-cresol, p-cresol, dimethyl sulfide, 1,4-butanedithiol, or 1,2-ethanedithiol. The 2,4-dinitrophenyl group used to protect the imidazole group of histamine can be removed by thiophenol treatment, while the formyl group used to protect the indole group of tryptophan can be removed by alkali treatment with a dilute sodium hydroxide solution or dilute aqueous ammonia, as well as by the aforementioned acid treatment in the presence of 1,2-ethanedithiol and 1,4-butanedithiol.
[0255] A method for protecting functional groups that should not participate in the reaction of the starting material, a protecting group that can be used, a method for removing the protecting group, and a method for activating functional groups that will participate in the reaction can all be carefully selected from known groups and methods.
[0256] Another method for obtaining an amide form of a polypeptide comprises first amidating the γ-carboxyl group of a C-terminal amino acid, then extending the peptide chain N-side to a desired chain length, then selectively deprotecting the α-amino group of the C-terminal peptide and the α-carboxyl group of the amino acid or peptide that will form the remainder of the target polypeptide, and condensing the two fragments in a mixed solvent, such as the one mentioned above, wherein the α-amino group and side chain functional group of the fragment are protected by the appropriate protecting group mentioned above. The parameters of this condensation reaction may be the same as those described above. From the protected peptide obtained by condensation, the target untreated peptide is provided by removing all protecting groups by the method described above. This untreated peptide can be purified by a known purification procedure, and the major fraction can be freeze-dried to provide the target amidated polypeptide. To obtain an ester of polypeptide, the α-carboxyl group of a C-terminal amino acid is condensed with a desired alcohol to provide an amino acid ester, and then the procedure described above for the production of amide follows.
[0257] Alternatively, recombinant expression methods are particularly useful. Recombinant protein expression using host cells (cells that are artificially engineered to contain nucleic acids encoding a peptide sequence, will perform transcription and translation, and optionally secrete the peptide into a cell growth medium) is routinely used in the relevant technical field. For the recombinant production process, nucleic acids encoding the amino acid sequence of the peptide are typically synthesized by conventional methods and incorporated into an expression vector. Such methods are particularly desirable for the production of polypeptide compositions comprising additional peptide sequences or peptides fused to other proteins, protein fragments, or domains. Optionally, the host cell may be at least one selected from E. coli, COS-1, COS-7, HEK293, BHT21, CHO, BSC-1, Hep G2, 653, SP2 / 0, 293, heLa, myeloma, lymphoma, yeast, insect or plant cells, or any derivatives thereof, immortalized or transformed cells.
[0258] The present invention also comprises a polynucleotide encoding the variant described above, which may be in RNA form or DNA form (DNA includes cDNA, genomic DNA, and synthetic DNA). The DNA may be double-stranded or single-stranded. The coding sequence encoding the composition of the present invention may vary as a result of redundancy or degeneracy of the genetic code.
[0259] The polynucleotide encoding the composition of the present invention may comprise only the coding sequence for the variant, or may comprise the coding sequence for the variant and additional coding sequences, such as functional polypeptides, or leader or secretion sequences or precursor-protein sequences, or may comprise the coding sequence for the variant and non-coding sequences, such as introns or non-coding sequences of the 5' and / or 3' of the coding sequence for the variant. Accordingly, the term “polynucleotide encoding the variant” includes polynucleotides that may also comprise polynucleotides comprising not only the coding sequence for the variant but also additional coding and / or non-coding sequences.
[0260] The present invention also relates to variants of the described polynucleotide encoding fragments, analogs, and derivatives of a polypeptide containing indicated substitutions. Variants of the polynucleotide may be naturally occurring allelic variants, non-naturally occurring variants, or truncation variants of the human GDF15 sequence as described above. Accordingly, the present invention also includes polynucleotides encoding the variants described above, as well as variants of such polynucleotides encoding fragments, derivatives, or analogs of the disclosed variants. Such nucleotide variants include deletion variants, substitution variants, truncation variants, and addition or insertion variants as long as at least one of the indicated amino acid substitutions of the first or second embodiment is present.
[0261] The polynucleotide of the present invention can be expressed in a host after the sequence is operably linked to an expression control sequence (i.e., positioned to ensure the functionalization of the expression control sequence). Typically, such an expression vector can be replicated in a host organism as an episome or as an integral part of host chromosomal DNA. Typically, the expression vector will contain selection markers, e.g., tetracycline, neomycin, and dihydrofolate reductase, to allow for the detection of cells transformed with the desired DNA sequence. GDF15 variants can be expressed in mammalian cells, insects, yeast, bacteria, or other cells under the control of a suitable promoter. A cell-free translation system may also be used to produce such proteins using RNA derived from the DNA construct of the present invention.
[0262] Escherikia Colai ( Escherichia Coli ) is a prokaryotic host particularly useful for cloning the polynucleotide of the present invention. Other microbial hosts suitable for use include Bacillus subtilis ( Bacillus subtilus ), Salmonella typhimurium ( Salmonella typhimurium ), and Seratia( Serratia ), Pseudomonas ( Pseudomonas ), Streptococcus ( Streptococcus ), and Staphilococcus ( StaphylococcusVarious species of ) are included, but other microorganisms may also be used as options. In these prokaryotic hosts, expression vectors can also be prepared that typically contain expression control sequences (e.g., replication origin) that are compatible with the host cell. Additionally, any of a number of widely known promoters may be present, such as the lactose promoter system, the tryptophan (Trp) promoter system, the beta-lactamase promoter system, or a promoter system from phage lambda or T7. Typically, the promoter will control expression, optionally along with an operator sequence, and will include ribosome binding site sequences for the initiation and completion of transcription and translation.
[0263] A person skilled in the art of protein expression will recognize that when expressed in E. coli, a methionine or methionine-arginine sequence may be introduced at the N-terminus of the maturation sequence and is considered in the context of the present invention. Accordingly, unless otherwise noted, the composition of the present invention expressed in E. coli has a methionine sequence introduced at the N-terminus.
[0264] Other microorganisms, such as yeast or fungi, may also be used for expression. If necessary, Pichia pastoris ( Pichia pastoris ) Saccharomyces cerevisiae( Saccharomyces cerevisiae ), Schizocaromyces pombe ( Schizosaccharomyces pombe ), and Pikia Angusta ( Pichia angusta ) is an example of a desirable yeast host. Aspergillus niger ( Aspergillus niger ), Trichoderma reessay( Trichoderma reesei ) and Schizophyllum commune( Schizophyllum commune This is an example of a fungal host, but other fungi can also be used as options.
[0265] Mammalian tissue cell cultures may also be used to express and produce the polypeptide of the present invention. A number of suitable host cell lines capable of secreting intact variants are known in the art and include CHO cell lines, various COS cell lines, NSO cells, Syrian hamster ovary cell lines, HeLa cells, or human embryonic kidney cell lines (i.e., HEK293, HEK293EBNA).
[0266] An expression vector for mammalian cells may include expression control sequences, such as a replication origin, a promoter, an enhancer, and sites for necessary processing information, such as a ribosome binding site, an RNA splice site, a polyadenylation site, and a transcription termination factor sequence. A preferred expression control sequence is a promoter from SV40, adenovirus, bovine papillomavirus, cytomegalovirus, Rous sarcoma virus, etc. A preferred polyadenylation site includes sequences derived from SV40 and bovine growth hormone.
[0267] Depending on the type of cellular host, a vector containing the polynucleotide sequence of interest (e.g., encoding the composition and expression control sequence of the present invention) may be delivered into the host cell by other widely known methods. For example, while calcium chloride transfection is commonly used for prokaryotic cells, calcium phosphate treatment or electroporation may be used for other cellular hosts.
[0268] Various protein purification methods may be used, and such methods are known in the relevant art, for example, described in the literature [Deutscher, Methods in Enzymology 182: 83-9 (1990)] and [Scopes, Protein Purification: Principles and Practice, Springer-Verlag, NY (1982)]. The selected purification step(s) will depend, for example, on the nature of the production process used in the composition of the present invention.
[0269] The polypeptide may be prepared in a substantially pure or isolated form (e.g., without other polypeptides). The polypeptide may be present in a composition in which such polypeptide is enhanced relative to other components that may be present (e.g., other polypeptides or other host cell components). For example, a purified polypeptide may be provided so that the polypeptide is present in a composition substantially free of other expressed proteins, for example, less than 90%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the composition consists of other expressed proteins.
[0270] Synthesis of fatty acid moiety
[0271] Reaction Scheme 1 describes the synthesis of a fatty acid moiety of chemical formula A2.
[0272] <Reaction Equation 1>
[0273]
[0274] [During the meal, P 1 and P 2 is a carboxylic acid protecting group, for example, methyl, ethyl, tert-butyl, methoxybenzyl, benzyl, benzyloxy, methoxymethyl, methylthiomethyl, tetrahydropyranyl, phenacyl, N-phthalimide, cinnamyl, triphenylmethyl, 9-anthrylmethyl, piperonyl, trimethylsilyl, t-butyldimethylsilyl or 2-alkyl 1,3-oxazoline; LG is a leaving group, e.g., halo (e.g., Br, Cl, I) or trifluoromethanesulfonyloxy, and R 4 and p are as defined in Embodiment 1].
[0275] Protected malonic acid ( 1A ) in the presence of a base (e.g., sodium hydride, potassium or cesium carbonate, sodium hydroxide, lithium diisopropylamide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, lithium tetramethylpiperidide, 1,8-diazacycloundec-7-ene, N,N-diisopropylethylamine, or 2,6-dit-butylfuthridine) and an alkylating agent (e.g., DMF, THF, or dimethylacetamide) 1B When alkylated with ), the protected fatty acid moiety ( 1C ) is generated. R 4 If α is OH or CO2H, protection of these functional groups may be required prior to the alkylation step. Protecting groups for hydroxyl are known in the relevant art, for example 1. Ethers such as methyl ether, methoxymethyl ether (MOM), tetrahydropyranyl ether (THP), t - Butyl ether, allyl ether, benzyl ether, t-butyldimethylsilyl ether, t-butyldiphenylsilyl ether, tribenzylsilyl ether, isopropyldimethylsilyl ether, triphenylmethyl ether, nitrobenzyl ether, 2. Esters and carbonates, such as acetic acid ester, formate ester, trichloroacetate ester, phenoxyacetate ester, pivaloate ester, benzoate ester, methyl carbonate, benzyl carbonate, allyl carbonate, nitrate ester, adamanoate ester, nitrophenyl carbonate.
[0276] A fatty acid moiety of formula A2 is obtained by deprotection using a suitable deprotection method. An intermediate ( 1C Standard methods can be applied for the hydrolysis of ). P 1 or P 2 If g is benzyl or methoxybenzyl, the preferred deprotection method is hydrogenation in the presence of a catalyst such as, but not limited to, palladium-carbon.
[0277] Reaction Equation 2 is R 1 This is the chemical formula A, C(O)2H. 1 Illuminates the synthesis of the fatty acid moiety.
[0278] <Reaction Equation 2>
[0279]
[0280] [During the meal, P 1 and P 2 , LG is as defined above, and R 2 , R 3 , n and m are as defined in Embodiment 1].
[0281] Protected malonic acid ( 1A alkylating agent ( 2A ) and ( 2C After two consecutive alkylation steps to ) (the order thereof may be reversed), deprotection is carried out using a suitable method as described in Reaction Scheme 1 above. R 2 and R 3 In the case of this OH or CO2H, protection of these functional groups may be required prior to the alkylation step.
[0282] Chemical formula A where R1 is CO2H 1 R by decarboxylation of the corresponding fatty acid moiety 1 This is the chemical formula A, which is H1 A fatty acid moiety can be prepared. Decarboxylation under decarboxylation conditions, such as basic conditions (e.g., ammonium hydroxide), is widely known in the relevant technical field.
[0283] Synthesis of biomolecular-linker constructs
[0284] <Reaction Equation 3>
[0285]
[0286] [In the formula, B is a biomolecule or a modified form thereof, and Z 1 A C1-C12 alkylene chain in which the alkylene chain is arbitrarily substituted with an oxo (=O) and one or more carbons are replaced with O or NH. 20 It is an alkylene linker; C1 is a monocyclic, bicyclic, or tricyclic carbon-cyclic or heterocyclic ring system in which C1 is optionally substituted with fluorine.
[0287] Cycloalkyne using standard amide coupling methods ( 3B ) biomolecules ( 3A It is attached to the amino residue of ) (e.g., the N-terminal amino functional group or the side chain of lysine). Intermediate ( 3B After converting ) to its active form [e.g., converting to the corresponding pyrrolidine-2,5-dione (using standard N-hydroxysuccinimide chemistry), or converting acid (3B) using a reagent such as triphosgene, carbonyldiimidazole, 4-nitrophenyl chloroformate, or disuccinimidyl carbonate, or acid ( 3B Convert ) to the corresponding acid halide using a reagent such as thionyl chloride or oxalyl chloride, or acid ( 3B[converting ) into the corresponding mixed anhydride using reagents such as ClC(O)O-isobutyl, 2,4,6-trichlorobenzoyl chloride, or propylphosphonic anhydride cyclic trimer (T3P)], oxazolidine-2,5-dione, acid halide, or mixed anhydride into a base, such as a tertiary amine (e.g., triethylamine or N,N - Biomolecules in the presence or absence of diisopropyl ethylamine) or K2CO3 ( 3A Known coupling methods, including but not limited to reacting with ), may be applied. Alternatively, dicyclohexylcarbodiimide ( DCC ), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), or benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) using peptide condensation reagents including, but not limited to, biomolecules 3A Gasan 3B It can be coupled with. Preferably, a cycloalkyne / acid intermediate ( 3B ) is converted into its active form using NHS chemistry and then reacts with the amino functional group on the biomolecule.
[0288] Selective acylation of the N-terminal amino functional group of a biomolecule has been developed and reported in co-filed U.S. applications No. 62 / 015,858 (Agent Case PAT056275-US-PSP) and 62 / 082,337 (Agent Case No. PAT056275-US-PSP02).
[0289] Selective acylation is an NHS-activated cyclooctine analog (( 3BIt involves the reaction of a biomolecule whose N-terminus is modified to include a histidine amino acid adjacent to the N-terminal amino acid, with an NHS derivative of ). Due to the presence of the neighbor effect of the histidine amino acid, this reaction is highly selective for the N-terminal amino functional group when performed at pH 4.
[0290] Synthesis of fatty acid residue linker structures
[0291] Fatty acid-linker constructs for click chemistry
[0292] Reaction scheme 4 describes the synthesis of a fatty acid-PEG linker construct having a terminal azido functional group.
[0293] <Reaction Equation 4>
[0294]
[0295] [In the formula, y is 0 to 34, FA is a fatty acid moiety as described in Formula A1, A2 or A3 attached to a PEG linker through one of its carboxylic acid functional groups, and FA is the following formula
[0296]
[0297] has
[0298] fatty acid moiety through amide coupling reaction ( 4B ) is a PEG-containing linker ( 4A It is attached to ). The known coupling method was described in detail above in Reaction Scheme 3. Preferably, the acid functional group on the fatty acid moiety is activated using NHS chemistry.
[0299] R 1 If this is CO2H and R2, R3, and R4 are CO2H or OH, it may be necessary to introduce a protecting group before the coupling reaction to control the reactive site. Protecting groups for the carboxylic acid and hydroxyl group were described above in Reaction Scheme 1. Alternatively, selective activation of the carboxylic acid can be achieved using NHS chemistry.
[0300] fatty acid linker for direct attachment to biomolecules of interest
[0301] Reaction scheme 5 describes the synthesis of a fatty acid-PEG linker construct having a terminal CO2H functional group.
[0302] <Reaction Equation 5>
[0303]
[0304] [In the equation, FA is as defined in reaction equation 4 above, and y is 0 to 34].
[0305] Using the amide coupling described above, fatty acids ( 4B ) this PEG-containing linker ( 5A It can be attached to ).
[0306] Fatty acid-linker constructs for attachment to biomolecules of interest using transglutaminase enzymes
[0307] Reaction Scheme 5A describes the preparation of a fatty acid-linker construct containing glutamate amino acids that allows site-selective modification of lysine when using the transglutaminase enzyme.
[0308] <Reaction Equation 5B>
[0309]
[0310] [In the formula, y and FA are as previously defined]. Such a construct allows for site-selective modification of the amino group on the side chain of lysine. Such site-selective transglutaminase modification of a protein is described in U.S. Application No. 61 / 845,273 (Agent Case No. PAT055641-US-PSP), filed July 11, 2013.
[0311] Synthesis of the conjugate of the present invention
[0312] Joints using click chemistry
[0313] <Reaction Equation 6>
[0314]
[0315] [In the formula, B is the biomolecule of interest or a modified form thereof (e.g., a mutant or a biomolecule containing a histidine tag), and y, C1, Z1, FA and y are defined above].
[0316] Cycloalkyne constructs ( 3C fatty acid-linker constructs in ) 4C A fusion of the terminal azide with the ) proceeds (commonly known as click chemistry). An example of click chemistry is described in U.S. 2009 / 0068738.
[0317] Joining through direct attachment using coupling conditions
[0318] <Reaction Equation 7>
[0319]
[0320] [In the formula, B is the biomolecule of interest or a modified form thereof (e.g., a mutant and / or a biomolecule containing a histidine tag), and a fatty acid-linker construct is attached to the N-terminus of the biomolecule].
[0321] Fatty acid-linker constructs using the standard amide coupling method ( 5B ) biomolecules ( 3A It is attached to the amino residue of (e.g., the N-terminal amino functional group or the side chain of lysine). A known coupling method is described in detail above in Reaction Scheme 3. Preferably, the acid functional group on the fatty acid-linker construct is activated using NHS chemistry.
[0322] Selective acylation of the N-terminal amino functional group of biomolecules has been developed and reported in co-filed U.S. applications No. 62 / 015,858 (Agent Case No. PAT056275-US-PSP) and 62 / 082,337 (Agent Case No. PAT056275-US-PSP02). Selective acylation is NHS-activated compounds (( 5BIt involves the reaction of a biomolecule whose N-terminus is modified to include a histidine amino acid adjacent to the N-terminal amino acid, with an NHS derivative of ). Due to the presence of the neighbor effect of the histidine amino acid, this reaction is highly selective for the N-terminal amino functional group when performed at pH 4.
[0323] Conjugation using the transglutaminase enzyme
[0324] <Reaction Equation 7B>
[0325]
[0326] Selective modification of the lysine side chain of a biomolecule can be achieved using a transglutaminase enzyme. Such modification was reported in U.S. Application No. 61 / 845,273 filed on July 11, 2013 (Agent Case No. PAT055641-US-PSP) or WO 2015 / 006728 (Example 25 of these applications).
[0327] Pharmaceutical composition
[0328] The conjugate of the present invention may be administered in various ways, including subcutaneously, intramuscularly, intravenously, intraperitoneally, by inhalation, intranasally, or orally. A particularly preferred embodiment of the present invention uses continuous intravenous administration of the conjugate of the present invention, or its amide, ester, or salt. The conjugate of the present invention may be administered over a period of time as a bolus or as a continuous infusion. An implantable pump may be used. In certain embodiments of the present invention, intermittent or continuous administration of the conjugate is continued for one day to several days (e.g., two to three days or more), or for a longer period, e.g., several weeks, several months, or several years. In some embodiments, intermittent or continuous administration of the conjugate is provided for at least about three days, preferably for at least about six days. In other embodiments, intermittent or continuous administration of the conjugate is provided for at least about one week. In other embodiments, intermittent or continuous administration of the conjugate is provided for at least about two weeks. It may be desirable to maintain the average plasma conjugate concentration above a specific threshold during administration or between multiple dose administrations. The desirable concentration may be determined, for example, based on the subject's physiological status, disease severity, etc. Such desirable value(s) can be confirmed by performing standard clinical trials. Alternatively, the peptide or its conjugate may be delivered orally via the FcRn mechanism. (Nat Rev Immunol. 7(9), 715-25, 2007; Nat Commun. 3;3:610, 2012, Am J Physiol Gastrointest Liver Physiol 304: G262-G270, 2013).
[0329] In another aspect, the present invention provides a pharmaceutical composition comprising a conjugate of the present invention or an amide, ester, or salt thereof, and one or more pharmaceutically acceptable carriers. The pharmaceutical composition may be formulated for specific routes of administration, such as oral administration, subcutaneous administration, parenteral administration, and rectal administration. Additionally, the pharmaceutical composition of the present invention may be prepared in a solid form (including, but not limited to, capsules, tablets, pills, granules, lyophilized products, powders, or suppositories) or in a liquid form (including, but not limited to, solutions, suspensions, or emulsions). The pharmaceutical composition may be applied to conventional pharmaceutical processes, such as preservative production and sterilization, and / or may contain conventional inert diluents, catechins, enteric agents, lubricants, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, and buffers.
[0330] Pharmaceutical compositions suitable for injectable use typically comprise a sterile aqueous solution (if water-soluble) or dispersion, and a sterile powder for the immediate preparation of the sterile injectable solution or dispersion.
[0331] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid to the extent that easy syringability exists. A preferred pharmaceutical formulation must be stable under production and storage conditions and preserved against the action of microorganisms, such as bacteria and fungi. Generally, the carriers involved may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Suitable fluidity may be maintained, for example, by the use of a coating agent such as lecithin, maintaining the required particle size in the case of a dispersion, and the use of a surfactant. Prevention of microbial activity can be achieved by various antimicrobial and antifungal agents, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is desirable to include isotonic agents in the composition, e.g., sugars, polyalcohols such as mannitol, amino acids, sorbitol, sodium chloride. Long-term absorption of the injectable composition may be achieved by including absorption-delaying agents, e.g., aluminum monostearate and gelatin, in the composition. In some embodiments, multifunctional excipients, e.g., recombinant albumin, may be incorporated into the formulation process to facilitate the stabilization of the conjugate product from degradation or aggregation, to improve solubility, and to assist in the administration and release of the active ingredient. (BioPharm International, 2012, Vol 23, Issue 3, pp 40-44).
[0332] A specific injectable composition is an aqueous isotonic solution or suspension, and a suppository is advantageously prepared from a lipid emulsion or suspension. The composition may be sterile and / or may contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solution promoters, osmotic pressure regulating salts and / or buffers. Additionally, it may also contain other substances of therapeutic usefulness. The composition is prepared by conventional mixing, granulation, or coating methods, respectively, and contains about 0.1-75% or about 1-50% of an active ingredient.
[0333] A sterile injectable solution can be prepared by incorporating the required amount of the active compound, if necessary, together with one or a combination thereof of the components listed above, into a suitable solvent and then sterile filtering. Generally, a dispersion is prepared by incorporating the active compound into a sterile vehicle containing a base dispersion medium and other necessary components from those listed above. For a sterile powder for the preparation of a sterile injectable solution, a preferred preparation method is vacuum drying and freeze-drying, in which a powder of the active component + any additional desired component is obtained from a previously sterile-filtered solution.
[0334] Oral compositions generally comprise an inert diluent or an edible carrier. For therapeutic oral administration, the active compound may be incorporated with an excipient and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binders and / or adjuvant substances may be included as part of the composition. Tablets, pills, capsules, troches, etc. may contain any of the following components or compounds of similar properties: a binder, e.g., microcrystalline cellulose, tragacanth gum, or gelatin; an excipient, e.g., starch or lactose; a disintegrant, e.g., alginate, Primogel, or corn starch; a lubricant, e.g., magnesium stearate or Sterotes; a lubricant, e.g., colloidal silicon dioxide; a sweetener, e.g., sucrose or saccharin; or a flavoring agent, e.g., peppermint, methyl salicylate, or orange flavoring. Advantageously, an agent to improve stability in the gastrointestinal tract and / or enhance absorption may be incorporated into the oral formulation.
[0335] In the case of administration by inhalation, the therapeutic agent of the present invention is preferably delivered in the form of an aerosol spray from a pressurized vessel or dispenser containing a suitable propellant, for example, a gas such as carbon dioxide, or from a nebulizer. It is noted that the lungs provide a large surface area for systemic delivery of the therapeutic agent.
[0336] For example, the agent may be encapsulated within polymeric microparticles, such as those described in U.S. Publication 20040096403, or by associating with any of the various other drug delivery vehicles known in the art. In another embodiment of the present invention, the agent is delivered by associating with a charged lipid, for example, as described in U.S. Publication 20040062718. It should be noted that the latter system has been used for the administration of insulin, a therapeutic polypeptide, thereby demonstrating the utility of such a system for the administration of peptide agents.
[0337] Systemic administration may be by transmucosal or transdermal means.
[0338] A suitable composition for transdermal application comprises an effective amount of the conjugate of the present invention together with a suitable carrier. A carrier suitable for transdermal delivery comprises an absorbable pharmacologically acceptable solvent that assists in passing through the host skin. For example, a transdermal device is in the form of a bandage comprising a backing member, a reservoir containing a compound (optional together with a carrier), optionally a rate-controlling barrier for delivering the compound to the host skin at a predetermined, controlled rate over a long period, and means for securing the device to the skin.
[0339] Compositions suitable for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels, or spray formulations (e.g., for delivery by aerosols, etc.). Such topical delivery systems will be particularly suitable for skin application. Therefore, they are particularly suitable for use in topical formulations (including cosmetic formulations) that are widely known in the relevant art. They may contain solubilizers, stabilizers, enteric enhancers, buffers, and preservatives.
[0340] In certain embodiments, the pharmaceutical composition is intended for subcutaneous administration. Suitable formulation components and methods for the subcutaneous administration of polypeptide therapeutics (e.g., antibodies, fusion proteins, etc.) are known in the art. For example, refer to U.S. Patent Application Publication No. 2011 / 0044977 and U.S. Patent No. 8,465,739 and U.S. Patent No. 8,476,239. Typically, the pharmaceutical composition for subcutaneous administration contains a suitable stabilizer (e.g., amino acids, e.g., methionine, and / or sugars, e.g., sucrose), a buffering agent, and an enterogenic agent.
[0341] Topical application as used herein also involves inhalation or intranasal application. This can be conveniently delivered in the form of dry powder from a dry powder inhaler (alone, as a mixture, e.g., as a dry blend with lactose, or as mixed component particles, e.g., as mixed component particles with phospholipids), or in the form of an aerosol spray presentation from a pressurized container, pump, spray, atomizer, or nebulizer with or without a suitable propellant.
[0342] The present invention further provides a pharmaceutical composition and a dosage form comprising one or more agents that reduce the rate at which the compound of the present invention as an active ingredient is degraded. Such agents, referred herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, and recombinant albumin.
[0343] As used herein, the term “pharmaceutical acceptable salt” refers to a salt that preserves the biological efficacy and properties of the conjugate of the present invention and is typically undesirable biologically or otherwise. In many cases, the conjugate of the present invention may form an acid and / or base salt by the presence of an amino and / or carboxyl group or a similar group.
[0344] Pharmaceutically acceptable acid addition salts may be formed with inorganic and organic acids, for example, acetate, aspartate, benzoate, besylate, bromide / hydrobromide, bicarbonate / carbononate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlortheophilonate, citrate, ethanedisulfonate, fumarate, gluteptate, gluconate, glucuronate, hypochlorite, hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl sulfate, maleate, maleate, malonate, mandelate, mesylate, methyl sulfate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, These are phosphate / hydrogen phosphate / dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate, and trifluoroacetate salts.
[0345] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, phosphoric acid, etc. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, etc. Pharmaceutically acceptable base addition salts may be formed with inorganic and organic bases.
[0346] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from groups I through XII of the periodic table. In certain embodiments, salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper, and particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.
[0347] Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, etc. Certain organic amines include isopropylamine, benzathine, cholinenate, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.
[0348] Pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, which is a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting these compounds in the form of free acids with a stoichiometric amount of a suitable base (e.g., Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, etc.), or by reacting these compounds in the form of free bases with a stoichiometric amount of a suitable acid. Typically, such reactions are carried out in water, in organic solvents, or in a mixture of both. Generally, where feasible, the use of non-aqueous media such as ethers, ethyl acetate, ethanol, isopropanol, or acetonitrile is preferred. For a list of additional suitable salts, see, for example, the literature ["Remington's Pharmaceutical Sciences" , This can be confirmed in [20th ed., Mack Publishing Company, Easton, Pa., (1985)]; and ["Handbook of Pharmaceutical Salts: Properties, Selection, and Use", Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002)].
[0349] The term “pharmaceutical acceptable carrier” as used herein includes any solvent, dispersion medium, coating agent, surfactant, antioxidant, preservative (e.g., antimicrobial, antifungal), isotonic agent, absorption retardant, salt, preservative, drug, drug stabilizer, binder, excipient, disintegrant, lubricant, sweetener, flavoring agent, dye, multifunctional excipient such as recombinant albumin, etc., and combinations thereof as known to a person skilled in the art (see, for example, [Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329]). Unless any ordinary carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is considered.
[0350] Method of the present invention
[0351] Various pathological and physiological conditions, most notably pregnancy (Moore AG 2000. J Clin Endocrinol Metab 85: 4781-4788), β-thalassemia (Tanno T 2007, Nat Med 13:1096-101) (Zimmermann MB, 2008 Am J Clin Nutr 88:1026-31), and congenital dysplastic anemia (Tamary H 2008, Blood. It has been reported that blood flow levels of GDF15 are elevated in 112:5241-4. GDF15 has also been associated with various biological activities in literature reports. Studies in GDF15 knockout and transgenic mice suggest that GDF15 may be protective against ischemic / reperfusion- or overload-induced cardiac injury (Kempf T, 2006, Circ Res.98:351-60) (Xu J , 2006, Circ Res. 98:342-50), and may be protective against age-associated motor and sensory neuron loss (Strelau J, 2009, J Neurosci. 29 : 13640-8), may be mildly protective against metabolic acidosis in the kidneys and may cause cachexia in cancer patients (Johnen H 2007 Nat Med. This suggested (11: 1333-40). Numerous groups have also investigated the role of GDF15 in cell apoptosis and proliferation, reporting controversial results using different cell culture and xenograft models. Studies in transgenic mice indicated that GDF15 is protective against carcinogens or Ape mutation-induced neoplasms in the intestines and lungs (Baek SJ 2006, Gastroenterology. 131: 1553-60; Cekanova M 2009, Cancer Prev Res 2:450-8).
[0352] GDF15 has also been reported to play a role in inflammation, cancer, and metabolism (Samule Breit et al. Growth Factors, October 2011; 29(5): 187-195). GDF15 has additionally been implicated in physiological appetite and body weight regulation (Vicky Wang-Wei Tsai et al. Public Library of Science: PLOS ONE 2013, Vol. 8, Issue 2, e55174).
[0353] The present invention provides a method for treating or preventing metabolic disorders or diseases, diabetes mellitus, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders in subjects requiring treatment or prevention of such disorders, comprising administering to subjects a therapeutically effective amount of the conjugate of the present invention, which is a biomolecule human growth differentiation factor 15 (GDF15), a homolog, variant, mutant, fragment and other modified form thereof, or an amide, ester or salt thereof, or a mixture of the conjugate thereof.
[0354] This method may have advantageous effects, such as reducing the frequency of administration.
[0355] Accordingly, as a further embodiment, the present invention provides a use for the treatment of metabolic disorders or diseases, type 2 diabetes, obesity, pancreatitis, dyslipidemia, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, complications of diabetes (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders, with the biomolecule being human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments and other modified forms as described herein, or its amides, esters, or pharmaceutically acceptable salts or mixtures of conjugates as described herein.
[0356] Accordingly, as a further embodiment, the present invention provides the use of a conjugate or its amide, ester, or pharmaceutically acceptable salt, or a mixture of conjugates, in therapy.
[0357] The effective amount of the pharmaceutical composition or combination of the present invention to be used therapeutically will depend, for example, on the therapeutic context and purpose. A person skilled in the art will understand that the appropriate dosage level for treatment will, in part, depend on the molecule being delivered, the indication for which the conjugate is used, the route of administration, and the size (body weight, body surface area, or organ size) and condition (age and general health) of the patient. Accordingly, a clinician may titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect. Typical dosages may range from about 0.1 μg / kg to about 100 mg / kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1 μg / kg to about 100 mg / kg; or from 1 μg / kg to about 100 mg / kg. In a further aspect of these embodiments, the dosage may range from 5 μg / kg to 25 μg / kg. In a further aspect of this embodiment, the dosage may be in the range of 10 μg / kg to 20 μg / kg.
[0358] The frequency of administration will depend on the pharmacokinetic parameters of the dual-function protein within the formulation used. Typically, the clinician will administer the composition until a dose is reached that achieves the desired effect. Thus, the composition may be administered as a single dose, over time as two or more doses (which may or may not contain the same amount of the desired molecule), or as a continuous infusion via an implantable device or catheter. Further refinement of the appropriate dose is routinely performed by a person skilled in the art and falls within their scope of routine practice. The appropriate dose can be determined through the use of appropriate dose-response data.
[0359] The terms “therapeutic effective dose” and “therapeutic effective amount” as used herein mean an amount of conjugate that elicits a biological or pharmacological response in a tissue system, animal, or human being sought by a researcher, physician, or other clinician, including the alleviation or improvement of symptoms of the disease or disorder being treated, that is, an amount of GDF15 (or GDF15 mutant) polypeptide that supports one or more desired biological or pharmacological responses at an observable level, e.g., lowering blood glucose, triglyceride, or cholesterol levels; reducing body weight; reducing food intake; or improving glucose tolerance, energy expenditure, or insulin sensitivity.
[0360] The terms "patient" or "subject" are used interchangeably to refer to humans or non-human animals (e.g., mammals).
[0361] In one embodiment, the terms “treat,” “treating,” or “treatment” of any disease or disorder as used herein mean to improve the disease or disorder (i.e., to slow, stop, or reduce the development of at least one of the disease or its clinical symptoms). In another embodiment, “treat,” “treating,” or “treatment” refers to alleviating or improving at least one physical parameter, including one that is not perceptible to the patient. In yet another embodiment, “treat,” “treating,” or “treatment” refers to adjusting the disease or disorder physically (e.g., stabilization of perceptible symptoms), physiologically (e.g., stabilization of physical parameters), or both. Therefore, treatment involves suppressing the active disease (i.e., halting the development or further development of the disease, disorder, or pathology, or associated clinical symptoms) (e.g., in the case of GDF15 conjugates, to reduce body weight, to reduce food intake, to reduce insulin and / or glucose levels in the bloodstream, to increase glucose tolerance to minimize fluctuations in glucose levels, and / or to protect against diseases caused by the disruption of glucose homeostasis).
[0362] In another embodiment, "to treat," "treating," or "treatment" refers to preventing or delaying the onset, development, or progression of a disease or disorder.
[0363] The term "in need of treatment," as used herein, refers to the judgment made by a physician or other administrator that a subject requires treatment or that treatment would be beneficial to the subject. Such judgment is based on various factors falling within the domain of the physician's or administrator's professional knowledge.
[0364] Terms such as "prevent," "preventing," and "prevention" generally refer to a course of action (e.g., administering the conjugate of the present invention or a pharmaceutical composition containing the conjugate) initiated in a manner that temporarily or permanently prevents, inhibits, suppresses, reduces, or delays the onset of the risk of the subject developing the disease, disorder, or condition (e.g., prior to the onset of the disease, disorder, condition, or its symptoms) in the context of a subject susceptible to a specific disease, disorder, or condition (e.g., prior to the onset of the disease, disorder, condition, or its symptoms). In certain cases, these terms also refer to slowing the progression of the disease, disorder, or condition or inhibiting its progression to a harmful or otherwise undesirable state.
[0365] The term “metabolic disease or disorder” refers to an associated set of characteristics including, but not limited to, hyperinsulinemia, abnormal glucose tolerance, obesity, fat redistribution to the abdominal or upper body compartment, hypertension, high triglycerides, low high-density lipoprotein (HDL) cholesterol, and dyslipidemia characterized by high small, dense low-density lipoprotein (LDL) particles. Subjects with metabolic disease or disorder are at risk of developing type 2 diabetes and, for example, atherosclerosis.
[0366] The phrase “glucose metabolism disorder” includes any disorder characterized by clinical symptoms or a combination of clinical symptoms associated with elevated glucose levels and / or elevated insulin levels in a subject compared to a healthy subject. Elevated glucose and / or insulin levels may be specified in the following diseases, disorders, and conditions: in particular, hyperglycemia, type II diabetes, gestational diabetes, type I diabetes, insulin resistance, impaired glucose tolerance, hyperinsulinemia, impaired glucose metabolism, prediabetes, metabolic disorders (metabolic diseases or disorders also referred to as syndrome X), and obesity. The GDF15 conjugate of the present disclosure and compositions thereof may be used, for example, to achieve and / or maintain glucose homeostasis, for example, to reduce glucose levels in the bloodstream, and / or to reduce insulin levels to a range found in a healthy subject.
[0367] The term "insulin resistance," as used herein, refers to a pathological condition in which normal amounts of insulin are unable to produce a normal physiological or molecular response. In some cases, hyper-physiological amounts of insulin, whether endogenously produced or exogenously administered, can overcome insulin resistance wholly or partially and produce a biological response.
[0368] The phrase “glucose tolerance” as used herein refers to a subject’s ability to control plasma glucose and / or plasma insulin levels when glucose intake fluctuates. For example, glucose tolerance includes a subject’s ability to reduce plasma glucose levels back to the level determined prior to glucose intake within about 120 minutes.
[0369] The terms "glucose intolerance" or "impaired glucose tolerance (IGT)" refer to a prediabetic dysglycemia associated with an increased risk of cardiovascular pathology. The prediabetic condition prevents the subject from efficiently transporting glucose into cells to utilize it as an efficient fuel source, leading to elevated glucose levels in the blood and some degree of insulin resistance.
[0370] The term "Type 2 diabetes" refers to a pathological condition characterized by excessive glucose production, and as a result of insufficient glucose elimination and the pancreas's inability to produce sufficient insulin, circulating glucose levels remain excessively high.
[0371] The term "hyperglycemia" as used herein refers to a pathological condition in which an elevated amount of glucose circulates in the blood plasma of a subject compared to a healthy individual. Hyperglycemia may be diagnosed using methods known in the relevant art, including the measurement of fasting blood glucose levels as described herein.
[0372] The term "hypoglycemia," also referred to as low blood sugar, occurs when blood glucose levels drop too low to provide sufficient energy for physical activity.
[0373] The term "hyperinsulinemia," as used herein, refers to a condition in which circulating insulin levels are elevated when blood glucose levels are concomitantly elevated or normal. Hyperinsulinemia can be caused by dyslipidemia, such as high triglycerides, high cholesterol, high low-density lipoprotein (LDL), and low high-density lipoprotein (HDL); high uric acid levels; polycystic ovary syndrome; and insulin resistance associated with type II diabetes and obesity. Hyperinsulinemia can be diagnosed when plasma insulin levels are higher than approximately 2 pU / mL.
[0374] The term "pancreatitis" refers to inflammation of the pancreas.
[0375] The term "dyslipidemia" refers to a disorder of lipoprotein metabolism involving the overproduction or deficiency of lipoproteins. Dyslipidemia may be identified by elevated levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides in the blood, and decreased levels of high-density lipoprotein (HDL) cholesterol.
[0376] The term "fatty liver disease (FLD)," also known as fatty liver, refers to a pathological condition in which large vacuoles of triglyceride fat accumulate in liver cells through a process of steatosis (i.e., the abnormal stagnation of lipids within cells). Despite various causes, fatty liver can be considered a single disease occurring globally in people who consume excessive alcohol and are obese (with or without insulin resistance). When this process of lipid metabolism is disrupted, fat can accumulate in the liver in excessive amounts, leading to fatty liver. This fat accumulation may be accompanied by progressive inflammation of the liver (hepatitis), referred to as steatohepatitis. Considering the contribution of alcohol, fatty liver may be named alcoholic steatosis or non-alcoholic fatty liver disease (NAFLD), and the more severe forms, alcoholic steatohepatitis and non-alcoholic steatohepatitis (NASH).
[0377] The term "steatitis" refers to a type of liver disease characterized by fatty changes in hepatocytes accompanied by intralobular inflammation and fibrosis. When not associated with excessive alcohol consumption, it is referred to as non-alcoholic steatohepatitis (NASH).
[0378] The term "progressive liver disease" refers to liver disease caused by a wide range of liver pathologies that progress from a relatively benign state, such as hepatic steatosis, to a more severe state, including hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. PNPLA3 has been particularly associated with progressive liver diseases, such as NAFLD / NASH, AFLD / ASH, viral hepatitis, Wilson's disease, hereditary hemochromatosis, and primary sclerosing cholangitis (Paola Dongiovanni et al. World Journal of Gastroenterology, 2013, 19(41), 6969-6978).
[0379] In the context of human subjects, the term "obesity" may be defined as an adult with a body mass index (BMI) of 30 or higher (Centers for Disease Control and Prevention). "Metabolic syndrome" may be defined as a group of risk factors that increase the risk of heart disease and other conditions, such as diabetes and stroke. These risk factors include: high blood glucose—at least 110 mg / deciliter (mg / dl) after fasting; high triglycerides—at least 150 mg / dL in the bloodstream; low HDL—less than 40 mg / dl; and blood pressure of 130 / 85 mmHg or higher (World Health Organization).
[0380] The term "cardiovascular disease" refers to a disease related to the heart or blood vessels.
[0381] The term "atherosclerosis" refers to a vascular disease characterized by irregularly distributed lipid deposits within the intima of large and medium-sized arteries, which sometimes leads to narrowing of the arterial lumen and eventually progresses to fibrosis and calcification. The lesions are generally localized, slow, and intermittent. Restriction of blood flow is the cause of most clinical signs, with varying distribution and severity of the lesions.
[0382] The term "coronary heart disease," also known as coronary artery disease, refers to the narrowing of small blood vessels that supply blood and oxygen to the heart.
[0383] "Diabetes complications" are problems caused by high blood glucose levels, along with other bodily functions such as the kidneys, nerves (neuropathy), feet (foot ulcers and poor blood circulation), and eyes (e.g., retinopathy). Diabetes also increases the risk of heart disease and bone and joint disorders. Other long-term complications of diabetes include skin problems, digestive issues, sexual dysfunction, and dental and gum problems.
[0384] As used herein, the phrase “weight disorder” refers to a pathological condition associated with excessive body weight and / or increased appetite. Various parameters, including the subject’s age, height, sex, and health status, are used to determine whether the subject is overweight compared to a healthy reference individual. For example, a subject may be considered overweight or obese based on an assessment of the subject’s Body Mass Index (BMI), which is calculated by dividing the subject’s body weight (in kilograms) by the square of the subject’s height (in meters). Adults with a BMI in the range of -18.5 to -24.9 kg / m² are considered to be of normal weight, adults with a BMI of -25 to -29.9 kg / m² are considered overweight (pre-obese), and adults with a BMI of -30 kg / m² or higher are considered obese. Increased appetite frequently contributes to excessive body weight. There are several pathological conditions associated with increased appetite, including, for example, nocturnal eating syndrome, which is characterized by a decrease in appetite in the morning and an increase in appetite in the evening (often associated with insomnia) but may be associated with damage to the hypothalamus.
[0385] Unless otherwise indicated herein or otherwise clearly contradictory in context, all methods described herein may be performed in any appropriate order. Any use of any examples provided herein, or exemplary expressions (e.g., “e.g.,”) is intended only to better illustrate the invention and does not limit the scope of the invention as otherwise claimed.
[0386] The activity and plasma stability of the conjugate according to the present invention can be evaluated by the following method described below.
[0387] Test methods and data
[0388] The activity and plasma stability of the GDF15 conjugates of Examples 1 and 19B according to the present invention can be evaluated by the following in vitro and in vivo methods described below.
[0389] Animal Research Methods
[0390] All animal studies described in this document were approved by the Novartis Institutes for Biomedical Research Animal Care and Use Committee in accordance with local and federal regulations and guidelines. Diet-induced obese male mice (C57BL / 6NTac) were purchased from Taconic and fed a 60% fat diet (Research Diets D12492i) continuously from 6 weeks of age. Upon arrival, mice were housed at a rate of one animal per cage under a 12h:12h inverted light-dark cycle. All animals were acclimatized for at least one week prior to random use. Typically, mice aged 3–4 months were studied. One day prior to the study, mice were randomized based on body weight to ensure similar mean body weights for each group. On the day of the study, mice were placed in new cages, and old food was removed. Approximately 1 hour later and immediately before the dark cycle, mice were administered a single subcutaneous dose of vehicle (30 mM sodium acetate, pH 4) or lipid-conjugated GDF15 analog (0.5 mg / kg). After all injections were completed, mice were weighed again and returned to a prescribed amount of food (~50 g per mouse). Food intake and body weight were measured at the time points indicated in the figure over a course of ~2 weeks. In surrogate animals treated as described above, plasma was collected at the indicated time points, and GDF15 levels were measured by ELISA according to the manufacturer's instructions (Quantikine Human GDF15 Immunoassay of R&D Systems; DGD150).
[0391] DIO mouse single 0.5 mg / kg subcutaneous dose
[0392] The activity and half-life of the conjugate of the present invention were tested using the assay described above.
[0393]
[0394]
[0395] The data in Table 1 demonstrate that the conjugate of the present invention has a significantly longer duration of action compared to non-conjugated hGDF15 and / or PEGylated hGDF15.
[0396] Efficacy of GDF15-conjugate in dogs fed the diet: GDF15-fatty acid conjugate
[0397] Study Objective: Evaluation of the effects of subcutaneous administration of 0.05 mg / kg of the GDF15-fatty acid moiety conjugate or vehicle control according to the present invention on food intake in an acute environment (6 hours) and food intake over a 96-hour period in Beagle dogs. Plasma samples were collected at various time points over a 14-day post-dose period to evaluate the PK profile of these compounds. Body weight was measured during the study.
[0398] Table 2
[0399] Animals: Baseline weight and treatment
[0400]
[0401] Administration procedure: Vehicle or GDF15 was administered after baseline body weight and blood sample collection. The GDF15-fatty acid moiety conjugate was supplied as a 0.97 mg / ml solution and administered by subcutaneous injection at 0.05 mg / kg without dilution. An equivalent amount of 30 mmol / l sodium acetate pH 4 vehicle (52 µl / kg) was administered to vehicle animals by subcutaneous injection.
[0402] Blood Collection: Blood samples were collected from the radial cutaneous vein or jugular vein (3 ml collected in a tube containing EDTA and the protease inhibitors Diprotin A and Aprotinin), and placed on ice until centrifuged at 3,000 rpm for 20 minutes at 4°C. Plasma was aliquoted and stored at -70°C until analysis. Samples were collected at the following time points: 0, 6.75, 24.75, 48.75, 72.75, and 96.75 hours. Additional samples were collected on Day 7, Day 10, and Day 14.
[0403] Measurement of food intake: Measurement of free food intake was initiated 45 minutes after drug administration. This measurement of food intake consists of two phases: acute measurement (0–6 hours) and subchronic measurement (0–96 hours).
[0404] During hours 0–2, the dogs were given 500 g of regular food (Hill's J / D food). At 2 hours, the remaining food was removed, weighed, and another 500 g of food was given for the period of 2–4 hours. At 4 hours, the remaining food was removed, weighed, and another 300 g of food was given for the period of 4–6 hours. At 6 hours, the remaining food was removed and weighed. Blood samples were collected at this point in time (6.75 hours). Afterwards, the dogs were given 500 g of food overnight. On the morning of Day 1–4, the remaining food was removed, weighed, and blood samples were collected from each animal. On Days 1–3, the dogs were then given 500 g of food for a period of 24 hours. On Day 4, the dogs were returned to their regular ration of food (260 g).
[0405] Additional food intake measurements: On days 7, 14, and 28, the study animals were provided with their daily feed (260 g) for 6 hours to consume. At the end of these periods, any remaining food was collected and weighed.
[0406] Body Weight Measurement: Body weight was measured at baseline and on days 2, 4, 7, 10, 14, 18, and 28. Baseline body weight was collected in a fasting state. Body weights collected on days 2 and 4 were not collected in a fasting state. For vehicle-treated animals, all other body weights were collected in a fasting state. For GDF15-treated animals, body weights measured from days 7 through 28 were not collected in a fasting state because food was continuously provided to stimulate appetite and restore body weight.
[0407] Efficacy testing method of the GDF15-fatty acid conjugate of the present invention in dogs fed the feed
[0408] Study Objective: Evaluation of the effects of subcutaneous administration of the GDF15-fatty acid moiety conjugate of the present invention at 0.015 mg / kg or 0.005 mg / kg to a vehicle control group and to food intake over a 96-hour period in Beagle dogs (in this study, the vehicle arm will be administered prior to the treatment arm in all dogs). Plasma samples were collected at various time points over a 14-day post-dose period to evaluate the PK profile of these compounds. Body weight was measured during the study.
[0409] Table 3
[0410] Animals: Baseline weight and treatment
[0411]
[0412] Administration Procedure: The vehicle was administered after baseline body weight and blood sample collection. 52 µl / kg of 30 mmol / l sodium acetate pH 4 vehicle (52 µl / kg) was administered to the vehicle animals by subcutaneous injection. GDF15 was administered after baseline body weight and blood sample collection. The GDF15-fatty acid moiety conjugate was supplied as a 1.20 mg / ml solution and administered by subcutaneous injection after dilution to 0.015 mg / kg and 0.005 mg / kg. The stock GDF15 solution was diluted to maintain the 52 µl / kg delivered in the previous study.
[0413] Blood Collection: Blood samples were collected for the vehicle and treatment arm of the study. Samples were collected from the radial cutaneous vein or jugular vein (3 ml collected in tubes containing EDTA and the protease inhibitors Diprotein A and Aprotinin), and placed on ice until centrifuged at 3,000 rpm for 20 minutes at 4°C. Plasma was aliquoted and stored at -70°C until analysis. Samples were collected at the following time points: 0, 6.75, 24.75, 48.75, 72.75, and 96.75 hours. Additional samples were collected on Day 7, Day 10, and Day 14.
[0414] Measurement of food intake: Food intake was measured during both the vehicle and treatment arms of the study. Measurement of free food intake was initiated 45 minutes after drug administration. These measurements of food intake consisted of two phases: acute measurements (0–6 hours) and subchronic measurements (0–96 hours).
[0415] During hours 0–2, the dogs were given 500 g of regular food (Hill's J / D food). At 2 hours, the remaining food was removed, weighed, and another 500 g of food was given for the period of 2–4 hours. At 4 hours, the remaining food was removed, weighed, and another 300 g of food was given for the period of 4–6 hours. At 6 hours, the remaining food was removed and weighed. Blood samples were collected at this point in time (6.75 hours). Afterwards, the dogs were given 500 g of food overnight. On the morning of Day 1–4, the remaining food was removed, weighed, and blood samples were collected from each animal. On Day 1–3, the dogs were then given 500 g of food for a 24-hour period. On Day 4, the dogs were returned to their regular ration of food (260 g).
[0416] Additional food intake measurements: On various days between days 7 and 14 in the vehicle arm and between days 7 and 28 in the treatment arm, the study animals were provided with their daily feed (225 g) for 6 hours to consume. At the end of these periods, any remaining food was collected and weighed. Once a week, food consumption was measured hourly. Consumption of the 225 g feed was measured 1, 2, 4, and 6 hours after feeding to determine whether each dog's feeding pattern had returned to normal.
[0417] Body Weight Measurement: Body weight was measured during both the vehicle and treatment arms of the study. During the vehicle arm, body weight was measured at baseline and on days 2, 4, 7, 10, and 14. During the treatment arm, body weight was measured at baseline and on days 2, 4, 7, 10, 14, 17, 21, 24, and 28. Body weights collected on days 2 and 4 were not fasted. All other body weights were determined on a fasted basis.
[0418] The conjugate of Example 2 was tested in the above verification method.
[0419] Table 4
[0420] Single subcutaneous dose
[0421]
[0422] GDF15-conjugates improve the scale of metabolic diseases, including diabetes and fatty liver disease, in obese mice.
[0423] Diet-induced obese mice were administered either the vehicle or Example 19Bm (0.5 mg / kg / subcutaneous) once a week for 4 weeks. Non-fasting glucose and insulin were measured 2 weeks after the first administration, and overnight fasting blood glucose and insulin were measured 4 weeks after the first administration. Example 19Bm reduced non-fasting glucose by 23% (207.1 mg / dl vehicle treatment vs. 160.4 mg / dl Example 19Bm; p<0.05). Example 19Bm reduced non-fasting insulin levels by 75% compared to vehicle-treated mice (2.1 vs. 8.7 ng / ml; p<0.05). Four weeks after the initial administration, Example 19Bm reduced fasting blood glucose by 28% (142.7 vs. 199.5 mg / dl; p<0.05) and fasting insulin by 78% (0.77 vs. 3.5 ng / ml; p<0.05). Markers of fatty liver disease were also improved by four once-weekly doses of Example 19Bm. Example 19Bm reduced hepatic steatosis by 57.5% (11.36 vs. 26.73% hepatic fat; p<0.05) and reduced serum levels of alanine aminotransferase (ALT), a marker of hepatocellular damage, by 58% (46.2 vs. 110.5 U / L; p<0.05). In addition, Example 19Bm reduced the liver expression of PNPLA3, a causative gene in progressive liver disease, by 77% (p<0.05).
[0424] The activity and plasma stability of the APJ-agonist conjugates of Examples 20 and 21 according to the present invention can be evaluated by the following in vitro and in vivo methods described below.
[0425] hAPJ Calcium Flow Test:
[0426] Stable Chem-5 APJ cells (Millipore # HTS068C) were plated at 10,000 cells / well in 25 µl growth medium in a 384-well format and grown in a 37°C tissue culture incubator for 24 hours. One hour prior to the assay, 25 µl / well FLIPR Calcium 4 dye (Molecular Devices R8142) + 2.5 mM probenecid were added, and the cells were incubated in a 37°C tissue culture incubator for 1 hour. The peptide was solubilized in HBSS, HEPES, and 0.1% BSA buffer and serially diluted tenfold from 50 µM to 5 pM in a triplicate manner. Using FLIPR Tetra, the peptide was added to the cells along with the dye (1:5, final peptide concentration ranging from 10 µM to 1 pM). The FLIPR dye inside the cell emitted fluorescence after binding to calcium, while fluorescence from outside the cell was blocked. Fluorescence was measured on FLIPR Tetra using excitation and emission wavelengths of 470–495°F and 515–575°F, respectively. Readings were taken for a total of 3 minutes, starting 10 seconds before peptide addition. Maximum and minimum values were calculated and plotted for each peptide concentration, and the EC at the curve inflection point for calcium flow stimulation by the peptide was calculated using GraphPad Prism software. 50 The value was calculated.
[0427] In vivo assay:
[0428] The conjugate was dissolved in PBS (phosphate-buffered saline) at a concentration of 1 mg / ml to form a dosing solution. The dosing solution was administered intravenously to male Sprague-Dawley rats via the lateral tail vein at a volume of 1 ml / kg body weight, corresponding to a dose of 1 mg / kg. At a predetermined time after administration, venous blood samples were obtained from the jugular catheter and immediately placed on wet ice. These samples were centrifuged at 4°C, and the supernatant plasma was transferred to a fresh tube for analysis.
[0429] Bioanalysis:
[0430] Preparation of standard curves: A stock solution was prepared by dissolving a peptide conjugate in water at a concentration of 1 mg / ml. 10 µL of the stock solution was mixed with 990 µL of rat plasma to form a working stock solution of 10,000 ng / ml in the plasma. This was serially diluted in the plasma to form standards of 5,000, 1,000, 500, 100, 50, 10, 5, and 1 ng / ml.
[0431] Preparation of samples and standards: 25 µL of plasma sample or standard was transferred to a clean plate. 150 µL of acetonitrile:MeOH (1:1) containing 100 ng / ml glyburide as an internal standard was added to each vial, and the plate was vortexed to mix the contents. The plate was centrifuged at 4000 rpm at 4°C. 125 µL of the supernatant was transferred to a clean plate, mixed with 50 µL of water, and analyzed by LC / MS.
[0432] LC / MS Analysis:
[0433] HPLC: Agilent 1290 HPLC with Autosampler
[0434] Column: MAC-MOD ACE C18, 3 µm, 30 mm × 2.1 mm inner diameter
[0435] Mobile phase A: 0.1% formic acid in acetonitrile
[0436] Mobile phase B: 0.1% formic acid in water
[0437] Gradient Program:
[0438]
[0439] Mass Spectrometer: AB Sciex 6500
[0440] MS conditions: Q1 (m / z+) 809.3; Q3 (m / z+) 923.7; DP: 60; CE: 25
[0441] Data Analysis: MS data was captured and analyzed using Watson LIMS v7.4 software.
[0442] Activity and stability of the APJ agonist-conjugate of the present invention using the assay method described above
[0443] Table 5
[0444]
[0445] The activity and plasma stability of the oxytocin conjugates of Examples 26A and 26B according to the present invention can be evaluated by the following in vitro and in vivo methods described below.
[0446] Explanation of In Vitro Testing Methods:
[0447] Material & Method
[0448] Compound plate manufacturing
[0449] The supplied compounds were prepared in DMSO and ultimately in Eurofins Discovery Services’ GPCRProfiler® assay buffer at a concentration three times higher than the final assay concentration. Similarly, vehicle controls and positive controls were prepared to ensure that all assays were adequately controlled.
[0450]
[0451] All wells were prepared using Eurofins Discovery Services' GPCR Profiler® assay buffer. The GPCR Profiler® assay buffer was a modified Hanks Balanced Salt Solution (HBSS) supplemented to contain 20 mM HEPES and 2.5 mM probenecid at pH 7.4.
[0452] Calcium Fluid Test Method
[0453] agonist testing method
[0454] The supplied compound(s) were double-plated for each tested concentration.
[0455] Oxytocin, a reference agonist, was prepared in a similar manner to serve as a control group for the assay. Oxytocin, the reference agonist, was included at Emax (the concentration at which the reference agonist elicited the maximum response).
[0456] After the fluorescence / luminescence baseline was established, the agonist assay was performed on a FLIPRTETRA instrument with the test compound(s), vehicle control, and reference agonist added to the assay plate. The agonist assay lasted a total of 180 seconds and was used to evaluate the ability of each compound to activate each tested GPCR.
[0457] Upon completion of the 3-minute agonist assay, the assay plate was incubated at 25°C for an additional 7 minutes.
[0458] Data processing
[0459] All plates were subjected to appropriate baseline correction. Once baseline correction was processed, maximum fluorescence / luminescence values were output, and the data was manipulated to calculate the percentage of activation and inhibition. Negative values ranging from 0 to -30% may result from biological variability. The data manipulation calculation is as follows: ((Maximum RLU) - (Baseline Mean)) / ((Average of Positive Values) - (Baseline Mean))
[0460] Explanation of In Vivo Assay:
[0461] The conjugate was dissolved in PBS (phosphate-buffered saline) at a concentration of 3 mg / ml to form a dosing solution. The dosing solution was administered intravenously via the lateral tail vein of male Sprague-Dolly rats at a volume of 1 ml / kg body weight, corresponding to a dose of 3 mg / kg. At a predetermined time after administration, venous blood samples were obtained from the jugular catheter and immediately placed on wet ice. These samples were centrifuged at 4°C, and the supernatant plasma was transferred to a fresh tube for analysis.
[0462] Bioanalysis:
[0463] Preparation of standard curves: Stock solutions were prepared by dissolving the peptide conjugate and peptide in dimethyl sulfoxide at 1 mg / ml in two separate vials. 10 µL of each stock solution was mixed with 980 µL of rat plasma to form a working stock solution of 10,000 ng / ml in the plasma. This was serially diluted in the plasma to form standards of 5,000, 1,000, 500, 100, 50, 10, 5, 1, 0.5, and 0.1 ng / ml.
[0464] Preparation of samples and standards: 25 µL of plasma sample or standard was transferred to a clean plate. 150 µL of acetonitrile containing 100 ng / ml glyburide as an internal standard was added to each vial, and the plate was vortexed to mix the contents. The plate was centrifuged at 4000 rpm at 4°C. 125 µL of the supernatant was transferred to a clean plate, mixed with 150 µL of water, and analyzed by LC / MS.
[0465] LC / MS Analysis:
[0466] HPLC: Agilent 1290 HPLC with Autosampler
[0467] Column: MAC-MOD ACE C18, 3 µm, 30 mm × 2.1 mm inner diameter
[0468] Mobile phase A: 0.1% formic acid in acetonitrile
[0469] Mobile phase B: 0.1% formic acid in water
[0470] Gradient Program:
[0471]
[0472] Mass Spectrometer: AB Sciex 6500
[0473] Peptide MS conditions: Q1 (m / z+) 945.20; Q3 (m / z+) 687.27; DP: 140; CE: 39
[0474] Peptide conjugate MS conditions: Q1 (m / z+) 1270.85; Q3 (m / z+) 468.30; DP: 140; CE: 77
[0475] Data Analysis: MS data was captured and analyzed using Watson LIMS v7.4 software.
[0476] Activity and stability of the oxytocin fatty acid conjugate of the present invention according to the assay method described above
[0477] Table 6
[0478]
[0479] Example 13 of WO2014 / 095773 is shown below:
[0480]
[0481] The oxytocin-fatty acid conjugate of the present invention demonstrates a 75-fold increase in half-life compared to a non-conjugated oxytocin analog.
[0482] The activity and plasma stability of the AgRP conjugates of Examples 27A and 27B according to the present invention can be evaluated by the following in vitro and in vivo methods described below.
[0483] A) HTRF cAMP assay protocol:
[0484] Passage of HEK293 / MC4R cells
[0485] Cells: Stable HEK293 / MC4R cell line
[0486] Complete medium: DMEM / F12 1:1 (Gibco, Catalog No. 11039; for the assay, non-phenol red medium Catalog No. 21041)
[0487] 10% FBS (Thermal Inert, Gibco, Catalog No. 10082)
[0488] 200 µg / mL Geneticin (Gibco, Catalog No. 10131)
[0489] 15 mM Hepes (Gibco, Catalog No. 15630)
[0490] 2 mM L-glutamine (Gibco, Catalog No. 25030)
[0491] Flask: 150 cm² tissue culture treatment flask (Corning, catalog number 430825).
[0492] - Aspirate the conditioning medium.
[0493] - After washing with 25 mL of DPBS (Gibco, catalog number 14190), aspirate it.
[0494] FBS inhibits trypsin-EDTA processing.
[0495] - Add 2.5 mL of 0.05% trypsin-EDTA (Gibco, catalog number 25300).
[0496] - After leaving it for a few minutes, tap the flask several times to detach the cells.
[0497] Stop the trypsin-EDTA treatment by adding 25 mL of complete medium.
[0498] For cell preparations used in assays, non-phenol red complete medium must be used.
[0499] - Gently pipette several times to resuspend the clumped cells.
[0500] - Transfer the suspension to a 50 mL centrifuge tube.
[0501] - Spin for 3 minutes at 1200 rpm.
[0502] - Aspirate the supernatant.
[0503] - Disperse cells by gently tapping the bottom.
[0504] - After adding 5-10 mL of complete medium, gently pipette to resuspend.
[0505] For cell preparations used in assays, non-phenol red complete medium must be used.
[0506] - Transfer 0.5 mL of the suspension to the sample vial for the Vi-cell.
[0507] - Count the number of cells using a bio-cell. * Record cell density and growth rate each time.
[0508] - 1-3×10 6 Transfer the cells to a new 150 cm flask.
[0509] For 3 days: 3×10 6 Number of cells / flasks
[0510] For 4 days: 1×10 6 Number of cells / flasks
[0511] Incubate with 5% CO2 at -37℃.
[0512] Cell seeding for HTRF cAMP assay (1 day before assay)
[0513] Prepare a cell suspension as in the passage section.
[0514] 2.34 × 10⁻⁶ of the suspension 5 Dilute to 1 cell / mL
[0515] 13 mL is sufficient for one 384-well plate.
[0516] Dispense 30 µl of cell suspension into each well of a Poly-D-Lysine Biocoat 384-Well Clear Plate (Becton Dickinson, Catalog No. 354660): 7000 cells / well
[0517] Poly-D-lysine coated plates are essential in this assay method.
[0518] There are no cells in the cAMP standard wells.
[0519] Incubate overnight at 37℃ with 5% CO2.
[0520] HTRF cAMP test
[0521] 1. Reagent preparation
[0522] 1 M IBMX
[0523] IBMX (MW 222.25 g / mol, ACROS Catalog No. 228420010) 111 mg
[0524] DMSO (Sigma Aldrich, Catalog No. D2650) 500 uL
[0525] Store at 4℃.
[0526] 40 mg / mL BSA solution
[0527] Bovine serum albumin (Sigma A7030-50G) 200 mg
[0528] 5 mL of dH2O
[0529] Store at 4℃.
[0530] 1 mg / mL (176 uM) AgRP Master Solution (in HBSS / 2 mg / mL BSA)
[0531] R&D Human AgRP C-terminus (Catalog No. 3726-AG-100) 100 ug / vial
[0532] 1× Hank Buffered Salt Solution (HBSS) (Gibco, Catalog No. 14065, containing Ca and Mg) 95 uL
[0533] 5 µL of 40 mg / mL BSA solution
[0534] Store at 4℃.
[0535] 2 mM NDP-aMSH master solution
[0536] NDP-aMSH (MW 1646.9, Bachem, Catalog No. H1100) 1 mg / vial
[0537] dH2O 304 uL
[0538] * Once dissolved, distribute a 10 µL aliquot into a 200 µL tube and store at -20℃.
[0539] Test method buffer 1
[0540] HBSS 10 mL
[0541] 1 M Hepes (Gibco, Catalog No. 15630) 0.2 mL
[0542] 1 M IBMX 20 uL
[0543] To prevent IBMX from precipitating, please vortex the buffer until it is completely dissolved.
[0544] Test method buffer 2
[0545] HBSS 20 mL
[0546] 1 M Hepes (Gibco, Catalog No. 15630) 0.4 mL
[0547] 1 M IBMX 40 uL
[0548] 0.25 mL of 40 mg / mL BSA solution
[0549] To prevent IBMX from precipitating, please vortex the buffer until it is completely dissolved.
[0550] 6 nM NDP-aMSH for IgG titration and AgRP titration
[0551] 2 µM NDP-aMSH (1000-fold dilution of master solution) 10.8 µL
[0552] Test method Buffer 1 3600 uL
[0553] * Example of a single 384-well test
[0554] 120 nM AgRP for IgG titration
[0555] 26 µL of 10x diluted master solution (17.6 µM)
[0556] Test method Buffer 2 3800 uL
[0557] * Example of a single 384-well test
[0558] NDP-aMSH working solution for titration (refer to reagents)
[0559] AgRP working solution for titration (refer to reagents)
[0560] IgG working solution for titration (refer to reagents)
[0561] cAMP standard solution (refer to reagents)
[0562] 2. Testing method (2-step protocol)
[0563] Test Method Kit: Cisbio’s cAMP HiRange HTRF Kit (Catalog No. 62AM6PEB)
[0564] - Preparation of IgG / AgRP mix (1:1)
[0565] After mixing 15 µL of IgG working solution and 15 µL of 120 nM AgRP, incubate at ambient temperature for 1 hour.
[0566] - Preparation of test plate
[0567] The 384-well assay plate containing cells is inverted onto a Wipeall, and the culture medium is discarded by tapping to remove the culture medium.
[0568] Add 100 µl of DPBS to each well and discard it in the same way.
[0569] If you have discarded the PBS, proceed to the next step as soon as possible to prevent drying.
[0570] Transfer 10 µl of the following reagent into each well based on sample alignment.
[0571] cAMP Standard: : cAMP Standard
[0572] Negative control for cAMP titration: Diluent in the HTRF kit
[0573] Positive control: cAMP positive control in the HTRF kit
[0574] MSH Titration: Typical Method Buffer 2
[0575] AgRP Titration: AgRP Working Solution
[0576] IgG Titration: IgG / AgRP Mixture
[0577] Negative control for the cytology assay: Scheme buffer 2
[0578] - Instantly spin the 384-well plate at 1200 RPM.
[0579] - Incubate the cells at ambient temperature for 15 minutes.
[0580] - Transfer 10 µl of the following reagent into each well based on sample alignment.
[0581] cAMP Standard: : Test Method Buffer 1
[0582] Negative control for cAMP titration: Typical buffer 1
[0583] Positive control: Test method buffer 1
[0584] MSH Titration: MSH Working Solution
[0585] AgRP Titration: 6 nM MSH Solution
[0586] IgG Titration: 6 nM MSH Mixture
[0587] Negative control for the cytology assay: Scheme buffer 1
[0588] - Instantly spin the 384-well plate at 1200 RPM.
[0589] - Incubate the cells at ambient temperature for an additional 30 minutes.
[0590] This incubation time is not strict. + / - 5 minutes should be allowed depending on the test method development data.
[0591] - Add 10 µl of cAMP-d2 (diluted 1:4 in the lysis buffer provided in the kit).
[0592] * Important!! For the negative control group, add only the lysis buffer, not cAMP-d2.
[0593] - Add 10 µl of anti-cAMP cryptate (diluted 1:4 in the lysis buffer provided in the kit).
[0594] - Spins instantaneously at 1200 RPM
[0595] - Incubate the test plate at ambient temperature for 45-60 minutes.
[0596] - Transfer 30 µl of each sample to a white tissue culture-treated polystyrene 384-well assay plate (Corning, Catalog No. 3572).
[0597] - Spins instantaneously at 1200 RPM.
[0598] - Measure fluorescence using the molecular device M5 or M5e with the following settings.
[0599] Molecular Device M5 / M5e Settings
[0600]
[0601] B) MC3 cAMP test method
[0602] substance:
[0603] cell : Stable HEK293 / MC3R cell line
[0604] Complete badge : DMEM / F12 1:1 (Gibco, Catalog No. 11039)
[0605] 10% FBS (Thermal Inert, Gibco, Catalog No. 10082) x
[0606] 200 µg / mL Geneticin (Gibco, Catalog No. 10131)
[0607] 2 mM L-glutamine (Gibco, Catalog No. 25030)
[0608] flask: 150 cm² tissue culture processing flask (Corning, catalog number 430825).
[0609] Testing method buffer
[0610] HBSS (Gibco - 14175-095) 10 mL
[0611] 1 M Hepes (Fisher, Catalog No. BP299-1) 0.2 mL
[0612] 500 mM IBMX (MW 222.25 g / mol, Acros Catalog No. 228420010) 40 ul
[0613] BSA 0.25%
[0614] plate
[0615] 384-well solid bottom, Greiner bio-one (Catalog No. - 781080)
[0616] Test method protocol (antagonist protocol):
[0617] I. Aspirate the conditioning medium.
[0618] II. Wash with 2.5 mL of DPBS (Gibco, Catalog No. 14190).
[0619] III. Add 2 mL of 0.25% trypsin-EDTA (Gibco, catalog number 25200-056).
[0620] IV. Leave the flask in the incubator for a few minutes, and tap the flask several times to detach the cells.
[0621] V. Add 10 mL of complete medium to stop the trypsin-EDTA treatment, and mix well by gently pipetting several times to resuspend the clumped cells.
[0622] VI. Transfer 1.5 ml of cells to a new 150 cm flask containing 20 mL of complete medium.
[0623] VII. Transfer the remaining suspension to a 50 mL centrifuge tube.
[0624] VIII. Spin at 1200 rpm for 4 minutes. Aspirate the supernatant.
[0625] IX. Add 6 mL of assay buffer to the tube and gently pipette to resuspend the cells.
[0626] X. Transfer 0.5 mL of the suspension to a sample vial for the cell, and add another 0.5 mL of PBS.
[0627] XI. Count the number of cells using a bio-cell. * Record cell density and growth rate each time.
[0628] i. Plate cells at a rate of 4000 / well in 10 ul / well assay buffer containing IBMX.
[0629] ii. Leave the plate in the incubator for ~30 minutes before starting the assay on the suspended cells.
[0630] Follow the 2-step cAMP protocol to determine cAMP.
[0631] procedure
[0632] I. Add 5 µl of AgRP, prepared at 3× in assay buffer, to 10 µl / well of cells only to the antagonist wells.
[0633] II. Add 5 µl of buffer to the positive control well (well containing NDP-α-MSH).
[0634] III. Incubate the plate at 37°C for ~20 minutes.
[0635] IV. Add 5 ul / well of agonist EC80 (NDP-α-MSH) prepared as 4× to the wells containing AgRP DRC.
[0636] V. To calculate the NDP-α-MSH EC50, 5 ul / well of agonist (NDP-α-MSH) DRC prepared at 4× (the final peak concentration on the plate is 100 nM) is added.
[0637] VI. Add buffer only to the negative control group.
[0638] VII. Pulse-spinning a 384-well plate, and incubating the cells in an incubator for 30 minutes.
[0639] VIII. Add 10 µl of the following reagent to each well:
[0640] a. 10 µl of cAMP-d2
[0641] b. *Important!! For the negative control, do not add cAMP-d2, and add only the lysis buffer and 10 ul / well of Tb-cryptate.
[0642] c. 10 µl of anti-cAMP cryptate
[0643] d. Pulse spin the plate and incubate at room temperature for 60 minutes.
[0644] C. Explanation of in vivo assay methods :
[0645] A 10 nanomolar conjugate was dissolved in 300 µL of PBS (phosphate-buffered saline) to form a dosing solution. The dosing solution (300 µM) was administered intravenously through the lateral tail vein of male Sprague-Dolly rats (corresponding to a 10 nanomolar dose per rat). At a predetermined time after administration, blood was collected via tail dissection and immediately placed on wet ice. These samples were centrifuged at 4°C, and the supernatant plasma was transferred to a fresh tube for analysis.
[0646] Bioanalysis:
[0647] Standard curve manufacturing Standards were prepared using the two fatty acid conjugates and one mature human AgRP peptide from Examples 27A and 27B. Stock solutions of the intermediates for each AgRP were prepared by diluting the peptides labeled with the stock solution to 100 µg / ml in ELISA sample diluent + casein. For the assay, the intermediates were diluted in ELISA sample diluent + bovine serum albumin (BSA) to a maximum standard concentration of 2500 pg / mL and then serially diluted twofold to 16 points containing a zero-dose standard.
[0648] Sample Dilution : After diluting the plasma sample 10-fold in ELISA sample diluent + BSA, it was serially diluted 5-fold up to 31,250-fold.
[0649] 5B1 Human AgRP ELISA Method : A 384-well microplate was coated with anti-human AgRP clone 5B1 at 30 µL / well in 1× PBS overnight at room temperature (RT). The plate was aspirated and blocked with 90 µL / well of a milk-based blocker at room temperature for 2 hours. All additional incubations were performed at 30 µL / well. The plate was aspirated again, and samples and standards were added to the wells at room temperature for 2 hours. Subsequently, the plate was washed three times with phosphate-based wash buffer + Tween-20, and biotinylated goat anti-human AgRP polyclonal antibody was added to the wells to detect bound AgRP at room temperature for 2 hours. The plate was washed again, and HRP-labeled streptavidin reagent was added to the wells at room temperature for 30 minutes. Finally, the wells were cleaned, the chemiluminescent substrate was added to all wells, and the plate was immediately read for light output on a Spectramax M5.
[0650] Data analysis The unprocessed data was structured, and the basic PK parameters were analyzed.
[0651] Activity and stability of the AgRP fatty acid conjugate of the present invention according to the inspection method described above :
[0652] Table 7
[0653]
[0654] The activity and plasma stability of the FGF23 conjugates of Examples 28A, 28B, and 28C can be evaluated by the following in vitro method described below.
[0655] In vitro activity test method
[0656] Egr-1-Luciferase: The biological activity of the purified hFGF23-FA conjugate was tested using the Egr-1-luciferase reporter assay. When the hFGF23-FA conjugate binds to the FGF23 receptor, it results in downstream activation of Egr-1 and the expression of the luciferase reporter regulated by the Egr-1 promoter. The Egr-1-luciferase reporter gene was constructed based on the literature [Urakawa et al., Nature, 2006, Vol 444, 770-774]. HEK293T cells seeded in 48-well poly-D-lysine plates were transfected with the Egr-1-luciferase reporter gene, the full-length transmembrane form of Clotho, and the transfection standardization reporter gene (Renilla luciferase). Five hours after transfection, the transfection mix was replaced with 3 ml DMEM + 1% FBS containing graded concentrations of test protein. After 20 hours, cells were lysed in passive lysis buffer (Promega, catalog #E194A), and luciferase activity was determined using the Dual-Glo luciferase assay system (Promega, catalog #E2940).
[0657] result
[0658] Table 8
[0659]
[0660] The activity and plasma stability of the cerylexin fatty acid conjugates of Examples 29A and 29B according to the present invention can be evaluated by the following in vitro and in vivo methods described below.
[0661] In vitro activity test method # 1:
[0662] substance:
[0663] DMEM: F12 Badge (Gibco, Catalog #11320)
[0664] IBMX (Sigma, Catalog #I5879)
[0665] 384 Solid Floor White Plate (Griner Bio-One, Catalog #781945)
[0666] 20,000 Dynamic-2 cAMP Kit (Sysbio, Catalog #62AM4PEC)
[0667] Adenosine 3', 5'-cyclic monophosphate (Sigma, Catalog #A9501)
[0668] Matrix-plate mate plus (used to add 5 µl of assay reagent)
[0669] PBS-Gibco (Catalog #10010-023)
[0670]
[0671] Protocol:
[0672] Day 1: 8k RXFP1-HEK293 / mother HEK293 cells were seeded into 10 µl of DMEM:F12 medium in a solid-bottomed PDL-coated white plate.
[0673] Day 2: The assay method was performed using the compound.
[0674] Agonist Mode (Overview):
[0675] Cells in 10 µl of DMEM:F12 medium, 37℃, overnight.
[0676] 5 µl of 2000 μM (4×) IBMX was added to cells at 37°C for 30 minutes.
[0677] 5 µl of 4× compound / cerylexin was added to the above at 37°C for 30 minutes.
[0678] (Compound dilution step 3, from 400 nM - the final is a maximum of 100 nM)
[0679] 10 µl of cAMP-d2 conjugate
[0680] 10 µl of anti-cAMP cryptate conjugate
[0681] Incubate at room temperature for 1 hour
[0682] FRET Signal Readout - Envision 665 nm / 620 nm
[0683] Compound preparation
[0684] Serilexine:
[0685] 1) The 683.3 μM stock solution was diluted; specifically, 11.7 μL was diluted in 188.3 PBS pH 7.4, and 15 μL of the compound was transferred to 30 μL, resulting in a 3×fold dilution in PBS (the final concentration is 40 μM) - Manual
[0686] 2) Diluted 1:10, that is, 6 μl of the above substance was diluted in 54 μl of DMEM:F12 (final is 4 μM) - Manual
[0687] 3) Diluted 1:10, that is, 10 µl of the above substance was diluted in 90 µl of DMEM:F12 (final is 400 nM) - Manual
[0688] Serilexin-FA conjugate
[0689] 1) The stock solution was diluted to 40 μM in PBS pH 7.4, and 15 μL of the compound was diluted 3× times in PBS by transferring it to 30 μL.
[0690] 2) Diluted 1:10, that is, 6 µl of the above substance was diluted in 54 µl of DMEM:F12 - manual.
[0691] 3) Diluted 1:10, that is, 10 µl of the above substance was diluted in 90 µl of DMEM:F12 (1:100 dilution) - manual.
[0692] fatty acid
[0693] 1) The stock solution was diluted to 40 μM in PBS pH 7.4, and 15 μL of the compound was diluted 3× times in PBS by transferring it to 30 μL.
[0694] 2) Diluted 1:10, that is, 6 µl of the above substance was diluted in 54 µl of DMEM:F12 - manual.
[0695] 3) Diluted 1:10, that is, 10 µl of the above substance was diluted in 90 µl of DMEM:F12 (1:100 dilution) - manual.
[0696] cAMP Standard Curve Dilution:
[0697] 1. 150 µl of cAMP standard diluted in DMEM:F12 medium was added to the first column (2800 nM).
[0698] 2. Add 100 µl of DMEM:F12 medium to up to 10 subsequent columns (1-11).
[0699] 3. Dilute by 3× by transferring 50 µl to 100 µl
[0700] 4. Place 20 µL from Step 3 into the appropriate wells of the standard curve plate.
[0701] 5. 10 µl anti-d2 & anti-cAMP cryptate conjugate
[0702] 6. Incubated at room temperature for 1 hour
[0703] 7. FRET Signal Readout - InVision 665 nm / 620 nm
[0704] analyze:
[0705] The cAMP nM concentration was converted to log(x) using a graph pad prism.
[0706] The amount of cAMP was interpolated from the standard curve using 4-parameter non-linear regression.
[0707] The interpolated value was converted to nM using the 10^Y transformation.
[0708] The calculated amount of cAMP was plotted against the compound concentration using 4-parameter non-linear regression.
[0709] result:
[0710] Table 9
[0711]
[0712] In vitro activity in the presence of bovine serum albumin and human serum #2:
[0713] substance:
[0714] DMEM: F12 Badge (Gibco, Catalog #11320)
[0715] IBMX (Sigma, Catalog #I5879)
[0716] 384 Solid Floor White Plate (Griner Bio-One, Catalog #781945)
[0717] 20,000 Dynamic-2 cAMP Kit (Sysbio, Catalog #62AM4PEC)
[0718] Adenosine 3', 5'-cyclic monophosphate (Sigma, Catalog #A9501)
[0719] Matrix-Plate Mate Plus (used to add 5 µl of assay reagent)
[0720] PBS-Gibco (Catalog #10010-023)
[0721] 1 M HEPES Gibco (Catalog-15630-080)
[0722] 1× HBSS Gibco (Catalog-14175-095)
[0723] Assay Buffer - 1×HBSS + 10 mM HEPES
[0724] Bovine Serum Albumin Catalog # A2153 (Sigma-Aldrich)
[0725] Sigma Aldrich-H4522 (Human Serum)
[0726] condition:
[0727] 600 μM BSA
[0728] 4% human serum
[0729] 10% Human Serum (Sigma-Aldrich-H4522)
[0730] Testing method buffer
[0731] Tested Compounds:
[0732] Serelexin
[0733] Serilexin-FA (Example 29A)
[0734] Compound handling :
[0735] Serilexin: The stock solution is 796.57 uM, or 4.75 mg / ml, and the MW is 5963 Daltons.
[0736] 10 µl of cerylexin stock solution (final concentration 40 μM) dissolved in 190 µl of PBS is diluted 3×fold by transferring 30 µl to 60 µl of assay buffer at point 11 (A2-A12, where point 12 is 0).
[0737] Serylexin-FA conjugate: The stock solution is 287.79 uM, i.e., 2.61 mg / ml, and the MW is 9069 Daltons.
[0738] 27.798 µl of cerylexin stock solution (final concentration 40 μM) dissolved in 172.2 µl of PBS is diluted 3×fold by transferring 30 µl to 60 µl of assay buffer at point 11 (A2-A12, where point 12 is 0).
[0739] BSA stock solution preparation:
[0740] 666.66 uM BSA: 30 mL of assay buffer was prepared by dissolving 1.32 g of BSA.
[0741] 600 uM BSA: 30 mL of assay buffer was prepared by dissolving 1.18 g of BSA.
[0742] In the absence of BSA, there is only the assay buffer.
[0743] human serum
[0744] 4.44% HS: 1.34 ml in 28.66 ml of assay buffer
[0745] 4% HS: 1.2 ml in 28.8 ml assay buffer
[0746] 11.11% HS: 3.33 ml in 26.67 ml of assay buffer
[0747] 10% HS: 3 ml in 27 ml assay buffer
[0748] procedure :
[0749] Day 1: 8,000 cells / well of RXFP1-HEK293 and HEK293 (mother) cells were seeded into basic DMEM:F12 medium on solid-bottom plates at a volume of 10 µl / well. Cells were incubated overnight at 37°C / 5% CO2.
[0750] Day 2:
[0751] 1. Wash the cells 2 times with 50 µl of assay buffer, and after the first and second washes, remove the assay buffer by gently tapping on a paper towel.
[0752] 2. Cells were pre-treated for 30 minutes at 37°C with 15 µl of medium containing each medium (600 µM BSA, 4% BSA, 10% human serum, and assay buffer alone) + IBMX (666.66 µM).
[0753] 3. Serially dilute the compound to the 11-point curve by 3× - Transfer 15 µl of the compound from the previous well to a subsequent well containing 30 µl of PBS, where well 11 contains only PBS.
[0754] 4. Dilute the solution from Step 3 in assay buffer (1:10) (i.e., dilute 10 µl in 90 µl of assay buffer).
[0755] 5. Dilute again from step 4 into each medium (666.66 μM BSA & 4.44% & 11.11% human serum and assay buffer) (1:10), with a final concentration of BSA of 600 μM and a final concentration of human serum of 4 & 10%.
[0756] 6. (* Before adding to cells, incubate the compound in its respective medium at room temperature for 1 hour.)
[0757] 7. Add 5 µl of 4× ceryllexin / ceryllexin-FA from Step 6 to 15 µl of cells at 37°C for an additional 30 minutes (the maximum concentration of ceryllexin is 100 nM).
[0758] 8. Add 10 ul of cAMP d2 conjugate.
[0759] 9. Add 10 ul of anti-cAMP-cryptate.
[0760] 10. Incubate at room temperature for 1 hour.
[0761] 11. Read FRET in InVision.
[0762] 12. cAMP standard curves were created for each medium.
[0763] cAMP Standard Curve Dilution:
[0764] The initial stock solution of the cAMP standard is 1,120,000 nM.
[0765] 1. Dilute the initial stock solution (1:4) by dissolving 20 µl of cAMP stock solution in 60 µl of assay buffer.
[0766] 2. Dilution of Step 1 (1:10) in assay buffer (i.e., dilute 20 µl in 180 µl of assay buffer)
[0767] 3. Dilution (1:10) of Step 2 at respective concentrations of 4.44% & 11.11% HS, 666.66 μM BSA or no BSA — the final concentrations will be 4%, 10% HS and 600 μM BSA.
[0768] cAMP standard curve
[0769] 1. Add 150 µl of each cAMP standard to the first column (2800 nM).
[0770] 2. Add 100 µl of assay buffer + 600 µM BSA (4% & 10% HS and 0%, respectively) to 11 subsequent columns, i.e., 2-12.
[0771] 3. Dilute by 3× by transferring 50 µl to a subsequent well of 100 µl, and well 12 is 0, which is free of cAMP.
[0772] 4. Place 20 µL from Step 3 into a suitable well of the standard curve plate.
[0773] 5. Add 10 µL of d2 conjugate.
[0774] 6. Incubate at room temperature for 1 hour.
[0775] 7. Read HTRF - Envision
[0776] analyze:
[0777] Use a graph pad prism to convert the cAMP nM concentration to log(x).
[0778] The amount of cAMP was interpolated from the standard curve using 4-parameter non-linear regression.
[0779] The interpolated value was converted to nM using the 10^Y transformation.
[0780] The calculated amount of cAMP was plotted against the compound concentration using 4-parameter non-linear regression.
[0781] result:
[0782] Table 10
[0783]
[0784] In vivo assay:
[0785] Compounds (cerylexin and cerylexin conjugates) can be tested in various rodent models to evaluate short-term and long-term cardiovascular responses.
[0786] short-term model― Mice (any strain, but DBA / 2 is preferred) or rats (any strain, but Sprague-Dolly is preferred) were anesthetized by isoflurane inhalation and maintained in stable surgical-level anesthesia with ~2% isoflurane in 100% oxygen, and their rectal temperature was maintained at a normal level. The carotid artery and jugular vein (mice) or femoral artery and vein (rats) were exposed through an upper skin incision, and a catheter was inserted into the vessel. The arterial catheter was connected to a pressure transducer, and signals were transmitted to a digital data acquisition system (e.g., Ponemah) for continuous measurement of arterial pressure and heart rate induction. Alternatively, heart rate induction was induced by electrocardiogram signals recorded via subcutaneous needle electrodes. After arterial pressure and heart rate were stabilized, a cocktail of autonomic blockers (e.g., 2 mg / kg each of atropine and propranolol) was administered intravenously over ~3-4 minutes. Once cardiovascular parameters stabilize again, serylexin or a serylexin conjugate is injected intravenously as a bolus over a period of ~3 seconds. Relaxin causes an increase in heart rate with a characteristic slow onset (peak response within ~6 minutes) and a sustained duration of action (several hours). In some animal specimens, ventricular cardiac function (e.g., ejection fraction, fractional shortening, cardiac output) is measured by collecting a series of echocardiographic images, which are then analyzed offline.
[0787] Long-term model— Mice (any strain, but DBA / 2 is preferred) or rats (any strain, but Sprague-Dolly is preferred) are anesthetized by isoflurane inhalation and maintained in stable surgical-level anesthesia with ~2% isoflurane in 100% oxygen. Analgesics are administered during the perioperative period and postoperatively. Cannulas are inserted into arteries and veins as described above, but the catheter is exposed externally through a dorsal skin area, flushed with heparinized saline, and occluded with a stainless-steel pin. In mice, a subcutaneous catheter may also be implanted subcutaneously and exposed externally in a similar manner. In rats, the catheter is managed via a spring-tether / swivel system. On the study day, an arterial catheter is connected to a pressure transducer, and autonomic blockade is achieved as described above, except that in mice, the blocker may be administered via a subcutaneous catheter, and then the blockade is maintained in both species by successive intravenous or subcutaneous infusions of autonomic agonists. Arterial pressure and heart rate are continuously monitored using a digital data acquisition system. After arterial pressure and heart rate are stabilized, the autonomic blocker is administered intravenously or subcutaneously over approximately 3-4 minutes. Once cardiovascular parameters are stabilized again, cerylexin or a cerylexin conjugate is injected as an intravenous bolus over approximately 3 seconds. To evaluate ventricular cardiac function and heart rate over a period of several weeks in mice or rats, the cerylexin conjugate is injected subcutaneously 1-3 times per week, and then a series of echocardiographic images are collected at baseline and weekly.
[0788] Serilexin Source:
[0789] Serilexin (Recombinant 1-Chained Human Relaxin)
[0790] Connetics Corporation, Lot # 00L605
[0791] 1.0 mg / mL (5 mL vial) in 20 nM Na acetate buffer (pH 5.0)
[0792] Dilute the stock solution in the vehicle to the target concentration of serylexin for each dose.
[0793] The activity and plasma stability of the PIP conjugate of Example 30 can be evaluated by the following in vitro and in vivo methods described below.
[0794] Glucose-Stimulated Insulin Secretion (GSIS) Test:
[0795] The GSIS test was performed to measure in vivo pancreatic beta-cell function following recombinant human prolactin-inducible protein (hPIP) in high-fat diet-induced obesity (DIO) mice. Briefly, mice (m=5-7 mice / group) were fasted overnight (5:00 PM–8:00 AM), and on the test day, body weight and blood glucose (BG; determined by an Embrace glucose meter) were measured and designated as the baseline time. Subsequently, mice were administered a single intravenous (IV) dose of either hPIP (natural and FA-conjugated PIP; solution in PBS; administered at 4 ml / kg body weight) or vehicle-control (PBS). Forty-five minutes after hPIP administration, all mice were administered oral glucose (3 g / kg dextrose; solution in PBS; administered at 4 ml / kg body weight). Blood glucose was measured immediately before glucose loading (designated as the 0-minute time point), and 15 minutes and 30 minutes after glucose. At 0 minutes, 15 minutes after glucose, and 30 minutes after glucose, blood samples were collected for plasma isolation, and plasma insulin was measured.
[0796] Pharmacokinetic (PK) assay:
[0797] Plasma exposure to hPIP was measured after a single IV administration in DIO mice. Briefly, hPIP (natural and FA-conjugated PIP; solution in PBS; administered at 4 ml / kg body weight) was administered once intravenously (IV) to free-feeding DIO mice (n=2). Blood samples were collected at 0.25, 0.5, 1, 3, 7, 24, and 48 hours after administration, plasma was isolated, and analyzed by the in-house ELISA assay (protocol presented below).
[0798] The test method was measured by the following steps:
[0799] The plate was coated overnight at room temperature with 30 µl of hPIP antibody (designated as PIP-8-AB; in-house production; NBC clone # 87.19G9A11, 8 µg / ml in PBS).
[0800] After aspiration, block was performed for 2 hours with 100 µl of blocking reagent.
[0801] Aspirated, 30 µl of sample was added and incubated for 2 hours, and the sample and standards were diluted in casein buffer (1% casein, 1.7 mM monobasic sodium phosphate, 8.1 mM dibasic sodium phosphate heptahydrate, 0.15 M sodium chloride, 0.7% Triton X-100, and 0.1% sodium azide).
[0802] The plate was cleaned with 3 × 100 µl of Teknova cleaning buffer (0.05% Tween in PBS).
[0803] 30 µl of biotinylated PIP antibody (designated as PIP-6 Ab; in-house production, MBC clone # 87.8C6B3, 10 µg / ml in casein buffer) was added and incubated for 1 hour.
[0804] Cleaning was performed as described above.
[0805] 30 µl of streptavidin-HRP (Pierce Catalog # 21140, 0.4 µg / ml in HRP buffer) was added (HRP buffer: 0.4% casein, 1.7 mM monobasic sodium phosphate, 8.1 mM dibasic sodium phosphate heptahydrate, 0.15 M sodium chloride, and 0.1% chloroacetamide), and incubated for 30 minutes.
[0806] Cleaning was performed as described above.
[0807] 30 Femto chemiluminescent substrates (Thermo Catalog #34096) were added and read immediately.
[0808] Activity and stability of the PIP fatty acid conjugate according to the present invention according to the inspection method described above
[0809]
[0810]
[0811] The PIP fatty acid conjugate of the present invention has extended exposure, resulting in improved efficacy.
[0812] The activity and plasma stability of the NPFF conjugate of Example 31 can be evaluated by the following in vitro method described below.
[0813] cAMP assay protocol using the Sysbio cAMP kit
[0814] The NPFF-FA conjugate of the present invention was tested in the presence of forskolin in the assay described below.
[0815] Reagent / Substance
[0816]
[0817] Day 1: Plate the cells into a 384-well plate.
[0818] " Subculture protocol Follows.
[0819] 1. Prepare a growth medium without antibiotics (if necessary).
[0820] 2. After spraying with 70% ethanol, equilibrate the antibiotic-free growth medium bottles in a 37°C water bath.
[0821] 3. Desorb the cells with Versen (3 ml per T.75 flask).
[0822] 4. Transfer to a 50 ml Falcon tube containing 17 ml of growth medium.
[0823] 5. Centrifuge at 150 g for 4 minutes.
[0824] 6. Resuspend the cell pellet in 10 ml of stimulation buffer. Count the cells.
[0825] 7. Prepare a cell suspension of 5,000 cells / 50 ul in a growth medium containing antibiotics.
[0826] 8. Plate 50 µl of cell suspension using a Viaflow 384-125 µl pipette.
[0827] 9. Place the plate in the TC hood for 15 minutes.
[0828] 10. Incubate at 37℃, 5% CO2, and 90% humidity.
[0829] Day 2 :
[0830] Preparation of reagent solution:
[0831] 1. Test method buffer:
[0832] 500 ml HBSS + 10 ml HEPES. Store at room temperature.
[0833] Test method buffer: 250 ml HBSS / HEPES + 250 ul IBMX 1000× solution + 0.1% BSA (825 ul). Prepare fresh daily.
[0834] 2. Forscolin 2× solution: Final 1 uM in the assay:
[0835] Compound Dilution: 40 ul FSK / 100 ml assay buffer.
[0836] NPFF Dilution: 10 ul DMSO / 10 ml 2× FSK.
[0837] 3. NPFF Diluent: The final 1 μM in the 1 mM stock solution assay in dH2O
[0838] a. 5 ul stock solution / 625 ul FSK 2× / DMSO.
[0839] b. 100 µl solution a + 300 µl FSK 2× / DMSO. Final 1 µM in the assay.
[0840] c. 10 1 / 4 dilution steps: 100 ul + 300 ul FSK 2× / DMSO.
[0841] 4. Diluted compound: 10 mM stock liquor in DMSO - final 40 uM in the assay
[0842] a. 5 ul stock solution / 625 ul FSK 2×.
[0843] b. 11 1 / 4 dilution steps: 100 ul + 300 ul FSK 2×.
[0844] 5. cAMP Standard:
[0845] a. 10 µl cAMP standard stock solution (1.12 mM) + 90 µl assay buffer.
[0846] b. 10 ul diluted a + 90 ul stimulation buffer.
[0847] c. 20 ul dilution b + 428 ul stimulation buffer: 500 nM.
[0848] d. 11 1 / 2 dilution steps starting from dilution c: 100 ul dilution c + 100 ul stimulation buffer.
[0849] 6. cAMP detection reagent:
[0850] a. d2-cAMP : 1000 ul / 20 ml lysis buffer. (250 ul / 5 ml for one 384-well plate).
[0851] b. cryptate conjugate : 1000 ul / 20 ml lysis buffer. (250 ul / 5 ml for one 384-well plate).
[0852] Examination method procedure
[0853] Step 1 :
[0854] 1. Prepare a stimulus buffer.
[0855] 2. Add CisBio dissolution buffer at room temperature.
[0856] 3. Prepare WellMate (clean with 70% alcohol followed by dH2O and HBSS / HEPES).
[0857] 4. Prepare forskolin and a diluted compound.
[0858] Step 2 : Forskolin stimulation
[0859] 1. Wash the cells with 50 µl of stimulation buffer:
[0860] a. Gently tap the plate to remove the O / N medium.
[0861] b. Place a white paper towel on top of the plate and, using a VWR Symphony 4417 centrifuge, invert the plate and centrifuge at 300 RPM for 20 seconds.
[0862] c. Add 50 µl of stimulation buffer using Wellmate.
[0863] d. Gently tap the plate to remove the O / N medium.
[0864] e. Place a white paper towel on top of the plate, and using a VWR Symphony 4417 centrifuge, invert the plate and centrifuge at 300 RPM for 20 seconds.
[0865] f. Examine the cells under a microscope.
[0866] 2. Add 10 µl of stimulation buffer containing IBMX using ViaFlo 384.
[0867] 3. Add 10 µl of 2× forskolin solution containing the compound using ViaFlo 384 (Layer 7). Mix the solution before adding it to the cells.
[0868] 4. Incubate at room temperature for 30 minutes. (Place the plate in a drawer to prevent temperature fluctuations.)
[0869] 5. Prepare a cAMP standard curve and a cAMP detection reagent.
[0870] 6. The 20 ul / well cAMP standard curve Standard curved plate Add to (the same plate as the test plate).
[0871] Step 3 Lance Camp Test
[0872] 1. Add 10 ul d2 cAMP / well to the assay plate using Combi 384.
[0873] 2. Manually add 10 ul / well cryptate conjugate to the assay plate.
[0874] 3. Seal the plate.
[0875] 4. Incubate at room temperature for at least 1 hour (plates can be read within 24 hours).
[0876] 5. Place the tape on the bottom of the plate.
[0877] 6. InVision Program "SysBio 384 Full Plate Reads from
[0878] 7. Check unprocessed data in a backup file.
[0879] 8. Analyze the data using GraphPad (check the files in the auxiliary file).
[0880] result:
[0881] Table 12
[0882]
[0883] The activity and plasma stability of the conjugate of the present invention, in which the biomolecule is siRNA, can be evaluated by the following in vitro method described below.
[0884] method
[0885] The conjugate of Example 24 is conjugated with GalNAc (Reference Example 3) and fatty acids APOC3 It is a compound of siRNA. Human APOC3 Transgenic mouse (B6;CBA-Tg( APOC3 A 3707Bres / J) was purchased from Jackson Laboratory (Bar Harbor, Maine). Mice were provided with standard rodent food and water freely on a 12-hour light / dark cycle. Under these conditions, APOC3 In transgenic mice, hypertriglyceridemia occurs spontaneously with a significant increase in plasma TG content (Aalto-Setala K, J Clin Invest 1992). Four mice in each group were subcutaneously injected with either Reference Example 3 (APOC3 siRNA-GalNAc) or the conjugate of Example 24 at a dose of 25 mg / kg body weight. Blood was collected at baseline immediately before injection, and at 2, 4, 7, and 14 days after injection. Using plasma, human APOC3 protein levels were measured using the HTRF assay from SysBio. Statistical differences between the groups were compared using one-way ANOVA.
[0886] result
[0887] Baseline plasma APOC3 levels were 176±21 mg / dL and 178±9 mg / dL in Reference Example 3 and Conjugate 24, respectively. Reference Example 3 reduced plasma APOC3 levels by 56% in a time-dependent manner 5 days after administration compared to baseline levels. In contrast, the conjugate of Example 24 reduced plasma APOC3 more effectively with an 80% reduction 5 days after administration (Fig. 1). As shown in Fig. 1, the duration of action is similar for both Reference Example 3 and Example 24.
[0888] The conjugate of the present invention has plasma stability of at least 5 hours, at least 10 hours, at least 20 hours, at least 30 hours, at least 40 hours, or at least 50 hours. In one embodiment, the improvement in plasma stability compared to a non-conjugated biomolecule is at least 2 times, 5 times, 10 times, 20 times, 30 times, 40 times, or 50 times, or 75 times.
[0889] Combination therapy
[0890] The conjugate of the present invention may be administered simultaneously with, before, or after one or more other therapeutic agents. The conjugate of the present invention may be administered individually by the same or different routes of administration, or together with other agents in the same pharmaceutical composition.
[0891] In one embodiment, the present invention provides a product comprising a conjugate of any one of the prior embodiments or a conjugate mixture as described in embodiments 10 and 13, and at least one other therapeutic agent as a combination formulation for simultaneous, individual, or sequential use in a therapy. In one embodiment, the therapy is the treatment of a subject requiring treatment for a metabolic disorder or disease, type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, and diabetic nephropathy, comprising administering to a subject a therapeutically effective amount of the conjugate of the present invention, or an amide, ester, or salt thereof, in which the biomolecule is human growth differentiation factor 15 (GDF15), a homolog, variant, mutant, fragment, and other modified form thereof.
[0892] A product provided as a combination formulation comprises a conjugate of any one of the prior embodiments and another therapeutic agent(s) together in the same pharmaceutical composition, or a composition comprising a conjugate of any one of the prior embodiments and another therapeutic agent(s) in individual forms, e.g., in a kit form.
[0893] In one embodiment, the present invention provides a pharmaceutical composition comprising a conjugate of any one of the prior embodiments or a mixture of conjugates according to embodiments 10 and 13, and another therapeutic agent(s). Optionally, the pharmaceutical composition may include pharmaceutically acceptable excipients as described above.
[0894] In one embodiment, the present invention provides a kit comprising two or more individual pharmaceutical compositions, wherein at least one of the pharmaceutical compositions comprises a conjugate according to any one of the prior embodiments. In one embodiment, the kit comprises means for holding the compositions individually, e.g., a container, a divided bottle, or a divided foil pocket. An example of such a kit is a blister pack, such as one typically used for packaging tablets, capsules, etc.
[0895] The kit of the present invention may be used for administration in different forms of administration, e.g., orally, subcutaneously, and parenterally; for administration of individual compositions at different dosing intervals; or for titrating individual compositions against one another. To assist with compliance, the kit of the present invention typically includes instructions for administration. In the combination therapy of the present invention, the conjugate and other therapeutic agents of the present invention may be manufactured and / or formulated by the same or different manufacturers. Additionally, the conjugate and other therapeutic agents of the present invention may be combined into a combination therapy at (i) before the combination product is distributed to a physician (e.g., in the case of a kit containing the conjugate and other therapeutic agents of the present invention); (ii) immediately before administration by the physician himself (or under the guidance of a physician); or (iii) by the patient himself, for example, during sequential treatment with the conjugate and other therapeutic agents of the present invention.
[0896] The present invention also provides a use of a conjugate according to any one of the prior embodiments for treating a disease or pathological condition described herein, which a patient has previously been treated with another therapeutic agent (e.g., within 24 hours). The present invention also provides a use of another therapeutic agent for treating a disease or pathological condition described herein, which a patient has previously been treated with a conjugate according to any one of the prior embodiments (e.g., within 24 hours).
[0897] The term “combined with” a second agent or treatment includes co-administering the conjugate of the present invention (e.g., a conjugate according to any of the prior embodiments or a conjugate described otherwise herein) and the second agent or treatment, administering the second agent or treatment after administering the compound of the present invention first, and administering the conjugate of the present invention after administering the second agent or treatment first.
[0898] The terms “second agent” and “co-agent” are used interchangeably and include any agent known in the art for treating, preventing, or reducing the symptoms of a disorder or disease selected from the diseases or disorders described herein, e.g., metabolic disorders or diseases, type 2 diabetes, obesity, pancreatitis, dyslipidemia, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral artery disease, stroke, heart failure, coronary heart disease, complications of diabetes (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
[0899] In one embodiment, the therapy comprises administering to a subject a therapeutically effective amount of the conjugate of the present invention, or its amide, ester, or salt, which is a biomolecule human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments, and other modified forms, or a biomolecule thereof. The therapy is the treatment thereof in a subject requiring treatment for metabolic disorders or diseases, type 2 diabetes, obesity, pancreatitis, dyslipidemia, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral artery disease, stroke, heart failure, coronary heart disease, complications of diabetes (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
[0900] Examples of a second agent in which a biomolecule is combined with a conjugate of the present invention, which is human growth differentiation factor 15 (GDF15), its homologs, variants, mutants, fragments, and other modified forms, include the following:
[0901] 1. Antidiabetic agents, e.g., insulin, insulin derivatives, and mimics; insulin secretagogues, e.g., sulfonylureas (e.g., chlorofamide, tolazamide, acetohexamide, tolbutamide, glyburide, glimepiride, glipizide); glyburide and Amaryl; insulin secretion-stimulating sulfonylurea receptor ligands, e.g., meglitinides, e.g., nateglinide and repaglinide; Thiazolidinediones that enhance insulin action (e.g., by insulin sensitization) to promote glucose utilization in peripheral tissues (e.g., rosiglitazone (AVANDIA)), troglitazone (REZULIN)), pioglitazone (ACTOS)), valaglitazone, riboglitazone, netoglitazone, troglitazone, englitazone, siglitazone, adaglitazone, darglitazone; protein tyrosine phosphatase-1B (PTP-1B) inhibitors, e.g., PTP-112; cholesteryl ester transfer protein (CETP) inhibitors, e.g., torcetrapib; GSK3 (glycogen synthase kinase-3) inhibitors, e.g., SB-517955, SB-4195052, SB-216763, NN-57-05441, and NN-57-05445; RXR ligands, e.g., GW-0791 and AGN-194204; sodium-dependent glucose co-transporter inhibitors, e.g., T-1095; glycogen phosphorylase A inhibitors, e.g., BAY R3401; biguanides, e.g., metformin and other agents, that act by promoting glucose utilization and / or reducing hepatic glucose production and / or reducing intestinal glucose output; alpha-glucosidase inhibitors, e.g., acarbose and miglitol and other agents, that reduce postprandial hyperglycemia by slowing carbohydrate digestion and consequently slowing absorption from the intestines; GLP-1 (glucagon peptide-1), GLP-1 analogs, e.g., Exendin-4 and GLP-1 mimics; and DPPIV (dipeptidyl peptidase IV) inhibitors, e.g., vildagliptin;
[0902] 2. Blood lipid-lowering agents, e.g., 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, e.g., lovastatin, pitavastatin, simvastatin, pravastatin, cerivastatin, mevastatin, belostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin, and rivastatin; squalene synthase inhibitors; FXR (farnesoid X receptor) and LXR (liver X receptor) ligands; bile acid sequestrants, e.g., cholestyramine and cholesevellam; fibrates; nicotinic acid and aspirin;
[0903] 3. Anti-obesity agents, e.g., orlistat or limonabant, phentermine, topiramate, Cunexa, and lorcaserin;
[0904] 4. Antihypertensive agents, e.g., loop diuretics such as ethacrynic acid, furosemide, and torsemide; angiotensin-converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril, and trandolapril; Na-K-ATPase membrane pump inhibitors such as digoxin; neutral endopeptidase (NEP) inhibitors; ACE / NEP inhibitors such as omapatrillat, sampatrillat, and fasidotril; angiotensin II antagonists such as candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan, particularly valsartan; Renin inhibitors, e.g., ditechiren, xankyren, terakiren, aliskiren, RO 66-1132, and RO-66-1168; β-adrenergic receptor blockers, e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol, and timolol; contraction promoters, e.g., digoxin, dobutamine, and milrinone; calcium channel blockers, e.g., amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, nisoldipine, and verapamil; aldosterone receptor antagonists; and aldosterone synthase inhibitors;
[0905] 5. Agonists of peroxisome proliferator-activated receptors, e.g., fenofibrate, pioglitazone, rosiglitazone, tesaglitazar, BMS-298585, L-796449, compounds specifically described in patent application WO 2004 / 103995, i.e., compounds of Examples 1 to 35 or compounds specifically listed in Claim 21, or compounds specifically described in patent application WO 03 / 043985, i.e., compounds of Examples 1 to 7 or compounds listed in Claim 19, in particular (R)-1-{4-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole-4-ylmethoxy]-benzenesulfonyl}-2,3-dihydro-1H-indole-2-carboxylic acid or salts thereof; and
[0906] 6. Literature [ Expert Opinion Investigation Drugs 2003 Specific antidiabetic compounds described in Figures 1 to 7 of [ , 12(4): 623-633].
[0907] Additionally, the present disclosure envisions agents or methods for promoting weight loss, such as agents that stimulate metabolism or reduce appetite, and combination therapies with dietary modifications and / or exercise therapy to promote weight loss.
[0908] Examples of the present invention
[0909] abbreviation
[0910] ACN Acetonitrile
[0911] BEH Ethylene cross-linked hybrid
[0912] BOC tert -Butyloxycarbonyl
[0913] BSA bovine serum albumin
[0914] DCM dichloromethane
[0915] DCC N,N'-Dicyclohexylcarbodiimide
[0916] DIC N,N' - Diisopropylcarbodiimide
[0917] DIPEA N,N -Diisopropylethylamine
[0918] DMAP dimethylaminopyridine
[0919] DMF N,N' -Dimethylformamide
[0920] DTT dithiothreitol
[0921] DOT 3,6-dioxa-1,8-octanedithiol
[0922] EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
[0923] EDTA Ethylenediaminetetraacetic acid
[0924] ESI Electrospray ionization
[0925] FFA Fluorescence Focus Test
[0926] Fmoc Fluorenylmethyloxycarbonyl chloride
[0927] HCTU: O-(6-chlorobenzotriazole-1-yl)-N,N,N',N'-tetramethyluroronium Hexafluorophosphate
[0928] HEP heptane
[0929] HFIP Hexafluoroisopropanol
[0930] HPLC High-performance liquid chromatography
[0931] HRMS High-resolution mass spectrometry
[0932] HOBT Hydroxybenzotriazole
[0933] HS human serum
[0934] LC / MS Liquid Chromatography / Mass Spectroscopy
[0935] MS Mass Spectrometry
[0936] MW molecular weight
[0937] MRT Average time of stay
[0938] NHS N-hydroxysuccinimide
[0939] NMM N-methylmorpholine
[0940] NMR nuclear magnetic resonance
[0941] PEG polyethylene glycol
[0942] pE Pyroglutamate
[0943] pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl
[0944] PG: protector
[0945] PK pharmacokinetics
[0946] Pol Polymer support
[0947] QTOF: Quadrupole Time-of-Flight Mass Spectrometer
[0948] Rt: Time of stay
[0949] Rt or RT: room temperature
[0950] Rpm: revolutions per minute
[0951] Sc subcutaneously
[0952] SFC supercritical fluid
[0953] SPPS Solid-phase peptide synthesis
[0954] TBME methyl tert-butyl ether
[0955] Trt Tritil
[0956] THF Tetrahydrofuran
[0957] TEA trimethylamine
[0958] TIS triethylsilane
[0959] t, s, quin, br, m, d (triple, single, pentate, wide, multiply)
[0960] UPLC Ultra-high performance liquid chromatography
[0961] synthesis:
[0962] Described LCMS method
[0963]
[0964]
[0965] HPLC - Analysis Method F
[0966] Column: Xbridge BEH300 C18 (100×4.6 mm), 3 µm; Part n°: 186003612
[0967] Eluent A: 0.1% TFA in water / Eluent B: 0.1% TFA in ACN
[0968] Flow: 1.0 ml / min
[0969] Temperature: 40℃
[0970] gradient:
[0971]
[0972] UPLC-HRMS - Analysis Method G
[0973] Waters Aquiti UPLC® BEH C18, 1.7 µm, 2.1×50 mm; Part n°: 186002350
[0974] Eluent A: 0.05% FA in water + 3.75 mM ammonium acetate; Eluent B: 0.04% FA in ACN
[0975] Flow: 1.0 ml / min
[0976] Temperature: 50℃
[0977] Gradient: 2 → 98% in 4.4 minutes
[0978] Method H: LC-MS method
[0979] HPLC: Mobile phase A: 2% HFIP + 0.1% TEA; Mobile phase B: Methanol;
[0980] Gradient: 0 min 95% A, 4 min: 75% A, 8 min 10% A, 8.1 min 95% A, 10 min 95% A;
[0981] Flow rate: 250 µL / min;
[0982] Column: Aquiti UPLC BEH C18, 1.7 µm, 2.1×50 mm (Waters);
[0983] Column temperature: 75℃
[0984] MS: QTOF (Waters) Voice Mode;
[0985] ESI: 2.9kv; Capillary temperature 350℃; Nebulized gas: 600 mL / min; Source temperature: 150℃
[0986] Method I: LC-MS method :
[0987] Mobile phase A: water + 0.1% formic acid;
[0988] Mobile phase B: Acetonitrile + 0.1% formic acid;
[0989] Gradient: 0 min 98% A, 0.06 min 98% A, 1.76 min 2% A, 2.06 min 2% A, 2.16 min 98%; Flow rate: 1 ml / min.;
[0990] Column: Aquiti UPLC BEH C18, 130 Å, 1.7 µm, 2.1 mm × 50 mm;
[0991] Column temperature: 50℃;
[0992] Detector: UV / Vis / CAD (Charged Aerosol Detector)
[0993] UPLC HRMS Method J:
[0994] Column: Aquiti BEH300 C4 1.7 µm, 2.1×50 mm
[0995] Eluent A: Water (0.1% TFA)
[0996] Lung agent B: ACN (0.1% TFA)
[0997] Flow: 0.5 mL / min
[0998] Temperature: 40℃
[0999] gradient: Maintain at 20% for 0.5 minutes, rise to 80% ACN within 10 minutes.
[1000] Method K:
[1001] Column: Waters Protein BEH C4 Column, 300 Angstroms, 3.5 µm, 4.6×100 mm
[1002] Mobile phase: A: Water (0.05% TFA) B: ACN (0.05% TFA)
[1003] Flow: 2 mL / min
[1004] Temperature: 40℃
[1005] Gradient: Hold at 25% B for 1 minute, increase to 25-60% ACN at 10 minutes, increase to 95% B at 10.50 minutes and hold for 2 minutes, then equalize at 25% for 2 minutes. The total run time is 15 minutes.
[1006] Mass Spectrometer: Waters ZQ Mass Spectrometer
[1007] UPLC: Column: BEH C4, 300 Angstroms, 1.7 µm, 2.1×50 mm
[1008] Method L:
[1009] Column: ProSwift Monolith 4.6 × 50 mm
[1010] Mobile phase: A: Water (0.1% formic acid) B: ACN (0.1% formic acid)
[1011] Flow: 1 mL / min
[1012] Temperature: 50℃
[1013] Gradient: 0 min 3% B; 3% → 80% B within 2 minutes; 2.1 min 10% B; 2.8 min 95% B; 2.9 min 3% B
[1014] Mass Spectrometer: Qtof ESI scan range 100-1900; deconvolved into Max Ent 1 within the MathLynx software package
[1015] UPLC: Waters Aquiiti
[1016]
[1017]
[1018] Analysis Method S:
[1019] Xbridge C18 column, 3.5 μM, 3.0 × 3.0 mm
[1020] Eluent: A: Water + 5 mM ammonium hydroxide B: ACN
[1021] Flow rate: 2 mL / min
[1022] Gradient: 0.0 min 2% B; 2% → 95% B within 1.70 mins; 2.00 min 95% B; 2.10 min 5% B;
[1023] Mass Spectrometer: Single Quadrupole ESI
[1024] HPLC: Agilent 1100 Series
[1025] Temperature: 40C
[1026] Analysis Method T:
[1027]
[1028] Intermediate 1: Benzyl 11-bromoundecanoate
[1029]
[1030] 11-bromoundecanic acid (4 g, 15.08 mmol), benzyl alcohol (1.875 mL, 18.10 mmol), and DMAP (92 mg, 0.754 mmol) were dissolved in DCM under N2 at room temperature. EDC-HCl (4.34 g, 22.63 mmol) was added, and the reaction mixture was stirred for 17 hours. After concentrating the reaction mixture, it was diluted with Et2O (150 mL). The mixture was extracted with water (30 mL), and the aqueous phase was extracted with Et2O (150 mL). The combined organic matter was washed with brine (20 mL) and dried over Na2SO4. The solvent was removed, and the residue was purified using a flash column (silica 120 g, 0-10% Et2O / petroleum ether), yielding Intermediate 1 as a colorless liquid (6.75 g, quantitative): LCMS Method - Method A, Rt = 1.79 min, M+H 355.2; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.18 - 1.36 (m, 10 H) 1.37 - 1.47 (m, 2 H) 1.64 (quin, J =7.33 Hz, 2 H) 1.85 (dt, J =14.56, 7.06 Hz, 2 H) 2.35 (t, J =7.58 Hz, 2 H) 3.40 (t, J =6.88 Hz, 2 H) 5.11 (s, 2 H) 7.28 - 7.45 (m, 5 H).
[1031] Intermediate 2 : Tribenzyl undecane-1,1,11-tricarboxylate.
[1032]
[1033] NaH (113 mg, 2.83 mmol) was suspended in DMF (6 mL) under N2 at 0°C. Dibenzyl malonate (0.704 mL, 2.82 mmol) was added to the stirred suspension over 30 minutes. Intermediate 1 (903 mg, 2.54 mmol) dissolved in DMF (3 mL) was added, and the reaction mixture was stirred at 0°C for 2.75 hours, then heated to room temperature and stirred overnight. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (20 mL). The aqueous phase was extracted with Et2O (75 mL), and the combined organic matter was washed with brine (30 mL). The organic matter was dried over Na2SO4 and concentrated. The concentrate was purified using a flash column (silica 80 g, 0-10% EtOAc / HEP), yielding a colorless oil of 70% purity (770 mg, 1.38 mmol, 34%): LCMS Method - Method B, Rt = 1.41 min, M+H 559.6.
[1034] Intermediate 3: Tribenzyl docosan-1,11,11-tricarboxylate
[1035]
[1036] Intermediate 2 in DMF (4 mL) to a suspension of NaH (66.1 mg, 1.65 mmol) in DMF (2 mL) at 0°C under N2 (770 mg, 1.38 mmol) was added. After 35 minutes, a solution of 1-bromoundecane (0.338 mL, 1.52 mmol) in DMF (2 mL) was added to the reaction mixture, stirred for 25 minutes, and then heated to room temperature. The reaction mixture was stirred for 2 days. The reaction mixture was diluted with Et2O (75 mL) and extracted with 10% LiCl (25 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was washed with brine, dried over Na2SO4, and the solvent was evaporated. The residue was purified by flash column (silica 80 g, 0-10% EtOAc / HEP), and intermediate 3 was obtained as a colorless oil (590 mg, 0.827 mmol, 33%): LCMS Method - Method B, Rt= 1.89 min, M+Na 735.5; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.87 - 0.95 (m, 3 H) 1.07 (br. s., 4 H) 1.14 - 1.36 (m, 28 H) 1.66 (quin, J =7.43 Hz, 2 H) 1.85 - 1.95 (m, 4 H) 2.37 (t, J =7.58 Hz, 2 H) 5.12 (s, 4 H) 5.14 (s, 2 H) 7.27 (d, J =2.32 Hz, 1 H) 7.28 - 7.43 (m, 14 H).
[1037] Intermediate 4 : Dokosan-1,11,11-tricarboxylic acid
[1038]
[1039] Intermediate 3 (590 mg, 0.827 mmol) dissolved in THF (12 mL) was combined with a suspension of 10% Pd-carbon in THF (8 mL). The suspension was stirred and placed under a hydrogen atmosphere via a balloon. After 1 hour, the reaction mixture was passed through a membrane filter, and the solid was washed with EtOAc. The filtrate was evaporated, yielding the title compound as a colorless oil (353 mg, 0.798 mmol, 96%): LCMS Method - Method B, Rt = 1.16 min, M+H 443.5; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.77 - 0.84 (m, 3 H) 1.06 - 1.33 (m, 32 H) 1.59 (quin, J =7.18 Hz, 2 H) 1.83 - 1.92 (m, 4 H) 2.32 (t, J =7.03 Hz, 2 H).
[1040] Intermediate 5: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-undecyltridecandioic acid
[1041]
[1042] A solution of DCC (126 mg, 0.610 mmol) in DCM (1.57 mL) was added to a solution of intermediate 4 and N-hydroxysuccinimide in DCM (5 mL) and THF (5 mL) under N2. After 3.5 hours, the solvent was evaporated, and the residue was purified by supercritical fluid chromatography (SFC; Princeton 2-ethyl-pyridine, 20×150 mm, 20-30% MeOH / CO2), yielding the title compound as a colorless oil (138 mg, 0.256 mmol, 50%): LCMS - Method B, Rt = 1.21 min, M+H 540.5; 1 ¹H NMR (600 MHz, acetonitrile- d 3) δ ppm 0.91 (t, J =7.20 Hz, 3 H) 1.22 - 1.42 (m, 34 H) 1.57 (quin,J =7.34 Hz, 2 H) 1.93 - 1.96 (m, 2 H) 2.28 (t, J =7.47 Hz, 2 H) 2.79 (br. d, J =6.30 Hz, 4 H).
[1043] Intermediates 6 and 6A: 2-(azido-PEG23-carbamoyl)-2-undecyltridectodiosic acid construct (6) and 12-(azido-PEG23-carbamoyl)tricosonic acid construct (6A)
[1044]
[1045] Intermediate 5 (36 mg, 0.066 mmol) and azido-dPEG23-NH2 (Quanta Biodesign: 73 mg, 0.066 mmol) were combined in THF (1.5 mL) and mixed on a shaker plate for 15 minutes, after which DIPEA (17 µL, 0.10 mmol) was added. The reaction mixture was placed on a shaker plate overnight. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm, 55-80% ACN / water + 0.1% TFA) to obtain intermediate 6 (39 mg, 0.025 mmol, 38%) and intermediate 6a (20 mg, 0.013 mmol, 20%) was calculated: LCMS - Method B, Rt = 1.11 min, [M+2H] +2 763.4; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.86 - 0.93 (m, 3 H) 1.10 - 1.19 (m, 2 H) 1.20 - 1.29 (m, 23 H) 1.32 (br. s., 7 H) 1.58 - 1.69 (m, 2 H) 1.69 - 1.79 (m, 2 H) 1.96 - 2.10 (m, 2 H) 2.35 (t, J =7.15 Hz, 2 H) 3.41 (t, J=5.07 Hz, 2 H) 3.51 - 3.57 (m, 2 H) 3.58 - 3.62 (m, 2 H) 3.62 - 3.73 (m, 90 H) 7.46 (br. s., 1 H); LCMS - 방법 B, Rt = 1.23분, [M+2] +2 740.9; 1 H NMR (400 MHz, 클로로포름- d ) δ ppm 0.83 - 0.96 (m, 3 H) 1.27 (br. s., 25 H) 1.29 - 1.37 (m, 7 H) 1.37 - 1.46 (m, 2 H) 1.53 - 1.73 (m, 4 H) 2.34 (t, J =7.21 Hz, 2 H) 3.41 (t, J =5.07 Hz, 2 H) 3.44 - 3.52 (m, 2 H) 3.55 - 3.60 (m, 2 H) 3.60 - 3.74 (m, 90 H) 6.19 - 6.30 (m, 1 H).
[1046] Alternatively, construct 6A was obtained according to the following procedure: a solution of intermediate 5 (48 mg, 0.042 mmol) in THF (1 mL) was added to a vial filled with azido-PEG23-amine (Quanta Biodesign Catalog # 10525) (46 mg, 0.042 mmol). After vortexing the reaction mixture for 20 minutes, DIPEA (11 µL, 0.063 mmol) was added and maintained overnight. Azido-PEG23-amine (23 mg, 0.021 mmol) and DIPEA (5 µL, 0.029 mmol) were added, and the reaction mixture was vortexed for one more day. The solvent was evaporated, and the residue was purified by HPLC (Exbridge C18 30×50 mm, 10-30% ACN / 5 mM NH4OH). Lyophilization of the fractions resulted in a mixture of products. The material was purified by HPLC (Sunfire C18 30×50 mm, 45-70% ACN / water + 0.1% TFA), yielding title intermediate 6A (30 mg, 0.020 mmol, 48%): LCMS method - B, Rt = 0.81 min, [M+H+H3O] +2 764.5; 1 ¹H NMR (400 MHz, acetonitrile- d 3) δ ppm 1.30 (br. s., 28 H) 1.40 - 1.50 (m, 2 H) 1.50 - 1.62 (m, 6 H) 2.14 (t, J =7.52 Hz, 2 H) 2.23 - 2.35 (m, 3 H) 3.32 (q, J =5.58 Hz, 2 H) 3.37 - 3.43 (m, 2 H) 3.47 - 3.52 (m, 2 H) 3.53 - 3.68 (m, 90 H) 6.54 (br. s., 1 H).
[1047] Intermediate 7: (((11-bromoundecyl)oxy)methanetriyl)tribenzene
[1048]
[1049] Trityl chloride (2.49 g, 8.92 mmol), 11-bromoundecan-1-ol (2.00 g, 7.96 mmol), and DMAP (10 mg, 0.080 mmol) were dissolved in DCM (16 mL) under N2. While stirring, DIPEA (1.39 mL, 7.96 mmol) was added, and the reaction mixture was maintained for 7 days. The reaction mixture was fractionated between DCM (20 mL) and water (10 mL). The organic phase was extracted with water (20 mL), dried over MgSO4, and concentrated. The concentrate was purified using a flash column (120 g silica, 0-6% EtOAc / HEP), Intermediate 7 (2.50 g, 5.07 mmol, 64%) was produced as a colorless oil: 1H NMR (400 MHz, chloroform- d ) δ ppm 1.19 - 1.49 (m, 14 H) 1.58 - 1.69 (m, 2 H) 1.79 (dt, J =14.50, 7.00 Hz, 1 H) 1.87 (dt, J =14.55, 7.03 Hz, 1 H) 3.07 (t, J =6.66 Hz, 2 H) 3.43 (t, J =6.85 Hz, 1 H) 3.55 (t, J =6.79 Hz, 1 H) 7.18 - 7.36 (m, 10 H) 7.42 - 7.52 (m, 5 H).
[1050] Intermediate 8: Dibenzyl 2-(11-(trityloxy)undecyl)malonate
[1051]
[1052] NaH (113 mg, 2.83 mmol) was suspended in DMF (6 mL) under N2 at 0°C. Dibenzyl malonate was slowly added to the stirred suspension. After 30 minutes, in DMF (3 mL) Intermediate 7A solution of (1.26 g, 2.54 mmol) was added. After stirring for 15 minutes, the resulting mixture was heated to room temperature. After 3 days, the reaction mixture was diluted with Et2O (75 mL) and extracted with water (40 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was dried over Na2SO4 and concentrated. The concentrate was purified using a flash column (80 g silica, 0-10% EtOAc / HEP), and the title compound was obtained as a colorless oil (815 mg, 1.17 mmol, 41%): HPLC - Method B, Rt = 1.68 min; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.16 - 1.40 (m, 16 H) 1.58 - 1.69 (m, 2 H) 1.94 (q, J =7.38 Hz, 2 H) 3.06 (t, J =6.66 Hz, 2 H) 3.45 (t, J =7.52 Hz, 1 H) 5.16 (s, 4 H) 7.21 - 7.28 (m, 3 H) 7.28 - 7.39 (m, 16 H) 7.42 - 7.51 (m, 6 H).
[1053] Intermediate 9: Tribenzyl 22-(tritiloxy)docosan-1,11,11-tricarboxylate
[1054]
[1055] Intermediate in DMF (2 mL) 8A solution of (815 mg, 1.17 mmol) was added to a suspension of NaH (56 mg, 1.40 mmol) in DMF (2 mL) at 0°C under N2. The mixture was stirred for 1 hour. Benzyl 11-bromoundecanoate (457 mg, 1.29 mmol) in DMF (2 mL) was added to the reaction mixture. After addition, the reaction mixture was heated to room temperature for 20 minutes and stirred overnight. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (25 mL). The aqueous phase was extracted with Et2O (75 mL), and the organic matter was combined. The combined organic matter was dried over Na2SO4 and evaporated. The residue was purified using a flash column (40 g silica, 0-10% EtOAc / HEP), and the title compound was obtained as a colorless oil (780 mg, 0.803 mmol, 69%): 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.99 - 1.14 (m, 4 H) 1.15 - 1.41 (m, 26 H) 1.58 - 1.71 (m, 4 H) 1.82 - 1.96 (m, 4 H) 2.37 (t, J =7.52 Hz, 2 H) 3.06 (t, J =6.66 Hz, 2 H) 5.12 (s, 4 H) 5.14 (s, 2 H) 7.28 (s, 24 H) 7.42 - 7.52 (m, 6 H).
[1056] Intermediate 10: 22-(tritiloxy)docosan-1,11,11-tricarboxylic acid
[1057]
[1058] A suspension of 10% Pd-carbon (11 mg, 0.010 mmol) in THF (2.5 mL) as an intermediate in THF (2.5 mL) 9It was added to a solution of (200 mg, 0.206 mmol). The stirred suspension was placed under hydrogen via a balloon. After 2.25 hours, the reaction mixture was passed through a membrane filter, and the solid was washed with EtOAc. The filtrate was evaporated to obtain the intermediate 10 (150 mg, quantitative) was calculated: 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.04 - 1.33 (m, 30 H) 1.45 - 1.62 (m, 4 H) 1.76 - 1.91 (m, 4 H) 2.21 - 2.36 (m, 2 H) 2.97 (t, J =6.60 Hz, 2 H) 7.06 - 7.18 (m, 4 H) 7.19 - 7.24 (m, 5 H) 7.33 - 7.50 (m, 6 H).
[1059] Intermediate 11: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-(11-(trityloxy)undecyl)tridecandioic acid (11).
[1060]
[1061] intermediate 10 (150 mg, 0.214 mmol) and N-hydroxysuccinimide (25 mg, 0.214 mmol) were combined in DCM (4 mL). DCC (49 mg, 0.235 mmol) dissolved in DCM (0.61 mL) was added, and the reaction mixture was stirred at room temperature for 7 hours. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm; 65-95% ACN / water + 0.1% TFA) followed by SFC (Princeton 2-ethylpyridine column 20×100 mm, 25-35% MeOH / CO2) to obtain the intermediate 11 (34 mg, 0.043 mmol, 20%) was obtained as a colorless oil: LCMS - Method B, Rt = 1.47 min, M-CO2H 752.7; 1 ¹H NMR (400 MHz, chloroform- d) δ ppm 1.13 - 1.42 (m, 30 H) 1.56 - 1.73 (m, 4 H) 1.94 - 2.14 (m, 4 H) 2.37 (t, J =7.21 Hz, 2 H) 2.83 (br. s., 4 H) 3.06 (t, J =6.66 Hz, 2 H) 7.15 - 7.28 (m, 3 H) 7.29 - 7.36 (m, 6 H) 7.41 - 7.50 (m, 6 H).
[1062] Intermediate 12: 2-((azido-PEG23)carbamoyl)-2-(11-hydroxyundecyl)tridecandioic acid construct
[1063]
[1064] Azido-dPEG23-amine (Quanta Biodesign, 42 mg, 0.038 mmol) in THF (1.5 mL) as an intermediate under N2 11 It was combined with (34 mg, 0.043 mmol). The reaction mixture was placed on a shaker plate and vortexed for 20 minutes. DIPEA (7.44 µL, 0.043 mmol) was added, and the reaction mixture was vortexed for 2 hours. DIPEA (4 µL, 0.023 mmol) was added, and the reaction mixture was kept overnight. The solvent was evaporated, and the residue was dissolved in DCM (3 mL) and TFA (0.5 mL). The solution was vortexed for 1 hour, at which point the solvent was removed. The residue was purified by HPLC (Sunfire C18 30×50 mm, 45-70% ACN / water + 0.1% TFA), and the intermediate 12 (4 mg, 1.8 μmol, 4.2%) was calculated: LCMS - Method B, Rt = 0.75 min, [M+2H] +2 771.4; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.05 - 1.39 (m, 30 H) 1.52 - 1.82 (m, 6 H) 1.97 - 2.09 (m, 2 H) 2.35 (t, J =7.21 Hz, 2 H) 3.41 (t,J =5.07 Hz, 2 H) 3.51 - 3.63 (m, 6 H) 3.63 - 3.75 (m, 90 H) 4.36 (t, J =6.72 Hz, 1 H) 7.49 - 7.65 (m, 1 H).
[1065] Intermediate 13: 13-(benzyloxy)-12-((benzyloxy)carbonyl)-13-oxotridecanic acid
[1066]
[1067] Dibenzyl malonate (0.88 mL, 3.52 mmol) in DMF (3 mL) was slowly added to a suspension of NaH (274 mg, 6.86 mmol) under N2 at 0°C. The mixture was stirred for 1.5 hours, after which it was heated to room temperature. 11-bromoundecanic acid (933 mg, 3.52 mmol) in DMF (3 mL) was added, and the reaction was allowed to proceed overnight. The reaction mixture was heated to 80°C for 3 hours, after which it was cooled. The reaction mixture was diluted with EtOAc (50 mL) and Et2O (50 mL) and extracted with 1 M HCl (25 mL). The aqueous phase was extracted with EtOAc / Et2O (100 mL). The combined organic matter was dried over Na2SO4, and the solvent was evaporated. The residue was purified using a flash column (C18 50 g 30-100% ACN / water + 0.1 TFA), and the intermediate 13 (315 mg, 0.672 mmol, 19%) was produced as a white powder: LCMS - Method B, Rt = 1.05 min, M+H 469.5.
[1068] Intermediate 14: 23-(benzyloxy)-12,12-bis((benzyloxy)carbonyl)-23-oxotricosanic acid
[1069]
[1070] NaH (54 mg, 1.34 mmol) was suspended in DMF (1 mL) under N2 at 0°C. The intermediate in DMF (3 mL) in the mixture 13(315 mg, 0.672 mmol) was added dropwise. After stirring the reaction mixture for 1 hour, the intermediate in DMF (1 mL) 1 (239 mg, 0.672 mmol) was added. The reaction mixture was held at 0°C for an additional 45 minutes, then heated to room temperature. The reaction mixture was stirred overnight. The reaction mixture was diluted with 1:1 Et2O and EtOAc (75 mL) and extracted with 1 M HCl (20 mL). The aqueous phase was extracted with 1:1 Et2O and EtOAc (75 mL). The combined organic matter was dried over Na2SO4 and evaporated. The resulting residue was purified by HPLC (Exbridge C18 30×50 mm, 45-70% ACN / water + 5 mM NH4OH), yielding the title compound (132 mg, 0.178 mmol, 26%): LCMS method - B; Rt= 1.53 min, MH 741.8.
[1071] Intermediate 15 : 1,11,11-tribenzyl 21-(2,5-dioxopyrrolidine-1-yl)henicosan-1,11,11,21-tetracarboxylate
[1072]
[1073] DCC (44 mg, 0.213 mmol) in DCM (1 mL) as an intermediate in DCM (2.5 mL) 14 It was added to a solution of (132 mg, 0.178 mmol) and N-hydroxysuccinimide (20 mg, 0.178 mmol). The reaction mixture was vortexed on a shaker plate for 17 hours. The reaction mixture was filtered, and the solid was washed with DCM. The filtrate was concentrated and purified using a flash column (12 g silica, 0-40% EtOAc / HEP) to obtain the intermediate 15 (107 mg, 0.127 mmol, 72%) was calculated: LCMS - Method B, Rt = 1.53 min, M+Na 862.8.
[1074] Intermediate 16: 22-((2,5-dioxopyrrolidine-1-yl)oxy)-22-oxodochosan-1,11,11-tricarboxylic acid
[1075]
[1076] Intermediate in THF (2.5 mL) 15 A suspension of 10% Pd-carbon in 2.5 mL of THF was added to a solution of (107 mg, 0.127 mmol). The mixture was incubated under a hydrogen atmosphere for 1.5 hours. The reaction mixture was passed through a membrane filter, and the solid was washed with DCM and THF. The filtrate was evaporated to yield a colorless oil (95 mg, quantitative) containing the title compound: LCMS - Method B, Rt = 0.65 min, M+H 570.5.
[1077] Intermediate 17: 2-(11-(azido-PEG23-amino)-11-oxoundecyl)tridecandioic acid construct
[1078]
[1079] Intermediate in THF (1 mL) 16 A solution of azido-dPEG23-amine (48 mg, 0.042 mmol) was added to a vial filled with azido-dPEG23-amine (Quanta Biodesign: 46 mg, 0.042 mmol). After vortexing the reaction mixture for 20 minutes, DIPEA (11 µL, 0.063 mmol) was added and maintained overnight. Azido-PEG23-amine (23 mg, 0.021 mmol) and DIPEA (5 µL, 0.029 mmol) were added, and the reaction mixture was vortexed for one more day. The solvent was evaporated, and the residue was purified by HPLC (Exbridge C18 30×50 mm, 10-30% ACN / 5 mM NH4OH). Freeze-drying of the fractions resulted in a mixture of products. The substance was purified by HPLC (Sunfire C18 30×50 mm, 45-70% ACN / water + 0.1% TFA), and the title intermediate 17 (30 mg, 0.020 mmol, 48%) was calculated: LCMS SQ4, Rt = 0.81 min, [M+H+H3O] +2 764.5; 1 ¹H NMR (400 MHz, acetonitrile- d3) δ ppm 1.30 (br. s., 28 H) 1.40 - 1.50 (m, 2 H) 1.50 - 1.62 (m, 6 H) 2.14 (t, J =7.52 Hz, 2 H) 2.23 - 2.35 (m, 3 H) 3.32 (q, J =5.58 Hz, 2 H) 3.37 - 3.43 (m, 2 H) 3.47 - 3.52 (m, 2 H) 3.53 - 3.68 (m, 90 H) 6.54 (br. s., 1 H).
[1080] Intermediate 18: Tetrabenzyl henicosan-1,11,11,21-tetracarboxylate
[1081]
[1082] Intermediate in DMF (2 mL) in a suspension of NaH (48 mg, 1.21 mmol) in DMF (2 mL) at 0°C under N2 2 (337 mg, 0.603 mmol) was slowly added. After stirring the mixture for 15 minutes, the intermediate in DMF (2 mL) 1 (429 mg, 1.21 mmol) was added. The reaction mixture was stirred at 0°C for 20 minutes, then heated to room temperature. The reaction mixture was maintained at room temperature for 3 days while stirring. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (20 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was dried on a Na2SO4 phase and evaporated. The residue was purified using a flash column (silica 24 g, 0-15% EtOAc / HEP), yielding the title compound (315 mg, 0.378 mmol, 63%): LCMS - Method B, Rt = 1.70 min, M+Na 855.8; 1 ¹H NMR (400 MHz, chloroform- d) δ ppm 0.95 - 1.13 (m, 4 H) 1.13 - 1.40 (m, 24 H) 1.59 - 1.72 (m, 4 H) 1.82 - 1.95 (m, 4 H) 2.37 (t, J =7.52 Hz, 4 H) 5.12 (s, 4 H) 5.14 (s, 4 H) 7.14 - 7.44 (m, 20 H).
[1083] Intermediate 19 Henicosan-1,11,11,21-tetracarboxylic acid
[1084]
[1085] A suspension of 10% Pd-carbon (20 mg, 0.019 mmol) in THF (4 mL) as an intermediate in THF (6 mL) 18 It was added to a solution of (315 mg, 0.378 mmol), and the reactants were placed under a hydrogen atmosphere for 2 hours. The solid was removed using a membrane filter and washed with EtOAc. The filtrate was evaporated to obtain the intermediate 19 (179 mg, quantitative) was calculated as a white solid: LCMS - Method A, Rt = 1.24 min, M+H 473.4; 1 ¹H NMR (400 MHz, DMSO- d 6) δ ppm 0.99 - 1.15 (m, 4 H) 1.24 (br. s., 24 H) 1.48 (quin, J =6.94 Hz, 4 H) 1.62 - 1.76 (m, 4 H) 2.18 (t, J =7.34 Hz, 4 H) 12.23 (br. s, 4 H).
[1086] Intermediate 20 : 11-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)henicosic acid-1,11,21-tricarboxylic acid
[1087]
[1088] N-hydroxysuccinimide (20 mg, 0.170 mmol) and intermediate 19(90 mg, 0.190 mmol) was dissolved in DCM (3 mL) and THF (0.3 mL). A solution of DCC (39 mg, 0.190 mmol) in DCM (0.5 mL) was added, and the reaction mixture was vortexed overnight. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm; 35-60% ACN / water + 0.1% TFA), yielding the title compound as a white powder (21 mg, 0.037 mmol, 19%): LCMS-Method C, Rt = 1.01 min, M+H 570.3.
[1089] Intermediates 21 and 21a : 11-((azido-PEG23)carbamoyl)henicosan-1,11,21-tricarboxylic acid (21) and 12-((azido-PEG23)carbamoyl)tricosandiosan (21a)
[1090]
[1091] Azido-PEG23-amine (41 mg, 0.037 mmol) and intermediate 20 (21 mg, 0.037 mmol) was combined in THF (1 mL) and vortexed for 10 minutes. DIPEA (9.66 µL, 0.055 mmol) was added, and the reaction mixture was vortexed overnight. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm, 35-60% ACN / water + 0.1% TFA) to obtain the intermediate 21 (22 mg, 0.014 mmol, 38%) and 21a (4 mg, 2.6 μmol, 7%) was calculated: LCMS - Method B, Rt = 0.69 min, M+H 1555.3; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.27 (br. s., 19 H) 1.29 - 1.41 (m, 9 H) 1.65 (quin, J =7.12 Hz, 4 H) 1.78 (td, J =12.13, 4.22 Hz, 2 H) 1.95 - 2.08 (m, 2 H) 2.35 (t, J =7.21 Hz, 4 H) 3.41 (t, J=5.07 Hz, 2 H) 3.54 (q, J =5.05 Hz, 2 H) 3.58 - 3.77 (m, 92 H) 7.60 (t, J =4.95 Hz, 1 H); LCMS - 방법 B, Rt = 0.78분, M-H 1509.3; 1 H NMR (400 MHz, 클로로포름- d ) δ ppm 1.18 (br. s., 19 H) 1.21 - 1.38 (m, 11 H) 1.43 - 1.63 (m, 6 H) 1.91 - 2.04 (m, 1 H) 2.26 (t, J =7.15 Hz, 4 H) 3.31 (t, J =5.07 Hz, 2 H) 3.40 (q, J =5.14 Hz, 2 H) 3.46 - 3.50 (m, 2 H) 3.51 - 3.69 (m, 90 H) 6.23 (t, J =5.01 Hz, 1 H).
[1092] Intermediate 22: Dibenzyl 2-undecylmalonate
[1093]
[1094] Dibenzyl malonate (0.88 mL, 3.52 mmol) in DMF (1.5 mL) was added dropwise to a suspension of NaH (155 mg, 3.87 mmol) in DMF (6 mL) under N2 at 0°C. After stirring the mixture for 30 minutes, 1-bromoundecane (0.785 mL, 3.52 mmol) in DMF (1.5 mL) was added to the reaction mixture. The reaction mixture was heated to room temperature and stirred for 5 days. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (20 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was dried over Na2SO4 and evaporated. The residue was purified by flash column (silica 80 g, 0-10% EtOAc / HEP), and the title compound (974 mg, 2.22 mmol, 63%) was obtained as a colorless oil: LCMS - Method B, Rt = 1.55 min, M+H 439.5.
[1095] Intermediate 23: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-undecyltridecanoic acid
[1096]
[1097] Dibenzyl 2-undesylmalonate (intermediate 22: 400 mg, 0.912 mmol) in DMF (1 mL) was added dropwise to a suspension of NaH (44 mg, 1.09 mmol) in DMF (2 mL) under N2 at 0°C. After stirring the mixture for 45 minutes, 1-bromoundecane (0.285 mL, 1.28 mmol) in DMF (1 mL) was added to the reaction mixture. The reaction mixture was heated to room temperature and stirred for 1 day. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (20 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was dried over Na2SO4 and evaporated. The residue was purified using a flash column (silica 40 g, 0-5% EtOAc / HEP), yielding a colorless oil (412 mg). The oil was dissolved in THF / MeOH and passed through a Thales Nano H-Cube (1 mL / min, 2 bar H2, 22°C) equipped with a 10% Pd / C cartridge. The effluent was collected and evaporated to yield a waxy solid (272 mg). The waxy solid was dissolved in 3:1 DCM / THF and concentrated into oil. The oil was redissolved in DCM (6 mL) under N2, N-hydroxysuccinimide (68 mg) was added, followed by the addition of DCC (136 mg) in DCM (3 mL). The reaction mixture was stirred for 1 day. The reaction mixture was filtered, and the filtrate was concentrated. The concentrate was purified using a flash column (12 g C18, 25-100% ACN / water + 0.1% formic acid). The generated material was further purified by supercritical fluid chromatography (Princeton 2-ethylpyridine 20×150 mm; 5-15% MeOH / CO2) to obtain the intermediate 23 (37 mg, 0.073 mmol, 8%) was calculated: LCMS - Method B, Rt = 1.67 min, M+NH4527.6; 1 ¹H NMR (400 MHz, chloroform- d) δ ppm 0.80 - 0.94 (m, 6 H) 1.18 - 1.42 (m, 36 H) 1.97 - 2.14 (m, 4 H) 2.87 (br. s., 4 H).
[1098] Intermediate 24: 2-((azido-PEG23)carbamoyl)-2-undecyltridecanate
[1099]
[1100] Intermediate in THF (1 mL) 23 A solution of (37 mg, 0.073 mmol) was added to a vial filled with azido-dPEG23-amine (Quanta Biodesign: 80 mg, 0.073 mmol). The solution was vortexed on a shaker plate, and DIPEA (11 µL, 0.065 mmol) was added. After vortexing the reaction mixture overnight, an additional amount of DIPEA (12 µL, 0.071 mmol) was added, and the reaction was allowed to proceed overnight. The solvent was evaporated, and the residue was purified by supercritical fluid chromatography (Princeton Amino 21×150 mm; 20-30% MeOH / CO2), yielding the title compound (45 mg, 0.030 mmol, 41%): LCMS - Method B, Rt = 1.50 min, [M+2H] +2 748.1; 1 ¹H NMR (400 MHz, chloroform- d ) σ ppm 0.90 (t, J =6.85 Hz, 6 H) 1.09 - 1.38 (m, 30 H) 1.58 (br. s., 12 H) 1.64 - 1.76 (m, 2 H) 1.98 - 2.16 (m, 2 H) 3.41 (t, J =5.14 Hz, 2 H) 3.46 - 3.64 (m, 5 H) 3.64 - 3.91 (m, 83 H).
[1101] Intermediate 25: di-tert-butyl 2-undecymalonate
[1102]
[1103] Di-tert-butyl malonate (1.0 g, 4.62 mmol) in DMF (2 mL) was added to a suspension of NaH (213 mg, 5.32 mmol) in DMF (5 mL) under N2 at 0°C. After stirring the reaction mixture for 30 minutes, 1-bromoundecane in DMF (2 mL) was added. Upon addition, the reaction mixture was heated to room temperature and stirred for 2 days. The reaction mixture was diluted with Et2O (75 mL) and extracted with water (25 mL). The aqueous phase was extracted with Et2O (75 mL). The combined organic matter was dried over Na2SO4 and evaporated. The concentrate was purified using a flash column (120 g silica, 0-40% Et2O / petroleum ether) to obtain the intermediate 25 (0.998g, 2.69 mmol, 58%) was calculated: LCMS - Method B, Rt = 1.64 min, M+Na 393.5; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.85 - 0.94 (m, 3 H) 1.24 - 1.36 (m, 18 H) 1.41 - 1.52 (m, 18 H) 1.74 - 1.86 (m, 2 H) 3.13 (t, J =7.58 Hz, 1 H).
[1104] Intermediate 26 : 1-Benzyl 11,11-di-tert-butyl docosan-1,11,11-tricarboxylate
[1105]
[1106] intermediate 25 cast intermediate using starting material 9 The title compound was synthesized in a similar manner, yielding a colorless oil (980 mg, 1.52 mmol, 66%): 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.89 (t, J=6.91 Hz, 3 H) 1.06 - 1.20 (m, 4 H) 1.20 - 1.35 (m, 28 H) 1.45 (s, 18 H) 1.58 - 1.70 (m, 2 H) 1.72 - 1.83 (m, 4 H) 2.36 (t, J =7.52 Hz, 2 H) 5.12 (s, 2 H) 7.30 - 7.45 (m, 5 H).
[1107] Intermediate 27 : 12,12-bis(tert-butoxycarbonyl)tricosanic acid
[1108]
[1109] intermediate 26 Using, the title compound (472 mg, 0.851 mmol, 100%) as an intermediate 19 Synthesized in a similar manner to: LCMS - Method B, Rt = 1.76 min, MH 553.6; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.84 - 0.95 (m, 3 H) 1.07 - 1.21 (m, 4 H) 1.21 - 1.40 (m, 28 H) 1.46 (s, 18 H) 1.58 - 1.70 (m, 2 H) 1.72 - 1.84 (m, 4 H) 2.37 (t, J =7.46 Hz, 2 H).
[1110] Intermediate 28: 11,11-di-tert-butyl 1-(2,5-dioxopyrrolidine-1-yl) docosan-1,11,11-tricarboxylate
[1111]
[1112] intermediate 27(200 mg, 0.360 mmol) and N-hydroxysuccinimide (42 mg, 0.360 mmol) were dissolved in DCM (3 mL). A solution of DCC (89 mg, 0.433 mmol) in DCM (1.6 mL) was added, and the reaction mixture was stirred for 4.5 hours. The reaction mixture was filtered, and the filtrate was concentrated. The concentrate was purified using a flash column (silica 24 g, 0-40% EtOAc / HEP), and the title compound was obtained as a colorless oil (70 mg, 0.107 mmol, 30%): LCMS - Method B, Rt = 1.74 min, M+Na 674.7.
[1113] Intermediates 29 and 29A: 2-(11-((azido-PEG23)-amino)-11-oxo-undecyl)-2-undecylmalonic acid (29) and 13-((azido-PEG23)-amino)-13-oxo-2-undecyltridecanoic acid (29A)
[1114]
[1115] Intermediate in THF (1 mL) 28 A solution of (35 mg, 0.054 mmol) was added to a vial filled with azido-PEG23-amine (59 mg, 0.054 mmol). DIPEA (14 µL, 0.081 mmol) was added, and the reaction mixture was vortexed overnight. The solvent was evaporated, and the residue was redissolved in DCM (1 mL) and TFA (0.2 mL). After vortexing the reaction mixture for 1.25 hours, the solvent was evaporated. The residue was purified by HPLC (Sunfire 30×50 mm C18, 55-80% ACN / water + 0.1% TFA), the resulting material was redissolved in DCM (4 mL) and TFA (2 mL), and vortexed for 1.5 hours. The solvent was evaporated, and the residue was purified by HPLC (Sunfire 30×50 mm C18, 55-80% ACN / water + 0.1% TFA) to obtain the intermediate 29 (28 mg, 0.016 mmol, 29%) and intermediate 29A (1 mg, 0.6 μmol, 1%) was calculated: LCMS - Method B, Rt = 1.08 min, [M+H+H3O] +2 771.5; 1¹H NMR (400 MHz, chloroform- d ) σ ppm 0.90 (t, J =6.72 Hz, 3 H) 1.26 (br. s., 24 H) 1.32 - 1.41 (m, 8 H) 1.62 (quin, J =7.64 Hz, 2 H) 1.88 - 2.01 (m, 4 H) 2.31 (t, J =7.70 Hz, 2 H) 3.41 (t, J =5.07 Hz, 2 H) 3.46 - 3.56 (m, 3 H) 3.57 - 3.90 (m, 91 H); LCMS - Method B, Rt = 1.29 min, [M+2H] +2 741.1.
[1116] Intermediate 30: 22-((azido-PEG23)amino)-22-oxodochosan-1,11,11-tricarboxylic acid
[1117]
[1118] Intermediate in THF (1 mL) 16 A solution of (58 mg, 0.063 mmol) was added to a vial filled with azido-PEG23-amine (70 mg, 0.063 mmol). DIPEA (17 µL, 0.095 mmol) was added, and the reaction mixture was vortexed overnight on a shaker plate. The reaction mixture was concentrated and purified by HPLC (Sunfire C18 30×50 mm, 35-60% ACN / water + 0.1% TFA), and the intermediate 30 (57 mg, 0.036 mmol, 57%) was produced as a white waxy solid: LCMS - Method B, Rt = 0.62 min, M+H 1555.4; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.28 (br. s., 18 H) 1.30 - 1.40 (m, 10 H) 1.63 (m, J =7.10, 7.10, 7.10, 7.10, 7.10 Hz, 4 H) 1.88 - 2.02 (m, 4 H) 2.28 (t, J=8.10 Hz, 2 H) 2.35 (t, J =7.40 Hz, 2 H) 3.41 (t, J =5.07 Hz, 2 H) 3.50 (dt, J =9.20, 4.39 Hz, 2 H) 3.57 - 3.63 (m, 2 H) 3.63 - 3.73 (m, 90 H)
[1119] Intermediate 31: 1-Benzyl 3-tert-butyl 2-undecylmalonate
[1120]
[1121] Benzyl tert-butyl malonate (1.0 g, 4.0 mmol) in DMF (2 mL) was added to a suspension of NaH (160 mg, 4.0 mmol) in DMF (8 mL) at 0°C under N2. After stirring the mixture for 50 minutes, 1-bromoundecane in DMF (2 mL) was added. After stirring for an additional hour, the reaction mixture was heated to room temperature. The reaction mixture was kept overnight. Et2O (100 mL) and water (20 mL) were added to fractionate the reaction mixture. The aqueous phase was extracted with Et2O (100 mL), and the combined organic matter was dried over Na2SO4. The solvent was evaporated, and the residue was purified using a flash column (C18 12 g, 40-100% ACN / water + 0.1% TFA), yielding the title compound as a colorless oil (1.14 g, 2.82 mmol, 71%): LCMS - Method A, Rt = 1.58 min, M+Na 427.4; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.84 - 0.96 (m, 3 H) 1.28 (br. s, 12 H) 1.31 (m, J =3.90 Hz, 6 H) 1.41 (s, 9 H) 1.88 (q, J =7.38 Hz, 2 H) 3.29 (t, J =7.58 Hz, 1 H) 5.19 (q, J=12.27 Hz, 2 H) 7.30 - 7.42 (m, 5 H).
[1122] Alternatively, alkylation of tert-butyl malonate can be performed using 1-iodoundecane (1.2 equivalents) in the presence of potassium carbonate (2 equivalents) in DMF.
[1123] Intermediate 32 : 1,11-Dibenzyl 11-tert-butyl docosan-1,11,11-tricarboxylate
[1124]
[1125] intermediate 31 Using (650 mg, 1.61 mmol) as a starting material, the intermediate 9 The title compound was synthesized in a similar manner, yielding a colorless oil (823 mg, 1.21 mmol, 75%): 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.84 - 0.94 (m, 3 H) 1.12 (m, J =6.60 Hz, 4 H) 1.19 - 1.33 (m, 28 H) 1.35 (s, 9 H) 1.66 (quin, J =7.40 Hz, 2 H) 1.85 (t, J =8.44 Hz, 4 H) 2.37 (t, J =7.52 Hz, 2 H) 5.14 (s, 2 H) 5.16 (s, 2 H) 7.30 - 7.42 (m, 10 H).
[1126] Intermediate 33: 13-(benzyloxy)-2-((benzyloxy)carbonyl)-13-oxo-2-undecyltridecanate
[1127]
[1128] Intermediate in DCM (3 mL) 32TFA (0.6 mL) was added to a solution of (200 mg, 0.295 mmol), and the reaction mixture was stirred at room temperature for 3 hours. The solvent was evaporated, and the residue was purified using a flash column (12 g silica, 0-15% EtOAc / HEP), yielding the title compound (177 mg, 0.284 mmol, 96%): 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.87 - 0.94 (m, 3 H) 0.94 - 1.05 (m, 2 H) 1.19 (br. s., 14 H) 1.23 - 1.37 (m, 16 H) 1.65 (quin, J =7.40 Hz, 2 H) 1.78 - 1.91 (m, 2 H) 1.93 - 2.05 (m, 2 H) 2.37 (t, J =7.52 Hz, 2 H) 5.14 (s, 2 H) 5.27 (s, 2 H) 7.31 - 7.44 (m, 10 H).
[1129] Intermediate 34: 1,11-Dibenzyl 11-(2,5-dioxocyclopentyl)docosan-1,11,11-tricarboxylate
[1130]
[1131] intermediate 33 Using (177 mg, 0.284 mmol) as a starting material, the intermediate 15 The title compound was synthesized in a similar manner, yielding a colorless oil (153 mg, 0.213 mmol, 75%): 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.86 - 0.93 (m, 3 H) 1.12 - 1.21 (m, 2 H) 1.21 - 1.37 (m, 30 H) 1.66 (quin, J =7.40 Hz, 2 H) 1.89 - 2.07 (m, 4 H) 2.37 (t, J=7.58 Hz, 2 H) 2.84 (br. s., 4 H) 5.13 (s, 2 H) 5.25 (s, 2 H) 7.30 - 7.47 (m, 10 H).
[1132] Intermediate 35:
[1133]
[1134] Intermediate in THF (1.5 mL) and DCM (1.5 mL) 34 A solution of (145 mg, 0.201 mmol) was added to a vial filled with amino-PEG24-acid. DIPEA (88 µL, 0.504 mmol) was added, and the reaction mixture was vortexed on a shaker plate for 15 hours. The solvent was evaporated, and the residue was purified by supercritical fluid chromatography (Waters HILIC 20×150 mm; 15-25% MeOH / CO2) to obtain the intermediate 35 (151 mg, 0.086 mmol, 43%) was calculated: LCMS - Method D, Rt = 1.30 min, [M+2H]+2 876.4; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.86 - 0.93 (m, 3 H) 0.93 - 1.04 (m, 2 H) 1.19 (br. s., 15 H) 1.23 - 1.37 (m, 15 H) 1.61 - 1.68 (m, 2 H) 1.78 (td, J =12.44, 4.34 Hz, 2 H) 1.92 - 2.05 (m, 2 H) 2.37 (t, J =7.58 Hz, 2 H) 2.62 (t, J =6.05 Hz, 2 H) 3.49 (dd, J =6.72, 2.32 Hz, 2 H) 3.52 - 3.59 (m, 2 H) 3.59 - 3.73 (m, 92 H) 3.80 (t, J=6.05 Hz, 2 H) 5.13 (s, 2 H) 5.18 (s, 2 H) 7.31 - 7.42 (m, 10 H) 8.09 (t, J =5.26 Hz, 1 H).
[1135] Intermediate 36:
[1136]
[1137] DCC (22 mg, 0.103 mmol) in DCM (0.265 mL) as an intermediate in DCM (1.5 mL) 35 (150 mg, 0.086 mmol) and N-hydroxysuccinimide were added to a solution. The reaction mixture was stirred for 1.5 hours. Additional N-hydroxysuccinimide (10 mg) in THF (0.5 mL) and DCC (22 mg) in DCM (0.265 mL) were added, and the reaction mixture was stirred overnight. The solvent was evaporated, and the residue was purified using a flash column (silica 12, 0-5% MeOH / DCM) to obtain the intermediate. 36 (159 mg, quantitative) was calculated as a white solid: LCMS - Method B, Rt = 1.55 min, [M+H3O+H] +2 933.9.
[1138] Intermediate 37:
[1139]
[1140] Intermediate in THF (5 mL) 36A suspension of 10% Pd-carbon (4.6 mg, 4.3 μmol) in THF (1 mL) was added to a solution of (159 mg, 0.086 mmol). The reaction mixture was placed under hydrogen and stirred for 40 minutes. Pd-carbon (7 mg, 6.5 μmol) was further added and stirred under hydrogen for an additional 1 hour. The reaction mixture was passed through a membrane filter, and the filtrate was evaporated. The residue was purified by HPLC (Sunfire C18 30×50 mm, 45-70% ACN / water + 0.1% TFA), yielding the title compound (83 mg, 0.047 mmol, 54%): LCMS - Method B, Rt = 1.03 min, [M+2H]+2 835.2; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.84 - 0.94 (m, 3 H) 1.17 (br. s., 2 H) 1.21 - 1.39 (m, 30 H) 1.57 - 1.68 (m, 2 H) 1.69 - 1.80 (m, 2 H) 1.97 - 2.10 (m, 2 H) 2.34 (t, J =7.21 Hz, 2 H) 2.86 (s, 4 H) 2.92 (t, J =6.48 Hz, 2 H) 3.51 - 3.73 (m, 96 H) 3.87 (t, J =6.48 Hz, 2 H) 7.45 (t, J =4.46 Hz, 1 H)
[1141] Intermediate 38: 11-Bromoundeck-1-in
[1142]
[1143] Triphenylphosphine (3.43 g, 13.1 mmol) was added gradually over 30 minutes to a solution of 10-undekin-1-ol (2.29 mL, 11.9 mmol) and carbon tetrabromide (4.34 g, 13.1 mmol) in DCM (10 mL) at 0 °C under N2. Upon completion of addition, the reaction mixture was allowed to warm to room temperature. After 1.5 hours, the reaction mixture was poured into stirring cyclohexane (75 mL), and the precipitate was collected. The solid was washed with cyclohexane, and the combined filtrate was evaporated. The residue was purified using a flash column (80 g silica, 0-10% EtOAc / HEP), yielding the title compound (1.75 g, 7.57 mmol, 64%): 1H NMR (400 MHz, chloroform- d ) δ ppm 1.21 - 1.35 (m, 6 H) 1.35 - 1.48 (m, 4 H) 1.48 - 1.59 (m, 2 H) 1.80 - 1.91 (m, 2 H) 1.94 (t, J =2.63 Hz, 1 H) 2.19 (td, J =7.09, 2.69 Hz, 2 H) 3.41 (t, J =6.85 Hz, 2 H).
[1144] Intermediate 39 : di-tert-butyl 2-(undec-10-in-1-yl)malonate
[1145]
[1146] Di-tert-butyl malonate (800 mg, 3.70 mmol) was dissolved in DMF (9 mL) under N2 at 0°C, and NaH (148 mg, 3.70 mmol) was added. The reaction mixture was stirred at 0°C for 30 minutes, and the intermediate 38(770 mg, 3.33 mmol) was slowly added dropwise to produce a yellow solution. The reaction mixture was stirred at 0°C for 2 hours, then heated to room temperature and stirred for 16 hours. The mixture was dissolved in EtOAc (75 mL) and washed with H2O (25 mL). The aqueous layer was extracted with EtOAc (75 mL), and the combined organic layer was dried over Na2SO4, filtered, and concentrated. The mixture was purified twice using a flash column (12 g silica cartridge, 0-20% EtOAc / heptane), and the fractions were concentrated to yield 162.1 mg of the target product as a colorless oil (12%). LCMS (Waters Aquiti UPLC BEH C18, 130 Å, 1.7 µm, 2.1 mm × 50 mm, 50°C, Solvent Name A: Water + 0.1% formic acid, Solvent Name B: Acetonitrile + 0.1% formic acid, 98% B over 2.20 min): R t = 1.37 min, MS [M+H] Observation: 366.0, Calculated: 366.535. 1 H NMR (400 MHz, chloroform-d) δ ppm 1.29 (s, 10 H) 1.47 (s, 18 H) 1.52 (dd, J=14.78, 7.20 Hz, 3 H) 1.48 (d, J=1.26 Hz, 1 H) 1.75 - 1.83 (m, 2 H) 1.94 (t, J=2.65 Hz, 1 H) 2.18 (td, J=7.14, 2.65 Hz, 2 H) 3.11 (t, J=7.58 Hz, 1 H).
[1147] Intermediate 40: 11,11-di-tert-butyl 1-ethyldocos-21-phosphorus-1,11,11-tricarboxylate
[1148]
[1149] intermediate 39(162.1 mg, 0.442 mmol) was dissolved in DMF (2 mL) at 0°C, and NaH (21.23 mg, 0.531 mmol) was added. The reaction mixture was stirred at 0°C for 15 minutes, and ethyl 11-bromoundecanoate (143 mg, 0.486 mmol) was slowly added dropwise. The reaction mixture was heated to room temperature and stirred for 16 hours. The mixture was diluted with EtOAc (40 mL) and washed once with H2O (20 mL). The aqueous layer was extracted once with EtOAc (40 mL), the organic layer was combined, dried over Na2SO4, filtered, and concentrated to yield a clear yellow oil. The sample was dissolved in 1 mL of DCM and purified using a flash column (12 g silica column, 0-20% EtOAc / heptane, 15 min). The fractions were combined and concentrated to provide 90.1 mg of the target product (35%). 1 H NMR (400 MHz, chloroform-d) δ ppm 1.28 (br. s., 24 H) 1.45 (s, 18 H) 1.48 (s, 3 H) 1.53 (d, J=7.58 Hz, 3 H) 1.51 (s, 1 H) 1.64 (br. s., 1 H) 1.61 (d, J=7.33 Hz, 1 H) 1.77 (d, J=16.93 Hz, 2 H) 1.74 - 1.80 (m, 2 H) 1.94 (t, J=2.65 Hz, 1 H) 2.18 (td, J=7.07, 2.53 Hz, 2 H) 2.29 (t, J=7.58Hz, 2H) 4.13 (q, J=7.24 Hz, 2 H).
[1150] Intermediate 41: 12,12-bis(tert-butoxycarbonyl)tricose-22-phosphate
[1151]
[1152] t Intermediate in BuOH (1 mL) 40 In a solution of (21.7 mg, 0.037 mmol) at 30°C under N2 tA solution of KOtBu (114 mg, 1.012 mmol) in 2 mL of BuOH was added. The mixture was stirred at room temperature, and TLC (1:1 EtOAc / hexane, KMnO₄) was performed. 4, It was monitored under reflux. After 3 hours, the starting material was consumed, the reaction mixture was quenched with 1 M HCl (20 mL), and extracted twice with EtOAc (25 mL). The organic layers were combined, dried over Na2SO4, filtered, and concentrated to yield a clear, colorless oil (18 mg, 87%). The material was sent to the next step without further purification. 1 H NMR (400 MHz, chloroform-d) δ ppm 1.27 (br. s., 22 H) 1.44 (br. s., 18 H) 1.48 (s, 3 H) 1.52 (s, 3 H) 1.62 (br. s., 2 H) 1.77 (br. s., 4 H) 1.94 (br. s., 1 H) 2.18 (s, 2 H) 2.35 (s, 2 H).
[1153] Intermediate 42: dokos-21-phosph-1,11,11-tricarboxylic acid
[1154]
[1155] TFA (2 mL) as an intermediate 41 (12 mg, 0.022 mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with DCM (10 mL) and concentrated twice to yield a brown oil. The material was dissolved in EtOAc (10 mL) and washed with H2O (20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to yield a brown oil. The untreated material was dissolved in 1 mL MeOH and purified by MS-induced HPLC (Sunfire 30×50 mm 5 µm column, ACN / H2O + 0.1% TFA 75 ml / min, 1.5 ml injection, 45-70% ACN over 3.5 min): R t= 3.42 min; MS [M+H+Na] observed: 461.00, calculated: 461.597. The fractions were pooled and freeze-dried to provide 5.3 mg of the title compound in 56% yield.
[1156] Intermediate 43: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-(undec-10-phosphor-1-yl)tridecandioic acid
[1157]
[1158] Intermediate in THF (0.5 mL) 42 N-hydroxysuccinimide (1.53 mg, 0.013 mmol) was added to a solution of (5.3 mg, 0.012 mmol). A solution of DCC (2.493 mg, 0.012 mmol) in THF (0.5 mL) was added, and the mixture was stirred under N2 at room temperature for 4 hours. Complete conversion of the starting material was observed by LCMS. The mixture was concentrated and sent to the next step without further purification. LCMS (Sunfire C18 3.5 µm 3.0×30 mm, 40°C, acidic eluent A: water + 0.05% trifluoroacetic acid, basic eluent A: water + 5 mM ammonium hydroxide, eluent B: ACN, 5-95% over 2 min): R t = 1.72 min; MS [M+H+Na] Observed: 558.0, Calculated: 558.67.
[1159] Intermediate 44:
[1160]
[1161] Intermediate in DCM (0.5 mL) 43A solution of azido-dPEG23-amine (Quanta Biodesign, 7.88 mg, 7.17 μmol) in DCM (0.5 mL) and DIPEA (2.09 μL, 0.012 mmol) was added to a solution of (3.2 mg, 5.97 μmol), and the mixture was stirred at room temperature for 16 hours; at this point, the conversion of the starting materials was observed by LCMS. The reaction mixture was concentrated, dissolved in 1 mL of MeOH, and subjected to MS-induced HPLC (Sunfire 30×50 mm 5 μm column ACN / H2O + 0.1% TFA 75 ml / min, 1.5 ml injection, 55-80% ACN 5-minute gradient, R t = 1.92 min), the fractions were pooled and freeze-dried, providing 1.7 mg of the title compound in 19% yield. LCMS (Acquity BEH 1.7 μm 2.1×50 mm - 50°C, solvent name A: water + 0.1% formic acid, solvent name B: acetonitrile + 0.1% formic acid, 98% B over 2.20 min): R t = 1.89 min; MS [M+H / 2] Observed: 760.0, Calculated: 759.5.
[1162] Intermediate 45: dokos-21-en-1,11,11-tricarboxylic acid
[1163]
[1164] Intermediate 45 was prepared by substituting 11-bromo-deck-1-phosphorus with 11-bromo-deck-1-en following the procedure for intermediates 39-42.
[1165] Intermediate 46: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-(undec-10-en-1-yl)tridecandioic acid
[1166]
[1167] DCC (187 mg, 0.908 mmol) in DCM (2 mL) was added to a solution of N-hydroxysuccinimide (99 mg, 0.862 mmol) and docos-21-en-1,11,11-tricarboxylic acid (intermediate 45: 400 mg, 0.908 mmol) in DCM (7 mL) and THF (0.7 mL). The reaction mixture was stirred overnight, after which the solvent was evaporated. The residue was purified by HPLC (Sunfire C18 30×50 mm; 55-80% ACN / water + 0.1% TFA), yielding the title compound (155 mg, 0.288 mmol, 32%): LCMS - Method C, Rt = 1.51 min, M+H 538.3; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 1.16 - 1.46 (m, 28 H) 1.60 - 1.87 (m, 3 H) 1.91 - 2.17 (m, 5 H) 2.38 (t, J =7.03 Hz, 2 H) 2.86 (br. s., 4 H) 3.68 (dd, J =11.25, 7.34 Hz, 1 H) 3.78 (dd, J =11.31, 5.20 Hz, 1 H) 3.99 - 4.10 (m, 1 H).
[1168] Intermediates 47 and 47A :
[1169]
[1170] Azido-dPEG23-amine (Quanta Biodesign: 164 mg, 0.149 mmol) and intermediate 46 (80 mg, 0.149 mmol) was dissolved in THF (2.5 mL). DIPEA (39 µL, 0.233 mmol) was added, and the reaction mixture was vortexed overnight. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm; 45-70% ACN / water + 0.1% TFA) to obtain the compound 47 (97 mg, 0.061 mmol, 41%) and 47A(32 mg, 0.021 mmol, 14%) was calculated: LCMS - Method C, Rt = 1.35 min, [M+2H] +2 761.9; 1 ¹H NMR (400 MHz, acetonitrile- d 3) δ ppm 1.05 - 1.18 (m, 3 H) 1.19 - 1.32 (m, 20 H) 1.36 (t, J =7.15 Hz, 1 H) 1.48 - 1.59 (m, 2 H) 1.65 - 1.75 (m, 2 H) 2.01 - 2.06 (m, 2 H) 2.25 (t, J =7.46 Hz, 2 H) 3.33 - 3.39 (m, 2 H) 3.39 - 3.44 (m, 2 H) 3.50 - 3.67 (m, 98 H) 4.84 - 4.95 (m, 1 H) 4.95 - 5.06 (m, 1 H) 5.83 (ddt, J =17.07, 10.29, 6.68, 6.68 Hz, 1 H) 7.31 (t, J =5.44 Hz, 1 H); LCMS - Method C, Rt = 1.50 min, [M+2H] +2 739.9; 1 ¹H NMR (400 MHz, acetonitrile- d 3) δ ppm 1.16 - 1.42 (m, 30 H) 1.42 - 1.63 (m, 5 H) 2.00 - 2.07 (m, 2 H) 2.22 - 2.28 (m, 2 H) 2.40 - 2.52 (m, 2 H) 3.25 - 3.33 (m, 2 H) 3.33 - 3.42 (m, 2 H) 3.42 - 3.50 (m, 2 H) 3.50 - 3.68 (m, 88 H) 4.86 - 5.06 (m, 2 H) 5.83 (ddt, J =17.04, 10.26, 6.71, 6.71 Hz, 1 H) 6.40 - 6.74 (m, 1 H).
[1171] Intermediate 48 : 2-Undecylmalonic acid
[1172]
[1173] intermediate 22 Using (290 mg, 0.661 mmol), the title compound (185 mg, quantitative) as an intermediate 19 Synthesized in a similar manner to: LCMS - Method B, LCMS Rt = 0.82 min, MH 257.3
[1174] Intermediate 49: 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)tridecanoic acid
[1175]
[1176] DCC (122 mg, 0.592 mmol) as an intermediate in DCM (6 mL) and THF (0.5 mL) 48 It was added to a solution of (170 mg, 0.658 mmol) and N-hydroxysuccinimide (68 mg, 0.592 mmol). After stirring the reaction mixture for 16 hours, DCC (30 mg, 0.145 mmol) in DCM (0.5 mL) was further added. The reaction mixture was stirred for an additional 2 days. The solvent was evaporated, and the residue was purified by HPLC (Sunfire C18 30×50 mm, 45-70% ACN / water + 0.1% TFA), yielding the title compound as a white powder (46 mg, 0.129 mg, 20%): LCMS - Method B, Rt = 0.94 min, M+H 356.3; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.89 (t, J =7.00 Hz, 3 H) 1.20 - 1.40 (m, 16 H) 1.43 - 1.55 (m, 2 H) 1.99 - 2.14 (m, 2 H) 2.86 (s, 4 H) 3.71 (t, J =7.46 Hz, 1 H).
[1177] Intermediate 50 and 50A:
[1178]
[1179] The title compound is an intermediate49 From (30 mg, 0.084 mmol) 50 and 50A Synthesized in a similar manner, the intermediate 50 (18 mg, 0.013 mmol, 16%) and intermediate 50A (5 mg, 4 μmol, 5%) was calculated: LCMS - Method B, Rt = 0.85 min, M+H 1340.3; 1 ¹H NMR (400 MHz, chloroform- d ) δ ppm 0.82 - 0.98 (m, 3 H) 1.20 - 1.36 (m, 16 H) 1.36 - 1.51 (m, 2 H) 1.83 - 2.02 (m, 1 H) 2.11 - 2.27 (m, 1 H) 2.33 (dd, J =11.80, 4.22 Hz, 1 H) 3.41 (t, J =5.14 Hz, 3 H) 3.49 (d, J =5.01 Hz, 1 H) 3.56 - 3.79 (m, 92 H); LCMS - Method B, Rt = 0.96 min, M+H 1296.3.
[1180] Intermediates 51-57: Mutants of GDF15 protein
[1181] E. Expression of human GDF-15 protein in E. coli cells
[1182] E. E. coli strain BL21 (DE3) Gold (Stratagene) and Rosetta (DE3) pLysS cells (Novagen) were transformed into constructs 51 to 56 and construct MAHA-(200-308)-hGDF15, respectively, which were cloned into the pET26b vector. The transformed cells were grown under antibiotic screening in 3 ml first, followed by 50 ml of Luria Broth (Bacto-Tryptone 10 g / L, yeast extract 5 g / L, NaCl 5 / L, glucose 6 g / L) until an OD600 of 1.5 was reached. Using the pre-culture, two 1-L fermenters filled with Terrific Broth medium (NH4SO4 1.2 g / L, H2PO4 0.041 g / L, K2HPO4 0.052 g / L, Bacto-Tryptone 12 g / L, Yeast Extract 24 g / L) were inoculated. The culture was induced by the auto-addition of 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) when the pH increased above 7.1. Other fermentation parameters were as follows: temperature = 37°C; pH 7.0 + / - 0.2 (adjusted by the addition of 2N NaOH / H2SO4); pO2 > 30% + cascade stirrer speed, air flow, and oxygen addition. After 5 hours of induction, the culture was cooled to 10°C, and the cells were harvested by centrifugation.
[1183] Purification and Refolding of GDF15 Variants
[1184] a) Encapsulation body
[1185] A recombinant E. coli pellet expressing the protein of interest was resuspended in 50 mM NaH2PO4 / 150 mM NaCl / 5 mM benzamidine HCl / 5 mM DTT, pH 8.0 at 4°C (5% w / v), homogenized, and dissolved by passing through a French press twice (800 and 80 bar). The inclusion bodies (IB) were isolated by centrifugation at 12,000 rpm for 60 minutes at 4°C.
[1186] b) Purification of unfolded, untreated protein
[1187] IB was solubilized in 6 M guanidine / 100 mM NaH2PO4 / 10 mM Tris / 20 mM beta-mercaptoethanol, pH 8.0 (5% w / v) and stirred at room temperature for 2 hours. The mixture was centrifuged at 12,000 rpm to remove debris. The solubilized IB was further purified on a Ni-NTA-Superflow (constructions without the His tag also bind well to these resins due to their high histidine content). After baseline washing with 6 M guanidine / 100 mM NaH2PO4 / 10 mM Tris / 5 mM beta-mercaptoethanol, pH 8.0, the bound material was eluted with the same buffer adjusted to pH 4.5. The eluent was adjusted to pH 8.0, 100 mM DTT was added, and the solution was stirred overnight at 4°C. Afterward, trifluoroacetic acid (TFA, 10% stock solution in water) was added to adjust the pH to 2, and the solution was further diluted 1:1 with 0.1% TFA in water. The untreated protein solution was further purified by RP-HPLC (Poros) using a 0-50% acetonitrile gradient within 50 minutes. The fraction containing GDF-15 was pooled and freeze-dried.
[1188] c) Protein folding
[1189] Method 1: The lyophilized material was dissolved in 100 mM acetic acid at a concentration of 2 mg / ml, diluted 15-20 times in folding buffer (100 mM CHES / 1 M NaCl / 30 mM CHAPS / 5 mM GSH / 0.5 mM GSSG / 20% DMSO, pH 9.5, 4℃), and the solution was gently stirred at 4℃ for 3 days. After 3 days, 3 volumes of 100 mM acetic acid were added, the solution was concentrated to approximately 100-200 ml by ultrafiltration (5 kDa cutoff), diluted 10-fold with 100 mM acetic acid, and concentrated again. The refolded material was further purified by preparative RP-HPLC on a Vydac C4 column run at 50°C (Buffer A: 0.1% TFA in water; Buffer B: 0.05% TFA in acetonitrile). After loading, the column was washed with 15% buffer B and eluted with a gradient of 15% B → 65% B within 50 minutes. The collected fraction containing the protein of interest was diluted with an equal volume of buffer A and freeze-dried. The refolding yield was approximately 25% for both proteins.
[1190] Method 2: The same protocol as in Method 1 was followed with folding buffer of 100 mM CHES, pH 9.4, 0.9 M arginine, 0.5 M NaCl, 1 mM EDTA, 2.5 mM GSH, and 1 mM GSSG (final concentration).
[1191] The following GDF15 mutants were prepared according to the above procedure:
[1192] Intermediate 51: M-(His) 6 -hGDF15
[1193]
[1194] LCMS: Calculated mass: 26462 Observed mass: 26464
[1195] Intermediate 52: M-(His) 6 -M-hGDF15
[1196]
[1197] LCMS: Calculated mass: 26724 Observed mass: 26725
[1198] Intermediate 53: His-dGDF15:
[1199]
[1200] LCMS: Calculated mass (dimer): 26368 Observed mass: 26363
[1201] Intermediate 54: MH-(199-308)-hGDF15
[1202]
[1203] LCMS: Calculated mass: 24636 Observed mass: 24638
[1204] Intermediate 55: AH-(199-308)-hGDF15
[1205]
[1206] Step 1: M-His6-TEV(ENLYFQ / A)-H-hsGDF15 aa199-308 Manufacture of structures
[1207] The M-His6-TEV(ENLYFQ / A)-H-hsGDF15 aa199-308 construct was prepared according to the above procedure (steps a, b, and c).
[1208] Step 2 : TEV cleavage of the protein from Step 1
[1209] The lyophilized protein was solubilized in water to a final concentration of 1.75 mg / ml. The protein was unfolded again by diluting 1:1 in 6 M Guan / 50 mM Tris, pH 8.0 + 50 mM DTT, and stirred at room temperature for 1 hour. The material was purified again by preparative RP-HPLC on a Vidac C4 column and lyophilized. 26 mg of the lyophilized material was solubilized in 26 ml of 50 mM Tris / 3 M UREA, pH 7.5 + 3000 units of AcTEV protease (Invitrogen, 12575-023) and incubated for 4 days. Trifluoroacetic acid (TFA, 10% stock solution in water) was added to adjust the pH to 2.0, and the solution was further diluted to 150 ml with 0.1% TFA in water. After filtration through a 0.22 µm membrane, the material was purified again by preparative RP-HPLC on a BIDAC C4 column to successfully isolate the cleaved protein. The fractions were collected manually: the fraction containing the target protein was isolated and freeze-dried. Then, as described above, the cleaved GDF15 protein was refolded and the refolded protein was purified.
[1210] LCMS: Calculated mass (dimer): 24516 Observed mass: 24518
[1211] The following GDF15 mutants can be produced according to the above procedure:
[1212] Intermediate 56: MHA-(200-308)-hGDF15
[1213]
[1214] LCMS: Calculated Mass (Dimer): 24752
[1215] The following GDF15 mutants were prepared according to the above procedure:
[1216] Intermediate 57: AHA-(200-308)-hGDF15
[1217]
[1218] LCMS: Calculated Mass (Dimer): 24430: Observed Mass (Dimer): 24432
[1219] Intermediate 58 His-hGDF15 BCN conjugate
[1220]
[1221] His-hGDF15
[1222] (Sequence Identification Number: 2)
[1223] His-hGDF15 (intermediate 52 The stock solution of (0.6 mL, 4.8 mg / mL) was diluted to 0.5 mg / mL with 30 mM NaOAc pH 4.5 buffer (5.2 mL). A 10 mg / mL stock solution of (1R,8S,9s)-bicyclo[6.1.0]non-4-phosphorus-9-ylmethyl(2,5-dioxopyrrolidine-1-yl) carbonate (NHS-BCN) in DMSO (251 µL) was slowly added, and the reaction mixture was placed on a shaker plate at 24°C for 21 hours. The reaction mixture was diluted to 30 mL with 30 mM NaOAc pH 4.5 buffer and concentrated to 2 mL using a 10 kDa MWCO ultrafiltration cartridge (4 × 10⁻¹⁰ replicates), yielding 2.5 mL of concentrate. A 280 (ε = 29090M -1 cm -1 Based on , 26730 g / mol), the concentrate was 0.93 mg / mL (2.33 mg, 80%): LCMS QT2_15-60kDa_15 min_polarity (Method E). The resulting solution was analyzed by MALDI, which indicated that the major conjugations were +1 and +2 (N-terminal labeling of the monomer and dimer).
[1224]
[1225] His-hGDF15 + 1BCN (bicyclo[6.1.0]non-4-inyl) corresponds to the reaction at the N-terminal amino functional group on one molecule of the GDF15 homomer.
[1226] His-hGDF15 + 2BCN corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1227] His-hGDF15 +3BCN corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1228] Intermediate 59 His-hGDF15 BCN conjugate
[1229]
[1230] His-hGDF15 sequence:
[1231] (Sequence Identification Number: 1)
[1232] His-hGDF15 (intermediate 51 The stock solution of (7.04 mL, 1.42 mg / mL) was diluted to 0.5 mg / mL with 30 mM NaOAc pH 4.5 buffer (12.95 mL). A 10 mg / mL stock solution of (1R,8S,9s)-bicyclo[6.1.0]non-4-phosphorus-9-ylmethyl(2,5-dioxopyrrolidine-1-yl) carbonate (NHS-BCN) in DMSO (0.88 mL) was slowly added, and the reaction mixture was placed on a shaker plate at 24°C for 24 hours. An additional amount of NHS-BCN stock solution (176 µL) was added, and the reaction mixture was maintained at 24°C for 24 hours. The reaction mixture was diluted to 60 mL with 30 mM NaOAc pH 4.5 buffer and concentrated to 4 mL using a 10 kDa MWCO ultrafiltration cartridge (4 × 10⁻¹⁰ replicates), yielding 4.1 mL of concentrate. A 280 (ε = 29090M -1 cm -1 Based on , 26700 g / mol), the concentrate was 2.19 mg / mL (8.98 mg, 89%): LCMS QT2_15-60kDa_15 min_polarity (Method E).
[1233]
[1234] His-hGDF15 + 1BCN (bicyclo[6.1.0]non-4-inyl) corresponds to the reaction at the N-terminal amino functional group on one molecule of the GDF15 homomer.
[1235] His-hGDF15 + 2BCN corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1236] His-hGDF15 +3BCN corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1237] Intermediate 60: His-GDF15-BCN
[1238]
[1239] 100 µL of His-dGDF15 (0.68 mg / mL), 100 µL of pH 4.5 buffer, and 4 µL of 10 mg / mL BCN-NHS solution were combined and incubated at room temperature for 2 days. The resulting mixture was washed four times with Amicon 10k to prepare a 200 µL solution, which was used in the next step. The product was sent as untreated material for further conversion into a conjugate.
[1240] Examples of the present invention:
[1241] His-hGDF15 + fatty acid-PEG-N 3 General procedure for clicking.BCN-labeled GDF15 was diluted to 0.5 mg / mL in 30 mM NaOAc pH 4.5 buffer, while a 10 mg / mL solution of FA-PEG-N3 (fatty acid-PEG23-azide) in water was prepared. 10 equivalents of FA-PEG-N3 were added to the GDF15 solution, and the reaction mixture was placed on a shaker plate overnight at 24°C. The reaction progress was monitored using LCMS (QTOF method 15–60 kDa, 15 min, polarity), and additional FA-PEG-N3 was added up to 50 equivalents if necessary, until no unreacted BCN-labeled GDF15 was observed. Subsequently, the reaction mixture was diluted 5–10× with 30 mM NaOAc pH 4 buffer, and the buffer was replaced with fresh buffer using a 10 kDa MWCO ultrafiltration cartridge (dilution after 4 cycles of concentration). Sample A 280 The conjugate was concentrated to ~1 mg / mL as measured, and the recovery rate was quantitatively 34%. The final conjugate was analyzed by LCMS (QTOF method 15-60 kDa 15 min polarity) or MALDI.
[1242] Example 1 : His-hGDF15 BCN (I-59) conjugated to intermediate 21:
[1243]
[1244]
[1245] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1246] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1247] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1248] Example 2 : His-hGDF15 BCN (I-59) conjugated to intermediate 44:
[1249]
[1250]
[1251] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1252] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1253] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1254] Example 3: His-hGDF15 BCN (I-59) bonded to intermediate 29A:
[1255]
[1256]
[1257] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1258] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1259] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1260] Example 4 : His-hGDF15 BCN (Intermediate 58) conjugated to Intermediate 24:
[1261]
[1262]
[1263] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1264] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1265] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1266] Example 5: His-hGDF15 BCN (I-58) conjugated to intermediate 29:
[1267]
[1268]
[1269] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule of the GDF15 homomer.
[1270] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1271] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1272] Example 6: His-hGDF15 BCN (I-58) conjugated to intermediate 55:
[1273]
[1274]
[1275] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule of the GDF15 homomer.
[1276] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1277] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1278] Example 7: His-hGDF15 BCN (I-58) conjugated to intermediate 6A:
[1279]
[1280]
[1281] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1282] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both monomer units of the GDF15 homomer.
[1283] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1284] Example 9: His-hGDF15 BCN (I-58) conjugated to intermediate 30:
[1285]
[1286]
[1287] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (monomer unit) of the GDF15 homomer.
[1288] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both molecules (monomer units) of the GDF15 homomer.
[1289] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1290] Example 10: His-hGDF15 BCN (I-58) conjugated to intermediate 12:
[1291]
[1292]
[1293] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1294] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both molecules (monomer units) of the GDF15 homomer.
[1295] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1296] Example 13 : His-hGDF15 BCN (I-59) conjugated to intermediate 6:
[1297]
[1298]
[1299] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1300] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both molecules (both monomer units) of the GDF15 homomer.
[1301] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1302] Example 14: His-hGDF15 BCN (I-58) conjugated to intermediate 17:
[1303]
[1304]
[1305] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1306] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both molecules (both monomer units) of the GDF15 homomer.
[1307] His-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1308] Example 15:
[1309] Step 1:
[1310]
[1311] A solution of DCC (65.6 mg, 0.318 mmol) in THF (5 mL) was added to a solution of 2,2,13,13-tetramethyltetradecandioic acid (Aldrich CPR, order number PH002322) (100 mg, 0.318 mmol) and N-hydroxysuccinimide (40.3 mg, 0.35 mmol) in THF (5 mL), and the mixture was stirred overnight at room temperature. Partial conversion to the target product was observed by LC-MS analysis. The mixture was filtered, and the filtrate was concentrated. The residue was redissolved in DCM (40 mL), washed with water, dried over Na2SO4, purified by silica chromatography, and eluted with heptane / EtOAc / DCC (10:1:1) to provide the mixture. The mixture was further purified by MS-induced acid HPLC [(55-80% ACN 3.5 min gradient): rt= 2.48 min, calculated mass: 314.46, observed mass: 314.00], yielding a clean product (50 mg, 38.2% yield) and recovering the starting material.
[1312] Step 2 :
[1313]
[1314] Azido-dPEG3-amine (10 mg, 0.049 mmol) and DIPEA (9 μL, 0.049 mmol) were added to a solution of NHS-2,2,13,13-tetramethyltetradecandioic acid (10 mg, 0.024 mmol) in DCM (3 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated, redissolved in MeOH (3 mL), and purified by MS-induced HPLC (55-80% ACN 3.5 min gradient rt=2.35, estimated mass: 514.70, observed mass: 514.40), yielding 7 mg of a clear product in 58% yield.
[1315] Step 3:
[1316]
[1317] 100 µl BCN-dGDF15 ( I-60 To a solution of (0.68 mg / mL in pH 4.5 buffer), pH 4.5 buffer (100 µL) and azide (6 µL in DMSO, 10 mg / mL) were added, and the mixture was incubated overnight at room temperature. The mixture was washed four times with Amicon 10k. The resulting solution was analyzed by MALDI, which indicated major conjugations as +1 and +2. MALDI: Calculated mass: 26546, Observed mass: 26483; Calculated mass: 27060, Observed mass: 27128; Calculated mass: 27574, Observed mass: 27789.
[1318] Example 16 : His-hGDF15 BCN (I-58) conjugated to intermediate 44:
[1319]
[1320]
[1321] His-hGDF15 + 1FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on one molecule (one monomer unit) of the GDF15 homomer.
[1322] His-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional group on both molecules (both monomer units) of the GDF15 homomer.
[1323] Example 17: His-hGDF15-BCN conjugated to intermediate 52
[1324]
[1325] 3 mL of cyclooctine GDF15 in 7 mL of pH 4 sodium acetate buffer ( I-58 Fatty acid PEG azide (15 μL in 35 mg / mL DMSO, 0.36 μmol) was added to a solution of (0.46 mg / mL, 0.051 μmol), and the mixture was incubated overnight at room temperature. Complete conversion was observed by MALDI analysis. The product was purified by three Amicon filtration washes of 10 kD, providing 4.3 ml of the target product at 0.29 mg / ml in 90% yield. MALDI: Cyclooctine sm ~5% Estimated mass: 26902, Observed mass: 26997; +1 fatty acid ~40% Estimated mass: 28421, Observed mass: 28525; +2 fatty acid ~50% Estimated mass: 29940, Observed mass: 30191; +3 fatty acid 5% Estimated mass: 31459, Observed mass: 31874.
[1326] Example 18: MH-(199-308)GDF15 (I-54) conjugated to intermediate 37
[1327]
[1328] MH-(199-308)-GDF15 (intermediate 54: 0.393 mL, 0.028 μmol, 1.78 mg / mL) was added to 1.5 mL of 30 mM sodium acetate buffer. NHS fatty acid (474 µg, 0.284 μmol, 10 mg / ml) was added to the solution. After 5 hours, the reaction was complete according to MALDI. The product was purified by washing 5 times using an Amicon 10 kD ultrafiltration, providing 575 µg of conjugate in 73% yield. MALDI: sm (18%), estimated mass: 24638, observed mass: 24735; +1 fatty acid (38%), estimated mass: 26192, observed mass: 26268; +2 fatty acids (40%) Estimated mass: 27746, Observed mass: 27798; +3 fatty acids (4%) Estimated mass: 29300, Observed mass: 29333.
[1329] Example 19A: His-hGDF15 (I-59) bonded to intermediate 37
[1330]
[1331] His-GDF15 (0.493 ml, 0.026 μmol, 1.42 mg / ml) was added to 1.5 ml of 30 mM sodium acetate pH=4 buffer. NHS fatty acid (0.221 mg, 0.132 μmol, 10 mg / mL) was added to the solution. As the reaction was not complete due to the overnight reaction, an additional 2.5 equivalents of fatty acid NHS (0.110 mg, 0.066 μmol, 10 mg / mL) were added, and after 5 hours, the MALDI +2 conjugate appeared as the major product. The product was purified by washing 5 times using an Amicon 10 kD ultrafiltration, providing 565 μg of the conjugate in 76% yield. MALDI: sm (18%), estimated mass: 26468, observed mass: 26553; +1 fatty acid (38%) Estimated mass: 28022, Observed mass: 28099; +2 fatty acid (40%) Estimated mass: 29576, Observed mass: 29649; +3 fatty acid (4%) Estimated mass: 31130, Observed mass: 31201.
[1332] Example 19B: AHA-hGDF15 conjugated with intermediate 37
[1333]
[1334] A 10 mg / mL solution of intermediate 37 in molecular biology-grade water was prepared. 30 mM NaOAc pH 4.6 (acceptable range 4.5-5.0) was added to AHA-hGDF15 (6.67 mg / mL, 5.247 mL, 1.433 μmol in 30 mM NaOAc pH 4.0) to provide a final protein concentration of 0.88 mg / mL. Intermediate 37 (10 equivalents, 2.39 mL, 0.014 mmol) was added, and the reaction mixture was mixed at room temperature for 18 hours. A precipitate formed in the reaction vial. The reaction mixture was divided in a 4×15 mL 10 kDa Amicon centrifuge filter, and each was diluted to 15 mL with 30 mM NaOAc pH 4.0. Between washes, while vortexing the precipitate in the filter with a pipette tip, the material was buffer-exchanged 4× with 30 mM NaOAc pH 4.0, and the samples were combined to a volume of 25.6 mL. As precipitate remained in the solution, the mixture was left overnight at 4°C. A280 (30040 cm -1 M -1 The concentration was measured to be 1.62 mg / mL (100%) by (27538 g / mol). UPLC analysis showed 60% recovery of +1FA (retention time: 4.88 min) and +2FA products (retention time: 5.80 min) (Method J). LCMS Method T represented the target mass.
[1335] The untreated mixture of Example 19B (the ratio shown in the table below) was tested in vivo and is reported in Table 1:
[1336]
[1337] AHA-hGDF15 + 1FA (fatty acid) corresponds to a reaction at the N-terminal amino functional group (on the monomer unit) on one of the polypeptide chains of the GDF15 homomer (as shown in Example 11B, Chemical Formula H).
[1338] AHA-hGDF15 + 2FA (fatty acid) corresponds to the reaction at the N-terminal amino functional groups on both polypeptide chains of the GDF15 homomer (as shown in Example 11B, Formula G).
[1339] AHA-hGDF15 + 3FA (fatty acids) corresponds to a non-selective reaction at some other sites of the GDF15 homomer.
[1340] tablet:
[1341] The untreated product was purified by reverse-phase chromatography (buffer A: 0.1% TFA in water; buffer B: 0.1 M TFA in ACN; gradient; 99%-80% buffer A) on a Waters BEH300 (130 Å, 3.5 µm, 4.6 mm × 100 mm, flow rate 2.5 ml / min).
[1342] Fraction 1: Unreacted AHA-hGDF15: Rt=17.33 min
[1343] Fraction 2: (19B1): AHA-GDF15 + 1FA: Rt=20.2 min (approx. 15% yield) (Chemical Formula H)
[1344] Fraction 3: (19B2): AHA-GDF15 + 2FA: Rt=21.6 min (approx. 15% yield) (Chemical Formula G)
[1345] Fraction 4: (19B3): AHA-GDF15 + 3 FA: Rt=23.0 min (approx. 5% yield)
[1346] A 1:1 ratio mixture of 19B1 and 19B2 was prepared and tested (19Bm).
[1347] Alternatively, the reaction can be carried out in 10 mM Na2HPO4-7H2O and 30 mM NaOAc at pH 4.73: A 10 mg / mL solution of intermediate 37 in molecular biology-grade water was prepared. 30 mM NaOAc and 10 mM Na2HPO4-7H2O at pH 4.73 were added to AHA-hGDF15 (intermediate 57, 12.04 mg / mL in 30 mM NaOAc at pH 4.0, 4.15 µL, 0.002 μmol) to provide a final protein concentration of 0.88 mg / mL. Intermediate 37 (20 equivalents, 6.83 µL, 0.041 μmol) was added, and the reaction mixture was mixed at room temperature for 18 hours. The reaction mixture became turbid with the presence of a precipitate. UPLC analysis revealed 58% +1 and +2 products (Method J).
[1348]
[1349] The reaction may also be carried out in 30 mM NaOAc and 10 mM K2HPO4 at pH 4.6: A 10 mg / mL solution of intermediate 37 in molecular biology-grade water was prepared. 30 mM NaOAc and 10 mM K2HPO4 at pH 4.6 (acceptable range 4.5–5.0) were added to AHA-hGDF15 (intermediate 57, 6.21 mg / mL in 30 mM NaOAc at pH 4.0, 5.261 mL, 1.337 μmol) to provide a final protein concentration of 0.88 mg / mL. Intermediate 37 (10 equivalents, 68.3 μL, 0.409 μmol) was added, and the reaction mixture was mixed at room temperature for 7 hours. The reaction mixture became turbid with the presence of a precipitate. The reaction mixture was divided into four 9 mL portions on a 15 mL 10 kDa Amicon centrifuge filter and diluted to 15 mL with 30 mM NaOAc pH 4.0. Between each wash, the material was buffer-exchanged 4× with 30 mM NaOAc pH 4.0 while vortexing the precipitate with a pipette tip. The reaction mixture was concentrated to a volume of 75 mL. Since a precipitate remained, the material was stored at 4°C for 2 days. A280 (30040 cm -1 M -1 The concentration was measured to be 0.4 mg / mL (97%) by (27538 g / mol). UPLC analysis showed 61% recovery of +1 and +2 products (Method J).
[1350]
[1351] Reference Example 1: His-hGDF15 BCN (I-58) conjugated to the intermediate PEG-myristic acid construct:
[1352] Step 1:
[1353]
[1354] DCM (1 mL) and DIPEA (13 µL) were added to a mixture of azido-PEG23-amine (30 mg, 0.027 mmol) and myristic acid NHS ester (Toronto Research Chemicals, Catalog # S69080) (12 mg, 0.037 mmol), and the mixture was stirred overnight at room temperature. The mixture was purified by silica chromatography and eluted with EtOAc / heptane (0-100%) followed by MeOH / DCM (0-10%), providing a clean product in approximately 5% MeOH / DCM. LCMS: (Gradation: 40 → 98% B - flow 1 mL / min within 1.4 min, Eluent A: water + 0.05% formic acid + 3.75 mM ammonium acetate, Eluent B: acetonitrile + 0.04% formic acid). LCMS: rt=2.20 (Method C) Calculated mass +H: 1354.71, Observed mass: 1354.4.
[1355] Step 2:
[1356]
[1357] BCN-hGDF15 ( I-52 a (2 mg / mL in DMSO, 6.3 μL, 10 equivalents) was added to a solution of : 800 μL, 0.25 mg / mL), and the mixture was stirred overnight at room temperature. 1.1 mL 0.20 mg / mL (quantitative yield). (MALDI: +1 calculated mass: 28223, observed mass: 28640; +2 calculated mass: 29543, observed mass: 29962, +3 calculated mass: 30863, observed mass: 31426, +4 calculated mass: 32183, observed mass: 32911).
[1358] Reference Example 2 : his-hGDF15-PEG23
[1359]
[1360]
[1361] His-hGDF15 BCN in 30 mM NaOAc pH 4.0 (427 µL) I59 : Azido-dPEG in a solution of 427 μl, 1.17 mg / mL, 0.019 μmol). 23 -Amine (Quanta Biodesign, 104 ...
Claims
Claim 1 A compound of the following formula A1, or its amide, or a pharmaceutically acceptable salt: R 1 is -CO2H and;R 2 and R 3 One of them is -CO2H, and the other is H, -OH, -CH=CH2 or -C≡CH; n and m are integers from 6 to 30 independently of each other. Claim 2 A compound of the following formula A1, or its amide, ester, or pharmaceutically acceptable salt: R 1 is -CO2H and;R 2 and R 3 One of them is -CO2H, and the other is H, -OH, -CH=CH2 or -C≡CH; n and m are integers from 8 to 20 independently of each other. Claim 3 A compound of the following formula A1, or its amide, ester, or pharmaceutically acceptable salt: R 1 is -CO2H and;R 2 and R 3 are independently H, -OH, -CO2H, -CH=CH2 or -C≡CH; provided that R 2 and R 3 are not identical; n and m are independent integers from 6 to 30, and the following compounds are excluded: (i) CH3(CH2)5C(COOC2H5)2(CH2)9CH=CH2, (ii) CH3(CH2)6C(COOC2H5)2(CH2)9CH=CH2, (iii) CH3(CH2)7C(COOC2H5)2(CH2)9OCOCH3, (iv) CH3(CH2)8C(COOC2H5)2(CH2)8OCOCH3, (v) CH3(CH2)9C(COOC2H5)2(CH2)7OCOCH3, (vi) , (vii) , and (viii) . Claim 4 In Paragraph 3, R 2 and R 3 A compound in which one is -CO2H and the other is H, -OH, -CH=CH2 or -C≡CH, or its amide, ester, or pharmaceutically acceptable salt. Claim 5 In any one of claims 1, 3, or 4, n and m are independently 8 to 20 compounds, amides or pharmaceutically acceptable salts thereof when referring to claim 1, or amides, esters, or pharmaceutically acceptable salts thereof when referring to claim 3. Claim 6 In any one of claims 1 to 4, n and m are independently 10 to 16 compounds, or, if referring to claim 1, its amide or pharmaceutically acceptable salt, or, if referring to claim 2 or 3, its amide, ester, or pharmaceutically acceptable salt. Claim 7 In any one of claims 1 to 4, a compound selected from the following chemical formula: , and ,in the above formula, Ak 3 , Ak 4 , Ak 5 , and Ak 6 is independently (C 8-20 )alkylene, and R 5 is (C 8-20 ) an alkyl compound, or, if referring to Claim 1, its amide or pharmaceutically acceptable salt, or, if referring to Claim 2 or 3, its amide, ester, or pharmaceutically acceptable salt. Claim 8 A compound selected from the group consisting of the following, in any one of paragraphs 1 to 4: and , or, if citing Paragraph 1, its amide or pharmaceutically acceptable salt, or, if citing Paragraph 2 or 3, its amide, ester, or pharmaceutically acceptable salt. Claim 9 In any one of claims 1 to 4, a compound having the following chemical formula: , or, if citing Paragraph 1, its amide or pharmaceutically acceptable salt, or, if citing Paragraph 2 or 3, its amide, ester, or pharmaceutically acceptable salt. Claim 10 A fatty acid-linker construct comprising a fatty acid connected to a linker, wherein the fatty acid is a compound according to any one of claims 1 to 4, or, in reference to claim 1, an amide or a pharmaceutically acceptable salt thereof, or in reference to claim 2 or 3, an amide, ester, or a pharmaceutically acceptable salt thereof. Claim 11 A fatty acid-linker construct according to claim 10, wherein the linker comprises alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, polyethylene glycol, one or more natural or non-natural amino acids, or a combination thereof, wherein each alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, polyethylene glycol and / or natural or non-natural amino acid is optionally combined and linked together, or linked to a fatty acid moiety through a chemical group selected from -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -O-, -NH-, -S-, -C(O)-, -OC(O)NH-, -NHC(O)-O-, =NH-O-, =NH-NH- or =NH-N(alkyl)-. Claim 12 A fatty acid-linker construct according to claim 10, wherein the linker comprises a combination of amino acids, heterocyclyl moiety, polyethylene glycol (PEG), and / or alkyl moiety. Claim 13 A fatty acid-linker construct according to claim 10, wherein the linker comprises polyethylene glycol, one or more natural or non-natural amino acids, or a combination thereof. Claim 14 A fatty acid-linker construct according to claim 10, wherein the linker comprises an unbranched oligoethylene glycol moiety of the following chemical formula: , or Here, y is 0 to 34. Claim 15 In claim 14, a fatty acid-linker construct wherein the linker comprises a non-branched oligoethylene glycol moiety of the following chemical formula: y is 0 to 34. Claim 16 In paragraph 10, a fatty acid-linker construct in which the linker consists of amino acids connected together by peptide bonds. Claim 17 A fatty acid-linker construct according to claim 16, wherein the linker is composed of 1 to 20 amino acids connected by peptide bonds, and said amino acids are selected from 20 naturally occurring amino acids. Claim 18 A fatty acid-linker construct according to claim 10, wherein the linker comprises 1 to 20 amino acids selected from non-natural amino acids. Claim 19 In claim 10, the linker is 8-amino-3,6-dioxaoctanol, a non-natural amino acid having the following chemical formula. or a fatty acid-linker construct comprising repeating units thereof. Claim 20 , , , , , , and A compound selected from . Claim 21 Compounds selected from the following: 2-(11-((azido-PEG23)-amino)-11-oxoundecyl)-2-undecylmalonic acid, 11,11-di-tert-butyl 1-(2,5-dioxopyrrolidine-1-yl)docosan-1,11,11-tricarboxylate, 12,12-bis(tert-butoxycarbonyl)tricosonic acid, 1-benzyl 11,11-di-tert-butyldocosan-1,11,11-tricarboxylate, 2-(azido-PEG23-carbamoyl)-2-undecyltridecanic acid, 2-(((2,5-dioxopyrrolidine-1-yl)oxy)carbonyl)-2-undecyltridecanic acid, and tribenzyldocosan-1,11,11-tricarboxylate.
